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foreword
Today, over 46 million people live with dementia worldwide, more than the population of 
Spain. This number is estimated to increase to 131.5 million by 2050.
Dementia also has a huge economic impact. Today, the total estimated worldwide cost 
of dementia is US $818 billion, and it will become a trillion dollar disease by 2018. This 
means that if dementia care were a country, it would be the world’s 18th largest economy, 
more than the market values of companies such as Apple (US$ 742 billion), Google (US$ 
368 billion) and Exxon (US$ 357 billion). 
In many parts of the world, there is a growing awareness of dementia, but across the 
globe it remains the case that a diagnosis of dementia can bring with it stigma and 
social isolation. Today, we estimate that 94% of people living with dementia in low and 
middle income countries are cared for at home. These are regions where health and care 
systems often provide limited or no support to people living with dementia or to  
their families.
The 2015 World Alzheimer Report updates data on the prevalence, incidence, cost and 
trends of dementia worldwide. It also estimates how these numbers will increase in the 
future, leaving us with no doubt that dementia, including Alzheimer’s disease and other 
causes, is one of the biggest global public health and social care challenges facing 
people today and in the future. 
The two organisations we lead are ADI, the only worldwide federation of Alzheimer 
associations and global voice on dementia, and Bupa, a purpose-driven global health and 
care company that is the leading international provider of specialist dementia care, caring 
for around 60,000 people living with dementia each year. Together, we are committed 
to ensuring that dementia becomes an international health priority. We believe national 
dementia plans are the first step towards ensuring all countries are equipped to enable 
people to live well with dementia, and help to reduce the risk of dementia for future 
generations. There is now a growing list of countries which have such provision in place or 
which are developing national dementia plans, but it’s not enough. 
Given the epidemic scale of dementia, with no known cure on the horizon, and with a 
global ageing population, we’re calling on governments and every part of society to 
play an active role in helping to create a world where people can enjoy a better quality 
of life today, and also help reduce the risk of dementia for future generations. It is our 
belief that this report will help sustain the momentum of recent global collaboration, 
mobilising governments, policy makers, health care professionals, researchers, Alzheimer 
associations, and businesses, to work together on a solution for the global challenge of 
dementia.
Providing a better quality of life for people with dementia can be a reality, but only if 
governments and societies make it an urgent priority. We’re committed to making  
this happen.
Glenn Rees
Chairman
Alzheimer’s Disease  
International
Stuart Fletcher
CEO 
Bupa
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The Global observatory  
for Ageing and Dementia care
The Global Observatory for Ageing and Dementia Care, hosted at the Health Service 
and Population Research Department, King’s College London, was founded in 2013. 
Supported by Alzheimer’s Disease International, and King’s College London, the 
Observatory has a tripartite mission:
1. To build upon ADI’s 10/66 Dementia Research Group program of population-based 
and intervention research in low and middle income countries, maximising the impact 
that research findings from our data can have upon policy and practice.
2. To develop, evaluate, and promote primary care and community interventions for 
people with dementia.
3. To synthesise global evidence for policymakers and public, in particular, continuing 
and developing our role in the preparation of high impact evidence-based reports for 
Alzheimer’s Disease International (World Alzheimer Reports 2009, 2010, 2011, 2013 and 
2014, and Nutrition and dementia), the World Health Organization (Dementia: a public 
health priority, 2012) and other relevant intergovernmental organisations.
The World Alzheimer Report 2015 was independently researched and authored by Prof 
Martin Prince, Prof Anders Wimo, Dr Maëlenn Guerchet, Gemma-Claire Ali, Dr Yu-
Tzu Wu and Dr Matthew Prina, with contributions from others as listed. The evidence 
reported in Chapters 1-6, and the inferences drawn, are the responsibility of the authors 
alone. Chapter 7 was developed by the Global Observatory and Alzheimer’s Disease 
International.
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alzheImer’s DIsease InTernaTIonal: WorlD alzheImer reporT 2015
Contents
In summary   1   
chapTer 1   
Introduction   6
Dementia in a rapidly changing world   6
Economic development   7
Population ageing in a developing world   7
Most lower income countries will remain relatively poor, and 
face particular challenges   8   
chapTer 2   
The global prevalence of dementia   10
Introduction   10
Methods   10
Results   12
Conclusions and recommendations   25
References   27   
chapTer 3   
The incidence of dementia   30
Introduction   30
Methods   30
Results   31
Discussion   34
References   35   
chapTer 4   
Current and future secular trends   36
Introduction   36
Research evidence   37
Conclusion   43
References   45   
chapTer 5   
The impact of dementia worldwide   46
Introduction   46
The Global Burden of Disease approach (GBD)   46
Alternative approaches to understanding the impact of 
dementia   51
Conclusion   54
References   54  
chapTer 6   
The worldwide costs of dementia   56
Introduction   56
Methods   56
Results   58
Discussion   65
References   67   
chapTer 7   
Conclusions and recommendations   68
Summary   68
Global Action Against Dementia   70
Beyond the G7 process   71
Building upon the Global Action Against Dementia   71
Final conclusions and recommendations   78
References    79   
appenDIx a   
Global Burden of Disease (GBD) Regions   81
CHAPTER 1
Dementia and ageing in a developing world
1. We have updated our previous estimates of the 
global prevalence, incidence and costs of dementia. 
As a new feature, we have included a systematic 
review of the evidence for and against recent trends 
in the prevalence and incidence of dementia over 
time.
2. There are almost 900 million people aged 60 years 
and over living worldwide. Rising life expectancy is 
contributing to rapid increases in this number, and 
is associated with increased prevalence of chronic 
diseases like dementia. 
3. Between 2015 and 2050, the number of older people 
living in higher income countries is forecast to 
increase by just 56%, compared with 138% in upper 
middle income countries, 185% in lower middle 
income countries, and by 239% (a more than  
three-fold increase) in low income countries.
4. Older people also constitute an increasing 
proportion of total population, as the rise in life 
expectancy is being accompanied by declining 
fertility rates in most countries.
5. Poorer countries have fewer economic and human 
professional resources to meet the health and 
social care needs of their rapidly growing older 
populations. Many of these countries face the 
challenge of a ‘double burden’ of persistently 
high rates of maternal, childhood and infectious 
diseases, combined with a growing epidemic of 
chronic non-communicable diseases.
6. Even with the unprecedented benefits of double 
digit annual economic growth, rapidly developing 
countries in Asia and Latin America have struggled 
to establish comprehensive and effective systems 
of social protection for older people, failing to 
guarantee adequate income and universal access to 
health and social care.
7. Overall economic growth at the national level can 
conceal gross inequities in income distribution, and 
older people are often among the least likely and the 
last to benefit directly from economic development.
 
CHAPTER 2
The global prevalence of dementia
1. We have updated our 2009 systematic review of the 
global prevalence of dementia, bringing the total 
number of studies to 273. This is 116 more than we 
found in 2009. Changes in estimates in this chapter 
reflect inclusion of these new studies but cannot be 
interpreted as secular trends, which are discussed 
in Chapter 4.
2. Our regional estimates of dementia prevalence in 
people aged 60 years and over now range from 
4.6% in Central Europe to 8.7% in North Africa and 
the Middle East, though all other regional estimates 
fall in a relatively narrow band between 5.6 and 
7.6%.
3. When compared to our 2009 estimates, estimated 
prevalence has increased in Asia and Africa, but 
decreased in Europe and the Americas.
4. We estimate that 46.8 million people worldwide are 
living with dementia in 2015. This number will almost 
double every 20 years, reaching 74.7 million in 2030 
and 131.5 million in 2050. These new estimates 
are 12-13% higher than those made for the World 
Alzheimer Report 2009.
5. We estimate that 58% of all people with dementia 
live in countries currently classified by the World 
Bank as low or middle income countries. The 
proportion of people with dementia living in these 
same countries is estimated to increase to 63% in 
2030 and 68% in 2050.
6. Continuing the trend noted in our 2009 report, 
proportionate increases in the number of people 
living with dementia will be much steeper in low 
and middle income countries than in high income 
countries. Between 2015 and 2050, the number 
of people living with dementia in what are now 
high income countries will increase by 116%. This 
compares to a 227% increase in upper middle 
income countries, 223% in lower middle income 
countries, and 264% in low income countries.
7. Regions that stand out as persistently lacking in 
research – both in terms of number of studies and 
relative to population size – are Central Asia, Eastern 
Europe, Southern Latin America, and Eastern and 
Southern sub-Saharan Africa. Despite reasonable 
coverage in terms of numbers of studies, the 
evidence-base for South and Southeast Asia is still 
sparse with respect to population size.
WorlD reporT 2015 
In summary
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8. In our 2009 report, we noted a marked decrease 
in dementia prevalence research in high income 
countries since the 1990s. This trend has not been 
reversed, causing the evidence-base to become 
increasingly out of date.
9. Quality issues identified in 2009 are still common 
among recent studies. We urge researchers 
conducting prevalence studies to ensure that 
two-phase study designs are correctly applied and 
analysed, and to include an informant interview in 
their diagnostic assessment of dementia. 
CHAPTER 3
The incidence of dementia
1. We have updated our 2011 review of the global 
incidence of dementia, bringing the total number of 
studies to 62. This is 23 more than we found in 2011. 
Of these, 12 new studies provided data in a format 
that could be included in our age-stratified meta-
analysis, which now comprises 46 studies.
2. Through meta-analysis of the available evidence, 
we estimate over 9.9 million new cases of dementia 
each year worldwide, implying one new case every 
3.2 seconds. These new estimates are almost 
30% higher than the annual number of new cases 
estimated for 2010 in the 2012 WHO/ADI report (7.7 
million new cases, one every 4.2 seconds).
3. The regional distribution of new dementia cases 
is 4.9 million (49% of the total) in Asia, 2.5 million 
(25%) in Europe, 1.7 million (18%) in the Americas, 
and 0.8 million (8%) in Africa. Compared to our 2012 
estimates, these values represent an increased 
proportion of new cases arising in Asia, the 
Americas and Africa, while the proportion arising in 
Europe has fallen.
4. Overall incidence of dementia in low and middle 
income countries is only 10% lower (RR 0.90, 95% 
CI: 0.70-1.15) than in high income countries. In 
contrast to our previous meta-analysis, this is not 
statistically significant.
5. The incidence of dementia increases exponentially 
with increasing age. For all studies combined, the 
incidence of dementia doubles with every 6.3 year 
increase in age, from 3.9 per 1000 person-years at 
age 60-64 to 104.8 per 1000 person-years at age 
90+.
6. The number of new cases increases and then 
declines with increasing age in each region. In 
Europe and the Americas peak incidence is among 
those aged 80-89 years, in Asia it is among those 
aged 75-84, and in Africa among those aged 65-74
7. The evidence-base continues to be dominated by 
studies from Europe and North America, but less 
so than in 2011. Of the 46 studies that could be 
included in the meta-analysis, 19 were conducted 
outside Europe and North America, and 17 were 
conducted in low or middle income countries. 50% 
of the 12 new studies were conducted in low and 
middle income countries, up from just 32% of those 
included in the original meta-analysis.
8. The studies included in the meta-analysis account 
for 109,952 older people ‘at risk’, representing 
332,323 person-years of follow-up. The Western 
European studies account for 42% of the total 
person years, the North American studies 24%, 
the East Asian studies 16%, and the Latin 
American studies 13%. Just 5% of person-years 
are contributed by the studies from Australasia, 
Asia Pacific, South Asia and sub-Saharan Africa 
combined.
 
CHAPTER 4
Trends in the prevalence and incidence of 
dementia, and survival with dementia
1. Almost all current projections of the coming 
dementia epidemic assume that age- and gender-
specific prevalence of dementia will not vary over 
time, and that population ageing alone drives the 
projected increases. In reality, future prevalence 
could be affected by changing incidence and 
disease duration.
2. The prevalence of any condition is a product of 
its incidence and the average duration of the 
disease episode. Changes in either or both of these 
indicators could lead to changes in age-specific 
prevalence. Trends in the two indicators may not 
move in the same direction; for example, reductions 
in incidence might be accompanied by increases in 
duration of survival with dementia, or vice versa, the 
one effect tending to cancel out the other in terms of 
their overall impact on prevalence. 
3. One should not expect that secular trends will be 
the same across all world regions, or even among 
different population subgroups within one country. 
Experience with changing rates of cardiovascular 
disease, obesity, diabetes and cancer shows this 
clearly. The considerable variability in secular trends 
for these chronic diseases reflect different degrees 
of progress in improving public health, and in 
improving access to healthcare and strengthening 
health systems and services to better detect, treat 
and control these conditions.
4. In order to investigate this assumption, studies of 
secular trends in dementia prevalence, incidence 
and mortality were identified from the systematic 
review of dementia prevalence studies, from the 
reference lists of these studies, and by conducting a 
search using the terms “(dementia or alzheim*) and 
(mortality or survival) and trend*”.
5. Findings across the identified studies (mostly 
conducted in high income countries) are currently 
too inconsistent to reach firm and generalisable 
conclusions regarding underlying trends. Three 
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studies are reporting significant or non-significant 
decline in the prevalence of dementia (MRC-CFAS 
(UK), Zaragoza (Spain) and HRS (USA)) while other 
studies from Sweden and USA indicated a stable 
prevalence of dementia. Another Swedish study 
and two Japanese studies of trends in dementia 
prevalence reported that prevalence had increased.  
6. There has been a general trend in many high income 
countries towards less smoking, lower cholesterol 
and blood pressure, and increased physical activity. 
On the other hand, the prevalence of obesity and 
diabetes has been increasing. To the extent to which 
these factors are causally associated with dementia, 
one would expect to see corresponding changes in 
dementia incidence.
7. In many low and middle income countries, the 
trends in cardiovascular health among older 
people are in an adverse direction, with a pattern 
of increasing stroke, and ischaemic heart disease 
morbidity and mortality, linked to an epidemic of 
obesity, and increasing blood pressure levels. This 
could result in upward trends in the incidence and 
prevalence of dementia in LMIC.
8. Since most of the public health interventions that 
have been proposed to reduce the incidence of 
dementia also have benefits in reducing incidence 
and mortality from other chronic diseases, one 
should expect that reductions in prevalence arising 
from reduced incidence of dementia may be offset, 
at least to some extent, by reduced mortality and 
longer survival with dementia.
9. One indicator of successful dementia risk 
reduction is deferral of dementia incidence to older 
ages. By increasing the average age of onset, 
dementia mortality may increase and duration 
of survival with dementia fall, without changing 
age-specific mortality for people with dementia. 
This phenomenon – described by Langa as ‘the 
compression of cognitive morbidity’ – is a desirable 
outcome for public health and individual quality of 
life, as it represents dementia onset occurring closer 
to the ‘natural’ end of life.
10.Studies that use fixed methodology to estimate 
changes in dementia prevalence, incidence and 
mortality over time, in defined populations, are 
uniquely valuable assets. It is important in the future 
that more such studies are commissioned.
11. Previous modelling exercises have sought to predict 
future trends in dementia prevalence, given our best 
estimates of risk associations and changes in risk 
factor profiles over time. In the light of the current 
review, these estimations appear over-optimistic. 
An alternative approach is to observe and correlate 
actual changes in risk factor profiles and dementia 
incidence over time. Similar studies could, in the 
future, be carried out to monitor the impact of 
prevention programs on the future scale of the 
dementia epidemic. 
CHAPTER 5
The impact of dementia worldwide
1. The impact of dementia can be understood at three 
inter-related levels: the individual with dementia, 
their family and friends, and wider society.
2. While dementia does shorten the lives of those 
affected, its greatest impact is upon quality of life, 
both for individuals living with dementia, and for 
their family and carers.
3. Global Burden of Disease (GBD) estimates express 
disease ‘burden’ in terms of associated disability 
and mortality. The key indicator – disability adjusted 
life years (DALYs) – is calculated as the sum of Years 
Lived with Disability (YLD) and Years of Life Lost 
(YLL), thus reflecting disease effect on both quality 
and quantity of life.
4. Revised GBD estimates using Institute of Health 
Metrics and Evaluation (IHME) disability weights 
have caused dementia to fall from 5th to 9th most 
burdensome condition for people aged 60 years 
and over. While burden from years of life lost (YLL) 
remains stable across the two methodologies, there 
has been a substantial reduction in the estimation 
of years lived with disability attributed to dementia, 
with a knock-on effect on the DALY estimates. Per 
capita, the IHME GBD estimates of YLL are 0% 
lower than WHO GBD estimates, YLD 65% lower, 
and DALYs 54% lower. This is, for the most part, 
because of changes in disability weights, which are 
2/3 lower for the IHME than the WHO GBD, rather 
than in the estimates of the frequency of these 
disorders.
5. The most important critique of the GBD estimates 
is that they fail to capture the full impact of chronic 
diseases on disability, needs for care, and attendant 
societal costs. This limitation is most significant for 
older people and for conditions like dementia, where 
most of the impact comes from disability rather 
than associated mortality. Failure to reflect societal 
impacts of dementia relative to other chronic 
diseases makes the GBD estimates an unreliable 
tool for prioritising research, prevention, and health 
or social care among older people.
6. A UK study has estimated that the health and 
social care costs for dementia almost match the 
combined costs of cancer, heart disease and stroke. 
In a Swedish study, the annual costs of dementia 
exceeded those of depression, stroke, alcohol 
abuse and osteoporosis. An analysis using data 
from the 10/66 Dementia Research Group baseline 
surveys in Latin America, India and China found that 
the directly attributable cost of dementia exceeded 
that of depression, hypertension, diabetes, 
ischaemic heart disease and stroke in all countries 
except India.
7. Dementia is typically associated with particularly 
intense needs for care, exceeding the demands 
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associated with other conditions. In the USA, 
caregivers of people with dementia were more likely 
to be required to provide help with getting in and 
out of bed, dressing, toileting, bathing, managing 
incontinence and feeding than caregivers of people 
with other conditions.
 
CHAPTER 6
The worldwide costs of dementia
1. The estimates of global societal economic costs 
of dementia provided in this report have been 
generated using the same general approach as 
for the World Alzheimer Report 2010. Costs are 
estimated at the country level and then aggregated 
in various combinations to summarise worldwide 
cost, cost by Global Burden of Disease world 
region, cost by World Bank country income level, 
and cost for G7 and G20 countries.
2. For each country, we have estimated cost per 
person (per capita), which is then multiplied by 
the number of people estimated to be living with 
dementia in that country. Per capita costs are 
divided into three cost sub-categories: direct 
medical costs, direct social care costs (paid and 
professional home care, and residential and nursing 
home care) and costs of informal (unpaid) care. 
Informal care is valued using an opportunity cost 
approach, valuing hours of informal care by the 
average wage for each country.
3. The global costs of dementia have increased from 
US$ 604 billion in 2010 to US$ 818 billion in 2015, an 
increase of 35.4%. Our current estimate of US$ 818 
billion represents 1.09% of global GDP, an increase 
from our 2010 estimate of 1.01%. Excluding informal 
care costs, total direct costs account for 0.65% of 
global GDP.
4. Regional distribution of costs has not changed 
markedly from those published in 2010. Cost 
estimates have increased for all world regions, 
with the greatest relative increases occurring in the 
African and in East Asia regions (largely driven by 
the upwards revision of prevalence estimates for 
these regions).
5. Distribution of costs between the three major sub-
categories (direct medical, social care, and informal 
care) has not changed substantially. As reported in 
2010, direct medical care costs is modest account 
for roughly 20% of global dementia costs, while 
direct social sector costs and informal care costs 
each account for roughly 40%.
6. As country income level increases, the relative 
contribution of direct social care sector costs 
increases and the relative contribution of informal 
care costs decreases. The relative contribution of 
informal care is greatest in the African regions and 
lowest in North America, Western Europe and some 
South American regions, while the reverse is true for 
social sector costs.
7. These new estimates should be seen as a partial 
update of the previous (2010) estimates, rather than 
a full-scale revision. We did not carry out a fully 
systematic review of service utilisation and cost of 
illness studies, but these estimates do benefit from 
a fully systematic review of dementia prevalence 
studies, and we have identified several important 
cost of illness studies published since 2010.
 
CHAPTER 7
Conclusions and recommendations
1. We estimate that there are now 46.8 million people 
with dementia worldwide, with numbers projected 
to almost double every 20 years. There will be an 
estimated 9.9 million new cases of dementia in 
2015, equivalent to one every 3.2 seconds. The 2015 
global societal economic cost of dementia will be 
an estimated US$818bn, with huge quality of life 
impacts both for individuals living with dementia and 
for their families and carers.
2. In December 2013, the UK government used its 
presidency of the G8 (now the G7) to launch a 
Global Action Against Dementia. The outcome of 
the first summit was an impressive commitment to 
identifying a cure or disease-modifying therapy for 
dementia by 2025. This was supported by a series 
of initiatives linked to research: increase funding, 
promote participation in trials, and collaborate to 
share information and data.
3. Over the course of four ‘Legacy Events’, this agenda 
has broadened substantially. The broader agenda 
comprises five key elements: a global approach to a 
global problem; the need for ‘care now, if cure later’; 
a public health orientation (awareness, accessible 
services, and prevention); a focus on equity 
and rights; and a rational approach to research 
prioritisation.
4. Earlier this year, as a final event linked to the G7 
Global Action Against Dementia, the World Health 
Organization convened a ‘First WHO Ministerial 
Conference on Global Action Against Dementia’. The 
resulting ‘call for action’ identifies eight overarching 
principles and eleven action points for the global 
fight against dementia.
5. Alzheimer’s Disease International applauds the 
action taken by the G7 in launching a ‘Global Action 
Against Dementia’, and calls for this initiative to 
be continued with a broader agenda and wider 
representation from the countries and regions most 
affected by the ongoing dementia epidemic. Since 
92% of global dementia costs arise in the G20 
countries, we advocate for a transfer of political 
leadership to the full G20 group of nations.
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6. Alzheimer’s Disease International has proposed 
elements that should be part of a call for action 
at global and country levels, including awareness 
raising, dementia friendly communities, workforce 
strategies and good quality care. 
7. Dementia risk reduction should be made an 
explicit priority in the general work stream on non-
communicable diseases led by the World Health 
Organization, with clear linked actions including 
targets and indicators.
8. Research investment for dementia should be 
upscaled, proportionate to the societal cost of 
the disease. This research investment should be 
balanced between prevention, treatment, cure and 
palliative care. A specific work stream should be 
established for low and middle income countries, 
involving partners from these countries to develop 
programmes that raise awareness of dementia and 
improve health system responses.
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The World Alzheimer Report 2015 comprises an 
overview of current knowledge regarding the evolution 
of the dementia epidemic worldwide. For this purpose, 
we have updated our previous estimates of the global 
prevalence of dementia, and numbers affected 
(previously published in the World Alzheimer Report 
2009(1)), the incidence of dementia (WHO/ADI report 
2012(2)), and the Global Economic Impact of Dementia 
(World Alzheimer Report 2010(3)). As a new feature, we 
have included a systematic review of the evidence for 
and against recent trends over time in the prevalence 
and incidence of dementia. We have also reviewed the 
broader societal impact of dementia, compared with 
that of other chronic diseases, and how this is best 
measured.
The focus, as with previous reports, is upon people 
aged 60 years and over. Younger onset dementia is, 
thankfully, a rare condition, accounting according to 
previous estimates, for some 2-8% of all cases(2;4). The 
proportion may well be higher in countries in Southern 
Africa with a high seroprevalence of HIV infection(2). We 
did not find any new evidence to revise our previous 
estimates in this area, and more research is required. 
We address some of the particular needs of younger 
people living with dementia in the recommendations at 
the end of this report.  
As with all previous reports, we have tried to provide 
a global perspective throughout, with particular 
attention to low and middle income countries, where 
most older people, and most people with dementia 
live. In the preparation of this report, one issue that 
we had to address was that the distinction between 
‘low and middle income countries’ and ‘high income 
countries’ is not static, the classification of countries 
having changed significantly since 2009. This is one 
aspect of the current rapid pace of global transition, 
with changes in demography, health, and human and 
economic development. We therefore begin the report 
with a brief overview of some of the trends that are 
apparent, their global distribution, and likely future 
impact.
1.1 Dementia in a rapidly 
changing world 
The world’s older population currently comprises 
nearly 900 million people. Most live in what are 
currently relatively poor countries. Mortality rates 
among older people are falling, and life expectancy 
from age 60 continues to increase in all world regions, 
with no upper limit in sight (population ageing or 
the ‘demographic transition’). As people live longer, 
so chronic diseases become more prevalent, a 
trend exacerbated by changes towards lifestyles 
and behaviours that predispose towards them. This 
‘epidemiologic transition’, linked to increases in high 
fat, salt and sugar diets, sedentariness, and tobacco 
use, is particularly evident in middle income countries. 
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With urbanisation, and economic and industrial 
development, traditional societies are needing to 
adapt to rapidly changing circumstances. This ‘social 
transition’ is less often discussed, but is as profound 
in its impacts as the accompanying demographic and 
epidemiologic change. This is the context in which the 
coming dementia epidemic, largely concentrated in 
what are now considered to be low and middle income 
countries, will play out.
1.2 Economic development 
Each year the World Bank publishes a revised list of 
country income levels, dividing economies into four 
groups according to their Gross National Income 
(GNI) per capita. This index of average income is 
a general indicator of development status; people 
living in countries with higher GNI per capita tend to 
have longer life expectancies, higher literacy rates, 
better access to safe water, and lower infant mortality 
rates. The four groups are low income countries (LIC), 
lower middle income (L-MIC), upper middle income 
(UMIC), and high income countries (HIC). The first 
three of these groups (LIC, L-MIC and UMIC) are 
sometimes referred to as ‘developing economies’, 
or ‘developing countries’, and HIC as ‘developed 
economies/countries’, although this terminology is 
now considered controversial (the World Bank refers 
to economies rather than countries – in this report we 
have used ‘countries’ as a general term although some 
may be considered regions or territories). In 2009 the 
income thresholds were; LIC, $995 or less; L-MIC, 
$996-$3,945; UMIC, $3,946-$12,195; and HIC, $12,196 
or more. These thresholds are revised upwards for 
inflation so that by 2015 they were LIC, $1,045 or 
less; L-MIC, $1,046-4,125; UMIC $4,126-$12,735; HIC, 
$12,736 or more. The transitions between income 
categories provide a broad indication of the global 
pace of economic development. In all, 41 countries 
have achieved a higher income classification since 
2009 (14 have moved from LIC to L-MIC, 17 from 
L-MIC to UMIC, and 10 from UMIC to HIC). None have 
moved in the reverse direction, although South Sudan, 
originally part of Sudan, a L-MIC, has been reclassified 
as a LIC. The overall effect therefore is that fewer 
countries are now LIC or L-MIC, and more are UMIC  
or HIC.
1.3 Population ageing in a 
developing world
The effect of these revisions upon the older population, 
and its global distribution, is summarised in Table 
1.2. In this table, we indicate the distribution of the 
world’s older population in 2010, according to the 2009 
World Bank classification, which was applied for that 
year’s World Alzheimer Report. 70% of older people 
were living in low or middle income countries. If the 
same 2009 classification were applied to the -regional 
distribution of older people in 2015, then this proportion 
would have increased to 71%. However, because of 
upwards reclassification of 41 countries, when the 
new 2015 classification is applied, the proportion living 
in what are now considered low and middle income 
countries (LMIC) falls to 65%. Within LMIC, there has 
been a dramatic reduction in the proportion of older 
people living in what are now considered to be LIC 
and L-MIC, and a large increase in the proportion living 
in what are considered to be UMIC. These shifts are 
largely explained, given their very large population 
sizes, by the transition of Bangladesh from a LIC to a 
L-MIC, and of China from a L-MIC to an UMIC. 
If we apply the current 2015 World Bank classification 
to projections of population growth from 2015 to 2050, 
we can see that the proportion living in what are now 
considered LMIC will increase from 65% in 2015 to 
71% in 2030 and 76% in 2050. This is explained by 
more rapid population ageing in what are currently 
poorer, compared with what are currently richer, 
parts of the world. Through to 2050, numbers of older 
people are forecast to increase by just 56% in HIC, 
but by 138% in UMIC, 185% in L-MIC and by 239% 
(a more than threefold increase) in LIC. Population 
ageing is a crucial factor in determining the future 
global distribution of the dementia epidemic, given 
that age is the strongest risk determinant; more older 
people means more people at higher risk of developing 
the condition. Population ageing has another aspect; 
while older people are living longer, fertility rates are 
Table 1.1 
Transitions between income categories (World Bank 
Classifications 2009 and 2015)
LIC to L-MIC
14 countries
L-MIC to UMIC
17 countries
UMIC to HIC
10 countries
Bangladesh
Ghana
Guatemala
Kenya
Kyrgyz Republic
Lao PDR
Mauritania
Myanmar
Senegal
Tajikistan
Yemen
Zambia
Uzbekistan
Vietnam
Albania
Angola
Azerbaijan
Belize
China
Ecuador
Iran
Iraq
Jordan
Maldives
Marshall Islands
Mongolia
Paraguay
Thailand
Tonga
Tunisia
Turkmenistan
Argentina
Chile
Latvia
Lithuania 
Poland
Russia
Seychelles
St Kitts and Nevis
Uruguay
Venezuela, RB
7The Global ImpacT of DemenTIa
alzheImer’s DIsease InTernaTIonal: WorlD alzheImer reporT 2015
declining in most countries. Therefore, older people 
come to constitute a higher proportion of the total 
population. These trends are displayed in Figure 1.1, 
for the world population, and for the countries that 
are currently considered LIC, L-MIC, UMIC and HIC. 
In 2015, worldwide, 12.2% of the population is aged 
60 years or over. This proportion is highest in HIC and 
lowest in LIC; the country with the highest percentage 
of older people is Japan (33.2%), and the lowest is 
Uganda (3.7%). The stratification by country income 
level persists to 2050, with a range from 42.7% (Japan) 
to 5.1% (Mali). However, the process of population 
ageing, when expressed in these terms, will be most 
rapid in what are now UMIC, which will have nearly 
‘caught up’ with HIC by 2050. 
1.4 Most lower income countries 
will remain relatively poor, and 
face particular challenges
The projections provided above, stratified by country 
income level, fail to take into account continued 
economic development, which, barring catastrophes, 
should see more and more countries and their 
populations lifted out of poverty. Perusal of the World 
Bank list of promoted countries (Table 1.1) reveals 
several that have achieved this despite war, sanctions 
and political and economic upheaval.
Nevertheless, we believe that it is instructive and 
valid to consider the likely future evolution and impact 
of the epidemic in countries that are currently LIC, 
L-MIC, UMIC and HIC (see Chapter 2 on prevalence 
and numbers, and Chapter 6 on economic costs). 
Poorer countries evidently have fewer economic and 
human professional resources to meet the health 
and social care needs of their rapidly growing older 
populations. These profound structural limitations are 
not resolved with a few dollars increase in average 
income, albeit that this may be sufficient to cross a 
World Bank threshold (the current threshold for high 
income country status is less than a quarter, and that 
for UMIC status less than one fourteenth, of the per 
capita GNI for the USA). Many face the challenge of a 
‘double burden’ of persistently high rates of maternal, 
childhood and infectious diseases, combined with 
a growing epidemic of chronic non-communicable 
diseases, including cardiovascular diseases, cancer, 
diabetes and dementia. Figure 1.2 illustrates the 
significant burden of chronic disease already evident 
among older people living in low and middle income 
countries(5). Differences in population size are adjusted 
for by expressing the burden (Disability Adjusted 
Life Years – see Chapter 5) per 1,000 older people. 
While the impact of infectious diseases is many times 
greater in low and middle income countries than in 
HIC, the impact of cancer is only slightly less, and that 
of diabetes, chronic respiratory and cardiovascular 
disease is greater.   
Table 1.2  
The world’s population of older people (age 60 and over, millions), and their distribution according to country income level (World 
Bank Classification 2009 and 2015)
Current and projected numbers of older people (% of total population) % increase over time
Year 2010 2015 2030 2050 2015-2030 2015-2050
World Bank income 
classification
2009 2009 2015 2015 2015 2015 2015
HIC 232.3 (30.4%) 258.7 (28.9%) 309.4 (34.6%) 403.9 (29.4%) 482.5 (23.9%) 31% 56%
UMIC 116.4 (15.2%) 135.3 (15.1%) 319.8 (35.7%) 531.5 (38.7%) 760.8 (37.7%) 66% 138%
L-MIC 356.2 (46.6%) 431.7 (48.2%) 233.1 (26.0%) 386.0 (28.1%) 665.3 (32.9%) 66% 185%
LIC 59.8 (7.8%) 69.5 (7.8%) 32.9 (3.7%) 53.5 (3.9%) 111.4 (5.5%) 63% 239%
World 764.7 (100%) 895.2 (100%) 1347.8 (100%) 2020.0 (100%) 51% 126%
Figure 1.1  
Percentage of the total population aged 60 years and over, 
by country income level, 2015 to 2050
35
30
25
20
15
10
5
0
2015 2030 2050
LIC 5.2 6.0 8.4
L-MIC 8.1 11.2 16.3
UMIC 13.3 20.5 28.9
HIC 22.0 27.3 31.6
World 12.2 16.3 21.2
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With the demographic and health transitions come 
profound social as well as economic change. Rapidly 
declining fertility rates, the increased participation 
of women in the labour force, urbanisation and 
migration for work are all trends conspiring to reduce 
the availability of traditional informal family care(6). 
Even with the unprecedented benefits of double digit 
annual economic growth, rapidly developing countries 
in Asia and Latin America have struggled to establish 
comprehensive and effective systems of social 
protection for older people, guaranteeing adequate 
income, and universal access to health and social  
care(7-9) Overall economic growth at the national level 
can conceal gross inequities in income distribution, 
and it is probably fair to say that older people are often 
among the least likely and the last to benefit directly. 
 
References
1 Alzheimer’s Disease International. World Alzheimer Report 2009. 
London: Alzheimer’s Disease International; 2009. 
2 World Health Organization. Dementia: a public health priority. 
Geneva: World Health Organization; 2012. 
3 Wimo, A. and Prince M. World Alzheimer Report 2010; The Global 
Economic Impact of Dementia. London: Alzheimer’s Disease 
International; 2010. 
4 Prince, M., Knapp, M., Guerchet, M., McCrone, P., Prina, M., 
Comas-Herrera, A., Wittenberg, R., Adelaja, B., Hu, B., King, D., 
Rehill, A., and Salimkumar, D. Dementia UK: Update. London: 
Alzheimer’s Society; 2014. 
5 Prince MJ, Wu F, Guo Y, Gutierrez Robledo LM, O’Donnell M, 
Sullivan R et al. The burden of disease in older people and 
implications for health policy and practice. Lancet 2015 February 
7;385(9967):549-62.
6 Prince M, Acosta D, Albanese E, Arizaga R, Ferri CP, Guerra M 
et al. Ageing and dementia in low and middle income countries-
Using research to engage with public and policy makers. Int Rev 
Psychiatry 2008 August;20(4):332-43.
7 Cecchini, S. and Martinez, R. Inclusive Social Protection in Latin 
America: A Comprehensive, Rights-based Approach. Santiago, 
Chile: United Nations; 2012. 
8 Pozen, R. C. Tackling the Chinese Pension System. Chicago: The 
Paulson Institute; 2013. 
9 Gan, L. Income Inequality and Consumption in China.  Texas 
A&M University, USA and Southwestern University of Finance and 
Economics, Chengdu, China; 2013. 
900
800
700
600
500
500
300
200
100
0
High Income Low & Middle  
Income
■ Sensory
■ Respiratory Infection
■ Digestive
■ Diabetes
■ Unintentional Injury
■ Infection
■ Mental & Neurological
■ Musculoskeletal
■ Chronic Respiratory
■ Cancer
■ Cardiovascular
Figure 1.2  
Leading contributors to burden of disease among people 
aged 60 years and over - DALYs (per 1000 population) among 
people aged 60 and over, by cause and income region 5
9The Global ImpacT of DemenTIa
alzheImer’s DIsease InTernaTIonal: WorlD alzheImer reporT 2015
chapTer 2
The global prevalence of dementia
2.1 Introduction
In the World Alzheimer Report 2009(1), ADI published 
estimates of the global prevalence of dementia based 
on a systematic review of 154 studies conducted 
worldwide since 1980, with prevalence estimates 
applied to United Nations population projections 
through to the year 2050. We estimated that 36 million 
people were living with dementia in 2010, nearly 
doubling every 20 years to 66 million by 2030 and to 
115 million by 2050. In 2013, for the G8 ‘Global Action 
Against Dementia’ summit in London, we carried out 
a limited update of the numbers published in 2009 
by incorporating new evidence from sub-Saharan 
Africa and China(2) and recently revised United Nations 
population estimates. Six years on from the last 
comprehensive review the global evidence-base has 
expanded considerably, and a full update is required. 
As stressed throughout this chapter, any changes in 
our estimates of age-specific or age-standardised 
prevalence likely reflect changes in the quality and/
or quality of evidence available, and should not be 
construed as implying that there has been a change 
in the true underlying prevalence of dementia in the 
regions concerned since 2009. However, increases in 
the numbers of people affected are to be expected, 
given significant increases in the size of the older 
population.
This report uses essentially the same method as we 
had previously used in the World Alzheimer Report 
2009 (see Methods section below). We have conducted 
a new, fully systematic review of the prevalence studies 
conducted worldwide from 2009. Studies conducted 
in China are often not available in English, as was 
demonstrated in two comprehensive reviews published 
in 2013(2-4). For this report, following the precedent 
established by these reviews, we searched Chinese 
databases to include all available evidence. The 
systematic review presented in this report is therefore 
both the most exhaustive and up to date review carried 
out on the prevalence of dementia worldwide. 
2.2 Methods
2.2.1 Search strategy
Two teams searched English and Chinese databases 
separately. The English language search updated the 
previous World Alzheimer Report review conducted in 
2009(5), by searching for studies published from 2009 
onwards, and the Chinese database search updated 
Wu et al.’s review conducted in 2012(2), by searching 
for studies published from 2011 onwards. The following 
search strategies were used.
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English Database Search 
Search date: February 2015 
Databases: EMBASE, Global Health, MEDLINE, 
PsychExtra and PsychInfo 
Search terms: dementia AND (prevalence OR 
epidemiology)
Chinese Database Search 
Search date: March 2015 
Databases: CNKI, Wanfang, Airti
Search terms: (癡呆/dementia OR 失智/dementia OR  
阿爾茨海默/Alzheimer) AND (患病率/prevalence OR  
盛行率/prevalence OR 流行/epidemiology)
The Chinese search team also reappraised, for 
eligibility, those Chinese language publications that 
had been included in the 2009 World Alzheimer Report, 
on the basis of a review published in 2007 of studies 
conducted in China between 1980 and 2004(6). This 
had not been possible in 2009.
2.2.2 Inclusion criteria
Population-based studies of the prevalence of 
dementia among people aged 60 years and over 
(according to DSM-IV or ICD-10 criteria, or similar pre-
existing clinical criteria), for which the field work started 
on or after 1st January 1980.
2.2.3 Exclusion criteria
•	 Base population
•	 Studies of prevalence from the follow-up phase 
(rather than the inception phase) of a population 
cohort
•	 Studies sampling from an out-of-date population 
register (prepared more than three years prior to 
the survey)
•	 Studies of nursing home or residential care 
populations
•	 Studies of primary care attendees or other 
unrepresentative service-user populations
•	 Ascertainment/outcome definition
•	 Studies in which the ascertainment of dementia 
depended upon help-seeking and/or receipt of 
dementia care services
•	 Studies in which ‘dementia’ was diagnosed 
purely on the basis of cognitive impairment, for 
example according to a cutpoint on the MMSE
•	 Studies of the prevalence of Alzheimer’s disease 
or other subtypes of dementia
•	 Studies restricted to young-onset dementia (up 
to 59 years of age)
2.2.4 Procedures
All stages of the search were completed by two 
reviewers. For the English search, all abstracts were 
read by GA and by either YW or MG. Papers were 
excluded at this stage only when the abstract clearly 
demonstrated that the paper did not meet the above 
criteria. Full texts of the remaining publications were 
read by GA and by either YW or MG, and a consensus 
decision was made on those that met all criteria. These 
papers were published in English, French, Spanish and 
Portuguese, all of which could be read by our team 
using translation programmes. The Chinese search 
was conducted independently by Dr Yu-Tzu Wu and Dr 
Kit Yee Chan, who compared their study selection at 
each stage of screening and review.
All eligible studies were systematically coded for their 
study design and quality according to the following 
criteria:
1 Country
2 WHO/Global Burden of Disease World Region (see 
Appendix A for list of countries and regions)
3 Inclusion of residents of long term care institutions
4 Start and finish dates for fieldwork, and census 
dates if provided
5 Lower and upper age limits
6 Sampling (simple random, stratified random, whole 
population, other)
7 Design (one phase/two phase/three phase)
8 Overall sample size (first phase)
9 Numbers interviewed (first phase) and proportion 
responding
10 For two-phase surveys only
a. Numbers selected for the second phase (for two 
phase surveys)
b. Numbers interviewed (second phase) and 
proportion responding
c. Screen negatives sampled for the second phase 
(yes/no)
d. Screen negatives given same assessment as 
screen positives (yes/no)
e. Weighting back carried out (no weighting back/ 
appropriate weighting back/no weighting back, 
but no false positives)
f. Time interval between first and second phase
g. Screening instrument/s
11 Diagnostic criteria (not specified, ICD, DSM, GMS/
AGECAT, CAMDEX, other clinical criteria)
12 Use of multidomain cognitive assessment, 
informant interview, disability assessment, 
neuroimaging
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An overall quality score was derived by summing 
scores for the following elements:
Sample size – <500, 0.5 points; 500-1499, 1 point; 
1500-2999, 1.5 points; >=3000 2 points
Design – Two-phase study with no sampling of screen 
negatives, 0 points; two-phase study with sampling 
of screen negatives but no weighting back, 1 point; 
one-phase study or two-phase study with appropriate 
sampling and weighting, 2 points
Response proportion – <60%, 1 point; 60-79%, 2 
points; >=80%, 3 points
Diagnostic assessment – one point each for 
multidomain cognitive test battery, formal disability 
assessment, informant interview and clinical interview 
2.2.5 Data extraction
Prevalence data was extracted from the studies as 
follows.
For unweighted prevalence, we extracted (according to 
the data presented in the paper) either numerator and 
denominator, prevalence and denominator, prevalence 
and standard error, or prevalence and 95% confidence 
intervals. Numerator and denominator could then be 
calculated from any of these combinations.
For weighted prevalence we extracted (according 
to the data presented in the paper) either weighted 
prevalence and weighted standard error, or weighted 
prevalence and weighted 95% confidence intervals. 
Effective numerators and denominators (taking into 
account the design effect) could then be calculated 
from either of these combinations.
Prevalence estimates were stratified differently in 
different publications. To maximise the precision of 
our meta-analysis, we required prevalence estimates 
in five-year age-bands, separately for men and women 
(age- and gender-specific prevalence). In practice, 
some studies:
a) Simply gave an overall prevalence for the whole 
sample, stratified by neither age nor gender
b) Provided gender-specific estimates, not stratified by 
age
c) Provided age-specific estimates, not stratified by 
gender
In each of the above scenarios, we wrote to the authors 
to request age- and gender-specific prevalence data. 
Prevalence data in formats a) and b) could not be used 
in our meta-analyses, since the main aim was to model 
the effect of age on dementia prevalence. Such studies 
therefore had to be excluded. Age-specific prevalence 
data (c) above) could be used, and these data were 
generally available or could be calculated from age- 
and gender-specific estimates. We could therefore 
model the effect of age on dementia prevalence for all 
included studies, and the effects of age and gender 
for the subset of studies that had provided age- and 
gender-specific estimates.     
2.2.6 Meta-analytical methods for 
estimating dementia prevalence within 
regions 
Within each GBD region where there was sufficient 
data to conduct a meta-analysis, we used a random 
effect exponential (Poisson) model to assess the effect 
of age, and of age and gender, on the prevalence 
of dementia. Random effects are assumed to have 
a gamma distribution – the alpha coefficient is an 
estimate of over-dispersion and an index of between-
study heterogeneity.
Age was coded as the mean for each reported age 
group. For high income countries, this was calculated 
from the US Census, while for low and middle income 
countries we estimated this as the mean observed 
in the relevant 10/66 Dementia Research Group 
population-based study(7). For SSA countries, this was 
calculated from the mean observed in four population-
based studies in West and Central Africa for which 
individual data was available(8-10). We ran two models 
for each region: one for the effect of age, and one for 
the effects of age, gender, and an interaction between 
age and gender. We then applied the relevant mean 
ages and gender codings to the coefficients estimated 
by the models, producing age- and gender-specific 
prevalence estimates in five year age-bands from 60-
89 years, and for those aged 90 and over.
2.3 Results
2.3.1 The extent of the evidence-base
The initial searches yielded 8,736 English abstracts 
and 1,941 Chinese abstracts (a total of 10,677 unique 
hits). Through screening the titles and abstracts, 
10,483 publications were excluded as clearly ineligible, 
leaving 194 publications for further review (160 from 
the English abstract search and 34 from the Chinese 
search). We obtained full texts of all the full published 
papers, which were then carefully assessed against 
inclusion/exclusion criteria. A further 129 publications 
were excluded at this stage, leaving 65 publications 
that were provisionally eligible for inclusion. For 10 of 
these publications, we could not include the data in the 
form in which it was provided in the publication, and 
authors did not respond to requests for age-stratified 
data. These publications were coded ‘pending’, 
awaiting clarification from authors. Finally, 55 new 
publications (included in neither the 2009 World 
Alzheimer Report, nor the Wu et al. 2013 review) were 
fully eligible for inclusion in the meta-analysis. The 
Chinese database search identified 10 new studies 
from China, and one from Taiwan, published since Wu 
et al.’s 2013 review. Three recent English language 
publications describing China studies were identified 
from the English database search. Four studies from 
12
the 2007 review(6) used for the 2009 report were 
found not to meet our inclusion criteria. However, an 
additional 28 publications identified in Wu et al.'s 2013 
review(2) would have been eligible for inclusion in the 
2009 review, had they been identified at that time. 
All in all, we identified 86 eligible publications for the 
East Asia region (72 from the Wu et al. review, and 14 
from the updated searches), referring to 89 studies. 
78 of these provided data in the form that could be 
used for the meta-analysis (we were unable to source 
age-stratified prevalence estimates for 6 studies, and a 
further 5 provided age-stratified prevalence estimates 
without information from which we could back-
calculate number of cases and denominator).
Combining the new studies with the results of the 
original systematic reviews(2, 5), we were left with 273 
studies potentially eligible for inclusion in the meta-
analysis, with 224 in the required data format to be 
included. For a complete list of studies included in 
and excluded from the meta-analysis, see the online 
appendix at www.alz.co.uk/research/world-report-2015
2.3.2 The coverage of the evidence-base
The number of studies identified in each GBD world 
region, and the number of older participants studied 
are listed in Table 2.1.  
Good to reasonable coverage was identified for 12 
of the 21 GBD regions. Three regions – East Asia (89 
studies), Western Europe (71 studies) and Asia Pacific 
High Income (30 studies) – account for the majority of 
the world’s studies. The next best represented regions 
are North America (16 studies) and Latin America 
Table 2.1  
Coverage, by region, with respect to size of elderly population
Region Over 60 year 
old population 
(millions)
Number of 
eligible dementia 
prevalence studies 
(additional studies 
since WAR 2009)
Number of 
studies/ 
10 million 
population
Total 
population 
studied
Total population studied/ 
million population
ASIA 485.83 144 (71) 3.0 420143 865
Australasia 5.80 4 (0) 6.9 2223 383
Asia Pacific, High 
Income
52.21 30 (8) 5.7 46843 897
Asia, Central 7.43 0 (0) 0 0 0
Asia, East 218.18 89 (55) 4.1 342231 1569
Asia, South 139.85 14 (7) 1.0 19673 141
Asia, Southeast 61.72 6 (1) 1.0 7144 116
Oceania 0.64 1 (0) 15.6 2029 3170
EUROPE 176.61 78 (17) 4.4 106909 605
Europe, Western 107.89 71 (15) 6.6 104447 968
Europe, Central 26.92 6 (2) 2.2 2462 91
Europe, Eastern 41.80 1 (0) 0.2 Not available Could not be calculated
THE AMERICAS 145.51 34 (6) 2.3 94875 643
North America 74.88 15 (2) 2.0 42361 548
Caribbean 5.78 5 (1) 8.7 24625 4260
LA, Andean 5.51 3 (0) 5.4 3465 629
LA, Central 24.64 6 (2) 2.4 12665 514
LA, Southern 9.88 1 (0) 1.0 4689 475
LA, Tropical 24.82 4 (1) 1.6 7070 285
AFRICA 87.19 17 (12) 1.9 18126 208
North Africa/ Middle 
East
38.93 6 (4) 1.5 8371 215
SSA, Central 4.78 4 (4) 8.4 3020 632
SSA, East 19.86 1 (1) 0.5 1198 60
SSA, Southern 6.06 1 (0) 1.7 150 25
SSA, West 17.56 5 (3) 2.8 5387 307
WORLD 895.14 273 (106) 3.0 640053 715
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if considered as a single region (14 studies). Other 
regions with reasonable coverage are South Asia (14 
studies), Southeast Asia (6 studies) and Australasia (4 
studies). Sparse coverage only was achieved in three 
regions: Central Europe (5 studies), and Eastern and 
Southern sub-Saharan Africa (1 study each). No eligible 
studies were identified for Central Asia.
The participants per million older population (Table 
2.1) provides an index of the research effort relative to 
the size and probable diversity of the countries and 
regions concerned. According to these criteria, broadly 
similar coverage was achieved in the Asia Pacific, East 
Asia, Western Europe, North America, Latin America 
and Caribbean regions. There was a higher density 
of studies in Western Europe, but these tended to be 
smaller in size than those in North America and East 
Asia. The greatest improvements in coverage since our 
2009 review have been seen in Central and Western 
sub-Saharan Africa, where coverage has improved 
from sparse to reasonable. Apart from the region with 
no studies (Central Asia), the regions that stand out as 
persistently lacking in research relative to population 
size are Central Europe, and Eastern and Southern 
sub-Saharan Africa. Despite reasonable coverage in 
terms of numbers of studies in South and Southeast 
Asia, these are still sparse with respect to population 
size.
Adequate coverage of large and populous countries 
such as the USA or China would require a large 
number of studies in different regions encompassing 
the racial, cultural, economic and social diversity of 
the nation as a whole. This has been achieved for 
China(3). The most informative approach would be a 
study of a nationally representative sample, but to our 
knowledge such studies have only been carried out 
in the USA(11) (but on a very small sample), Canada(12), 
Mexico(13), Korea(14) and Singapore(15). The MRC CFAS 
study in the UK(16) provides good coverage of different 
regions and urban and rural populations, but is not 
nationally representative. By the same token, studies 
carried out in just one or two countries may not safely 
be generalised to a large number of other countries in 
the same GBD region. For example, the Caribbean’s 
evidence base derives from three studies in Cuba, one 
in Jamaica, and one in the Dominican Republic. The 
remaining 24 Caribbean countries include some of 
the world’s poorest (Haiti) and richest (The Bahamas). 
They also differ markedly due to different colonial 
histories. Limits to generalisability are particularly 
significant when the few available studies are small, 
were conducted some time ago, and/or are of poor 
methodological quality. All of these limitations apply, 
for example, to the one study identified in Southern 
sub-Saharan Africa(17).
When the 10/66 Dementia Research Group was 
founded in 1998, the group’s name (10/66) referred to 
the 10% of population-based research that had been 
conducted in low and middle income countries (LMIC), 
relative to the two-thirds of people with dementia 
living in those regions. By 2009, the situation had been 
transformed – 65 of the 167 dementia prevalence 
studies (39%) had been conducted in LMIC. With 
the additional evidence unearthed from China, and 
the recent preponderance of studies from LMIC, the 
updated proportion for studies conducted through 
to 2015 is 52%. Of more concern is the finding that 
studies in high income countries peaked in the early 
1990s and declined sharply thereafter. This trend, 
noted in our 2009 report, has continued. From 1980-
1994, 35% of all studies were conducted in LMIC, 
Figure 2.1  
Numbers of prevalence studies, by year of data collection and income level of the country where the research 
was carried out  
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compared with 69% from 1995-2004 and 76% from 
2005 onwards. This has an impact, also on the recency 
of the evidence-base; in HIC 45% of all studies were 
conducted post-1995, compared with 76% of available 
studies from LMIC.
2.3.3 The quality of the research
The principal characteristics of the included studies are 
described in Table 2.2, by world region.
2.3.3.1 Study design
The major quality control issue concerns the use of 
surveys with two or more phases. Multiphase survey 
designs are popular in dementia research because of 
perceived efficiencies in interviewer time and cost. A 
fundamental and common error is to fail to submit a 
random sample of those scoring above the pre-defined 
cutpoint on the first phase screening assessment 
(‘screen-negatives’) to the same diagnostic 
assessment as ‘screen-positives’. No screening 
assessment is perfectly sensitive, and it is therefore 
likely that some cases of dementia will be missed in 
phase one. The correct procedure is to estimate the 
false positive rate among the screen negatives and 
then ‘weight back’, calculating an overall prevalence 
that accounts for the different sampling proportions of 
screen positives and screen negatives. Unfortunately, 
most investigators using a multiphase design did not 
sample screen negatives, and those that did often did 
not weight back appropriately. 77% of the dementia 
prevalence studies included in our meta-analysis used 
a multiphase design, yet only 17% of these correctly 
applied the design and appropriately analysed the 
results. This problem therefore affects 64% of all 
studies. Failure to include a sample of negative screens 
and weight back accordingly will produce results that 
tend towards an under-estimation of true dementia 
prevalence and an over-estimation of precision. Even 
when applied correctly, multiphase studies are often 
complicated by the relatively high levels of loss to 
follow-up that occur between screening and definitive 
diagnostic assessment(18); this is again likely to lead 
to bias, which could over- or under-estimate true 
prevalence(19). Of the studies conducted in the last ten 
years (since 2005), 78% used a multiphase design and 
of these only 11% applied it correctly. In this respect, 
study quality has clearly not improved since our 2009 
meta-analysis.
2.3.3.2 Scope of definitive diagnostic 
assessment
Dementia diagnosis requires demonstration of 
cognitive impairment (and decline from a previous 
level of functioning) in memory and other domains of 
intellectual function, and demonstration of consequent 
social or occupational impairment. Other causes of 
cognitive and functional impairment, such as functional 
psychosis, depression and delirium, should be 
excluded. A diagnostic assessment should therefore 
include multi-domain cognitive testing, disability 
assessment, a clinical interview and an informant 
interview. Overall, only 34% of all included studies 
fully met this requirement. Informant interviews were 
the most commonly missed element. The effect of 
applying a less thorough diagnostic assessment 
of dementia prevalence is uncertain. In principle it 
could lead to either under- or over-estimation of true 
prevalence. Looking only at studies conducted since 
2005, the proportion with a comprehensive diagnostic 
assessment rises to 52%. Study quality in this respect 
does appear to be improving, although the informant 
interview is still too often missing.
2.3.3.3 Sample size
Over half (52%) of all eligible studies had sample sizes 
smaller than 1500, and this figure rises slightly to 54% 
when considering studies conducted since 2005. 
Nearly a third of Western European studies had sample 
sizes smaller than 500, though of the recent studies 
this falls to less than a quarter. East Asia (China, 
Hong Kong and Taiwan) contributed a relatively high 
proportion of the large studies sampling over 3000 
people. Sample sizes tended to be larger in studies 
conducted in LMIC. In principle, sample size should 
not have any consistent effect on prevalence, although 
larger studies will estimate prevalence with greater 
precision. A study of 500 participants could estimate 
a true prevalence of 6% with a precision of +/- 2.1%. 
Precision increases to +/- 1.2% for a sample size of 
1500 and to +/- 0.8% for a sample size 
2.3.3.4 Response proportion
Those who cannot be contacted or do not consent to 
take part in a survey may have different characteristics 
from those included in the final sample. People with 
dementia may be under-represented in the interviewed 
sample, due to relatives being reluctant for them to 
participate or because those that consent to participate 
find it more difficult to complete the questionnaires. 
Alternatively, they may be over-represented due 
to an increased likelihood of people with dementia 
being at home when interviewers call. The direction 
of the bias is hard to predict, but studies with higher 
proportions of participants responding should provide 
more accurate prevalence estimates. Participation 
rates in the studies included in our meta-analysis 
were generally adequate to good; only 13 studies
(5%) reported fewer than 60% of eligible participants 
responding, while more than half (58%) reported 80% 
or more responding. Response proportions seem to 
be slightly higher for studies carried out since 2005. 
However, in some studies conducted in high income 
countries, response proportions have declined over 
time(20).
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Western 
Europe
Central Europe North America Latin America 
and Caribbean
Asia Pacific 
High Income
Austral-asia Asia, East Asia, South Asia, South 
East
Sub-Saharan 
Africa
HIC LMIC All regions
Total Number  of studies1 65 4 14 18 24 4 82 11 6 9 117 130 247
Year of Research
1980-1989 13 (20%) 0 3 (21%) 0 7 (29%) 2 (50%) 4 (5%) 2 (19%) 1 (17%) 0 25 (21%) 7 (5%) 32 (13%)
1990-1999 37 (57%) 1 (25%) 9 (64%) 3 (16%) 10 (42%) 1 (25%) 36 (44%) 4 (36%) 2 (33%) 1 (11%) 64 (55%) 43 (33%) 107 (43%)
2000-09 10 (15%) 2 (50%) 2 (14%) 13 (72%) 6 (25%) 1 (25%) 24 (29%) 7 (64%) 3 (50%) 4 (45%) 21 (18%) 56 (43%) 77 (31%)
2010 onwards 3 (5%) 0 0 1 (6%) 1 (4%) 0 12 (15%) 0 0 3 (33%) 5 (4%) 15 (12%) 20 (8%)
Not specified 2 (3%) 1 (25%) 0 1 (6%) 0 0 6 (7%) 0 0 1 (11%) 2 (2%) 9 (7%) 11 (5%)
Sample size
<500 20 (31%) 1 (25%) 0 1 (6%) 3 (13%) 2 (50%) 10 (12%) 2 (19%) 1 (17%) 1 (11%) 28 (24%) 15 (12%) 43 (17%)
500-1499 25 (38%) 3 (75%) 4 (28%) 6 (35%) 8 (35%) 2 (50%) 21 (26%) 4 (36%) 4 (66%) 7 (78%) 43 (37%) 43 (33%) 87 (35%)
1500-2999 11 (17%) 0 5 (36%) 8 (47%) 7 (30%) 0 33 (40%) 4 (36%) 1 (17%) 1 (11%) 25 (21%) 51 (39%) 75 (30%)
>=3000 9 (14%) 0 5 (36 %) 2 (12%) 5 (22%) 0 18 (22%) 1 (9%) 0 0 21 (18%) 21 (16%) 42 (17%)
Outcome
ICD-10 1 (1%) 1 (25%) 1 (7%) 0 1 (4%) 0 5 (6%) 2 (18%) 0 1 (11%) 5 (4%) 9 (7%) 14 (6%)
DSM-IV/ III-R 48 (74%) 2 (50%) 9 (64%) 11 (61%) 21 (88%) 3 (75%) 63 (77%) 6 (55%) 4 (67%) 7 (78%) 87 (74%) 93 (72%) 180 (73%)
GMS/ AGECAT 3 (5%) 0 1 (7%) 0 0 0 2 (2%) 0 2 (33%) 0 4 (3%) 4 (4%) 8 (3%)
CAMDEX 7 (11%) 1 (25%) 0 0 0 0 0 0 0 0 8 (7%) 1 (1%) 9 (4%)
Other 6 (9%) 0 3 (21%) 7 (39%) 2 (8%) 1 (25%) 12 (15%) 3 (27%) 0 1 (11%) 13 (11%) 23 (18%) 36 (15%)
Design
1 phase 21 (32%) 1 (25%) 2 (14%) 10 (56%) 4 (17%) 3 (75%) 9 (11%) 3 (27%) 1 (17%) 2 (22%) 32 (27%) 25 (19%) 57 (23%)
2+ phases 44 (68%) 3 (75%) 12 (86%) 8 (44%) 20 (83%) 1 (25%) 73 (89%) 8 (73%) 5 (83%) 7 (78%) 85 (73%) 105 (81%) 190 (77%)
Multiphase design applied 
and analysed correctly2
20% 33% 50% 38% 15% 100% 5% 0% 0% 40% 24% 12% 17%
Response Proportion
<60% 8 (12%) 1 (25%) 1 (7%) 0 0 0 1 (1%) 0 0 0 11 (9%) 2 (2%) 13 (5%)
60-79% 26 (40%) 1 (25%) 6 (43%) 3 (17%) 5 (21%) 2 (50%) 10 (12%) 2 (18%) 1 (17%) 1 (11%) 42 (36%) 18 (14%) 59 (24%)
80-100% 29 (45%) 2 (50%) 5 (36%) 12 (66%) 12 (50%) 2 (50%) 58 (71%) 7 (64%) 2 (33%) 8 (89%) 52 (44%) 89 (69%) 142 (58%)
Not specified 3 (5%) 0 2 (14%) 3 (17%) 7 (29%) 0 13 (16%) 2 (18%) 3 (50%) 0 12 (10%) 21 (16%) 33 (13%)
Assessment Quality
Comprehensive diagnostic 
assessment3
37 (57%) 0 6 (43%) 13 (72%) 5 (21%) 0 12 (15%) 5 (45%) 1 (17%) 9 (100%) 50 (43%) 35 (27%) 84 (34%)
Overall Quality Score4
Mean (SD) 8.1 (1.7) 6.4 (2.1) 8.3 (1.6) 9.5 (1.8) 7.0 (1.6) 8.3 (0.9) 6.2 (1.8) 8.2 (1.8) 6.0 (0.9) 9.0 (0.8) 7.8 (1.7) 7.1 (2.3) 7.4 (2.0)
Table 2.2  
Study characteristics, by region and by country income level
1  These numbers differ from the totals listed in Table 2.1, as we 
were not able to ascertain some or all study characteristics for 
some of the ‘pending’ studies, about which we were seeking 
further information from authors.
2  As a proportion of all studies using a multiphase  design (i.e. with two or 
more phases, with screening performed on all in the first phase,  
and definitive diagnostic assessment on a sub-sample based on 
screening score)
3  Defined as a multi-domain cognitive battery, an informant 
interview, a formal assessment of disability, and a clinical 
interview
4  Derived from sample size, design, response proportion  
and assessment quality (see text for details)
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2.3.3.5 Overall quality
Mean scores for our quality index varied significantly 
between regions. Overall study quality was especially 
high in Latin America and sub-Saharan Africa, and 
particularly poor in East Asia, Southeast Asia, Central 
Europe and the Asia Pacific High Income regions. 
Study quality did not differ significantly between high 
income and low/middle income countries. Despite lack 
of progress regarding appropriate use of multiphase 
design, there remains a pronounced tendency for 
overall study quality to have improved over time.
2.3.4 Meta-analysis of dementia 
prevalence within GBD regions
We considered the evidence-base to be sufficient 
in terms of coverage and the number and quality 
of studies to conduct meta-analyses for 16 of the 
21 GBD regions: Western Europe, Central Europe, 
North America, Latin America (combining the Latin 
American Andean, Central, Southern and Tropical 
regions), Asia Pacific High Income, Australasia, East 
Asia, Southeast Asia, South Asia and sub-Saharan 
Africa (combining the central, southern, eastern and 
western sub-Saharan regions). This is five more regions 
than we were able to meta-analyse in 2009, due to 
increased evidence from Central Europe and evidence 
considered generalisable to all four of the regions 
comprising sub-Saharan Africa. Because the North 
American region included just two countries (Canada 
and the USA) and because Canada was represented 
by a large and well-conducted survey on a nationally 
representative sample(3), we used a slightly different 
approach for this region. We meta-analysed studies 
conducted in the US to generate estimates for the 
USA only, and applied the Canadian Study of Health 
and Aging (CSHA) prevalence findings to Canada. 
A summary of which countries are included in each 
region, the countries for which prevalence studies have 
been conducted, and the approach used to generate 
regional prevalence and numbers can be found in 
Appendix A.
2.3.4.1 The effects of age and gender
In fitting the models, we noted a strong effect of age 
in each region. The prevalence of dementia increased 
exponentially with age, doubling with every 5.5 year 
increment in age in North America, 5.7 years in Asia 
Pacific, 5.9 years in Latin America and, with every 6.3 
year increment in East Asia, every 6.5 years in West 
and Central Europe, every 6.6 year increment in South 
Asia, and every 6.9 years in Australasia, 7.2 years 
in the Caribbean and SSA, and 10.6 years in South 
East Asia. We also noted an independent effect of 
gender in some regions: East Asia, Asia South, the 
Caribbean, Western Europe and Latin America, where 
the predicted prevalence for men was between 14% 
and 32% lower than that for women. This effect wasn’t 
significant for the other regions. An interaction was 
noted between age and gender, with a tendency in all 
regions for the divergence in prevalence between men 
and women to rise with increasing age; however, this 
was statistically significant only for the Asia Pacific and 
Latin America regions. 
2.3.4.2 Heterogeneity of prevalence 
within regions
There was statistically significant overdispersion in 
all of the models other than that for Australasia and 
Europe Central, indicating significant heterogeneity in 
age-specific or age- and gender-specific prevalence 
between studies, within regions. Heterogeneity 
was most marked for South Asia (alpha=0.37), East 
Asia (alpha=0.20) and Western Europe (alpha=0.16). 
Heterogeneity in all regions was quite similar to that 
which was observed in 2009. 
An advantage of modelling prevalence with Poisson 
random effects exponential regression is that it allows 
us to explore possible sources of heterogeneity 
between study estimates. With the new data available 
from China, we are now able to carry out these 
meta-regressions for two world regions; East Asia, in 
addition to Western Europe. Given that limited data is 
available for some design and methodological factors 
from the Chinese studies, we limited the analyses 
to the effects of one or two phase design (correctly 
or incorrectly applied), whether or not an informant 
interview was included, the year in which the survey 
was carried out, and the country. All regressions were 
controlled for age in the first stage. The results are 
summarised in Table 2.3.
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Table 2.3  
Modelling the effects of study characteristics upon observed 
prevalence in East Asia (73 studies) and western Europe  
(63 studies)* 
Study 
characteristics
East Asia (73 
studies)
Europe (63 
studies)
Design
One phase survey 1 (ref) 1 (ref)
Two phase survey 
correctly applied
0.84 (0.39-1.79) 1.20 (0.84-1.72)
Two phase survey 
incorrectly applied
1.02 (0.66-1.56) 1.16 (0.85-1.58)
Informant interview 
not applied
0.84 (0.63-1.11) 0.98 (0.80-1.19)
Year
1980 – 1994 1 (ref) 1 (ref)
1995 – 2005 1.79 (1.26-2.53) 0.86 (0.69-1.08)
2005 – 2.32 (1.62-3.32) 0.94 (0.71-1.24)
Alpha 0.29 (0.21-0.40) 0.09 (0.06-0.13)
* controlling for other variables in the table, and for ‘country’
The most striking finding was a marked trend for 
a higher prevalence to be recorded in more recent 
studies in East Asia, an effect which was not evident in 
Western Europe. When the effect of year of survey was 
examined as a linear variable (per year) the trend was 
clearly apparent for East Asia (RR 1.041, 95% CI: 1.020-
1.062) but, again, not for Western Europe (RR 0.996, 
95% CI: 0.981-1.012). There appeared to be no effect 
of study design or methodological factors in either 
region. However, when additional factors were tested 
in Western Europe, prevalence was higher for those 
studies that had excluded long term care institutions 
from sampling (RR 1.66, 95% CI: 1.02-2.71), lower when 
a multi-domain cognitive test battery had not been 
applied (RR 0.51, 95% CI: 0.39-0.67), but with no effect 
of the absence of a structured disability assessment 
(RR 1.22, 95% CI: 0.79-1.90). Inspection of the alpha 
coefficient, as an index of residual variance at different 
stages of the model, confirmed that study year was 
the major source of heterogeneity for East Asia, and 
country for Western Europe (Table 2.4).
In East Asia, there was no significant variation by 
country; compared with Taiwan, the prevalence ratios 
were; China (PR 1.31, 95% CI: 0.80-2.17) and Hong 
Kong (PR 1.31, 95% CI: 0.26-6.52). These comparisons 
were evidently underpowered due to the relatively 
small number of studies from Taiwan and Hong Kong. 
For Western Europe, as noted in the 2009 World 
Alzheimer Report, Israel was a clear outlier with a 
substantially and significantly higher prevalence than 
that noted in almost all other countries. Excluding 
Israel, heterogeneity between countries is reduced, but 
still present, with no clear interpretable pattern (Table 
2.5). With reference to Italy (the country with the largest 
number of studies), prevalence is higher in France, and 
lower in Finland, San Marino and the United Kingdom.
 
Table 2.4  
Coefficient alpha, as an index of residual between study 
variability in dementia prevalence
Model East Asia  
meta-analysis
Western Europe 
meta-analysis
Age only 0.38 0.15
+ methodology 0.36 0.14
+ study year 0.30 0.14
+ country 0.30 0.09
+ country 
(excluding Israel)
N/A 0.07
Table 2.5  
The effect of country on dementia prevalence (Western 
Europe, excluding Israel) – 61 studies
Country Prevalence ratio
Italy 1 (ref)
France 1.93 (1.09-3.42)
Netherlands 0.76 (0.53-1.09)
Sweden 0.78 (0.55-1.10)
Germany 1.01 (0.66-1.57)
Finland 0.55 (0.30-1.00)
Denmark 0.88 (0.57-1.35)
Spain 1.02 (0.81-1.29)
Belgium 1.28 (0.83-1.96)
Norway 1.04 (0.59-1.84)
San Marino 0.66 (0.34-1.29)
United Kingdom 0.68 (0.51-0.93)
Switzerland 0.95 (0.48-1.86)
Portugal 0.94 (0.48-1.85)
2.3.5 Generating prevalence estimates
As described earlier, we generated both age-specific 
and age- and gender-specific meta-analysed dementia 
prevalence estimates for each region. For the East 
Asia region, given the prominent temporal trend for 
estimated prevalence observed in our meta-regression 
analysis, we restricted the meta-analysis of prevalence 
to studies conducted in China from 2005 onwards 
and included all the other studies from the region. 
The origins of the temporal trend have been debated, 
specifically whether or not it reflects a true change 
in underlying prevalence over time, or alternatively 
merely an artefact of a shift towards the use of more 
current dementia diagnostic criteria(21, 22). Regardless, 
this decision seemed justified as likely to represent 
the most accurate estimation of current prevalence in 
the region (see Discussion, and Chapter 5 for further 
details). We prioritised the age- and gender-specific 
estimates where these had been provided for a large 
proportion of all studies, since these should in principle 
provide the most precise overall prediction of regional 
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Table 2.6 
Meta-analysed estimates of dementia prevalence, generated from Poisson random effects models, by GBD region
Global 
Burden of 
Disease 
Region
Number of Included Studies Gender Age group Standardised 
prevalence† 
for those aged 
60+
Number in 
age-specific 
meta-
analysis
Number in 
age- and 
gender-
specific 
meta-
analysis
60-
64
65-
69
70-
74
75-
79
80-
84
85-
89
90+
ASIA
Australasia 3 0 All 1.8 2.8 4.5 7.5 12.5 20.3 38.3 6.91*
Asia Pacific, 
High Income
17 11 M 1.5 2.3 3.8 6.5 11.2 18.4 35.7 6.54*
F 1.0 1.8 3.3 6.3 12.1 22.5 50.6
All 1.0 1.9 3.3 6.0 11.0 19.6 41.8 5.96
Asia, East
(2005-15 
only for 
China)
44 15 M 1.2 1.9 3.0 5.1 8.6 14.2 27.2 6.19
F 1.5 2.5 4.2 7.3 12.8 21.6 43.0
All 1.5 2.4 4.0 7.0 12.1 20.3 40.5 6.61*
Asia, South 11 8 M 1.2 1.9 3.0 5.1 8.5 13.8 26.2 5.63*
F 1.6 2.5 4.0 6.7 11.2 18.1 34.3
All 1.9 3.0 4.9 8.3 14.0 23.0 44.1 7.70
Asia, 
Southeast
6 2 M 1.8 2.6 3.9 6.2 9.8 15.0 26.4 7.64
F 1.8 3.0 5.1 9.0 16.0 27.2 54.9
All 3.3 4.4 6.0 8.3 11.5 15.6 23.5 7.15*
EUROPE
Europe, 
Western
65 54 M 1.1 1.8 2.8 4.7 7.8 12.6 23.7 6.67*
F 2.0 3.2 5.2 8.7 14.6 23.7 45.1
All 1.6 2.6 4.3 7.3 12.4 20.5 39.8 6.80
Europe, 
Central
4 3 M 1.6 2.3 3.3 4.9 7.3 10.6 17.3 5.18
F 1.8 2.6 4.0 6.3 10.0 15.4 27.1
All 1.1 1.8 2.9 5.0 8.5 14.0 27.1 4.65*
THE AMERICAS
North 
America 
(USA only)
10 6 M 1.3 2.1 3.7 6.8 12.3 21.6 45.2 6.77*
F 1.0 1.8 3.3 6.4 12.5 23.2 52.7
All 1.0 1.7 3.0 5.7 10.6 19.1 41.6 5.73
Latin 
America
13 9 M 1.4 2.4 4.3 7.4 12.6 21.6 43.7 8.41*
F 1.3 2.5 4.7 8.9 16.5 30.7 69.4
All 1.5 2.6 4.8 8.6 15.2 27.0 57.5 8.34
AFRICA
Sub-
Saharan 
Africa
9 7 M 1.0 1.5 2.3 3.8 5.7 9.2 17.5 *5.47
F 2.0 3.0 4.6 7.5 11.5 18.6 35.8
All 1.3 2.0 3.1 5.1 8.0 13.1 25.7 4.63
† Standardised using Western Europe as the standard population
* These estimates were used to generate the numbers of people with dementia
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prevalence. Age-specific estimates had to be used for 
Australasia, East Asia, Southeast Asia, and Central 
Europe.  To facilitate comparison between regions 
and with previous estimates for the same regions, 
we calculated overall standardised prevalence for all 
those aged 60 and above, using Western Europe as the 
standard population(23).
2.3.6 Generation of prevalence estimates 
for other GBD regions where it was not 
possible to conduct a meta-analysis
When a lack of available data for a region prevented 
us from conducting a meta-analysis, our default 
option was to apply the relevant estimates from the 
Lancet/ADI Delphi consensus conducted in 2005, 
representing the best available estimates of likely 
dementia prevalence in those regions(24). This process 
was no longer necessary for Central Europe or the 
sub-Saharan Africa regions, for which meta-analyses 
were conducted as part of this update. Lancet/ADI 
Delphi consensus estimates were therefore only 
applied to Central Asia, Oceania, Eastern Europe, the 
Caribbean and North Africa/Middle East. This was 
complicated by the mismatch between the 14 WHO 
world regions (based on geography and patterns of 
mortality) and the 21 new WHO GBD regions (based 
on geography alone). Using the same general strategy 
as for the 2009 World Alzheimer Report, we therefore 
applied the relevant ADI/Lancet regional age-specific 
estimates to each country in the GBD region, and 
then aggregated prevalence as a weighted average 
across the region. For some countries, we felt that 
recent good quality studies arguably provided better 
estimates for that country (and in some instances for 
some of its neighbours) than the ADI/Lancet regional 
estimate. This applied to the following GBD regions 
and countries:
Caribbean – Cuba(7, 25, 26), Dominican Republic(7) and 
Puerto Rico(27) 
North Africa/Middle East – Egypt(28-30) (applied to 
Egypt, and three other EMRO D countries - Iraq, 
Morocco and Yemen, and Algeria (AFRO D), Turkey(31-
33) (applied to Turkey)
The age-specific aggregated dementia prevalence 
estimates for each region are provided in Table 2.5. To 
facilitate comparison between regions, we have again 
calculated overall age- and age- and gender-specific 
standardised prevalence for all those aged 60 and over, 
using Western Europe as the standard population. 
2.3.7 Final summary of estimated 
prevalence
Estimated prevalence for all those aged 60 years and 
over, standardised to the Western European population 
structure, can be compared directly between the 21 
GBD regions and between our 2009 and updated 
estimates (Figure 2.3). The highest standardised 
prevalences were those in North Africa/Middle East
(8.7%) and Latin America (8.4%), and the lowest in 
Central Europe (4.7%). The other regions occupied 
a fairly narrow band of prevalence, ranging between 
roughly 5.6% and 7.6%. When compared with the 
results of our 2009 systematic review and meta-
analysis (age, or age and gender standardised to the 
same Western European population) the estimates 
for most regions remain broadly similar. This is not 
surprising given the relatively small number of new 
studies for most regions. However, the evidence base 
has expanded significantly for the East Asia, sub-
Table 2.7  
Estimates of dementia prevalence (%) for GBD regions where it was not possible to carry out a quantitative meta-analysis
Sources of prevalence 
data used to calculate 
regional weighted 
average
60-64 65-69 70-74 75-79 80-84 85+ Age-standardised 
prevalence
For all those aged 
60 years and over
ASIA
Asia, Central EURO B, EURO C 0.9 1.3 3.2 5.8 12.1 24.7 5.75
Oceania WPRO B 0.6 1.8 3.7 7.0 14.4 26.2 6.46
EUROPE
Europe, Eastern EURO C 0.9 1.3 3.2 5.8 11.8 24.5 5.70
THE AMERICAS
Caribbean AMRO B, AMRO D, 
Cuba(7, 25), Dominican 
Republic(7), Puerto 
Rico(27)
1.6 2.9 4.4 8.5 14.3 30.7 7.58
AFRICA
North Africa / Middle 
East
EMRO B, Egypt(28-30), 
Turkey(31-33)
2.2 3.6 6.0 9.7 16.4 29.4 8.67
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Saharan Africa, and North Africa/Middle East regions, 
and review of the additional evidence has resulted, in 
each case, in a revision upwards of previous estimates. 
It should be stressed that this should not be taken 
to indicate a trend towards an increasing prevalence 
over time. For China, many of the ‘new’ studies were 
conducted pre-2009 but were not available for the 
previous review, which excluded Chinese language 
publications. For North Africa/Middle East, evidence 
from studies has replaced the opinion of the ADI/
Lancet Delphi expert consensus panel(24) for several of 
the more populous countries in the region. Even where 
more recent studies do record a higher prevalence, 
as previously highlighted, factors other than temporal 
trends may account for the more recent studies having 
recorded higher prevalences.      
2.3.8 Estimation of numbers of people 
with dementia
Having applied the age-specific, or age- and gender-
specific prevalence estimates to the UN population 
projections (see method section for details), we 
estimate that 46.8 million people worldwide are 
living with dementia in 2015 (Table 2.6 and Figure 
2.4). This number will almost double every 20 years, to 
74.7 million in 2030 and 131.5 million in 2050. These 
new estimates are 12-13% higher than those made for 
the World Alzheimer Report 2009 (41.5m in 2015, 65.7m 
in 2030 and 115.4m in 2050).
Much of the currently projected increase through 
to 2050 is attributable to increases in the numbers 
of people with dementia in low and middle income 
countries (LMIC). In 2009 we estimated that 58% 
of all people with dementia lived in LMIC, rising to 
63% in 2030 and 71% in 2050. Since then the World 
Bank classification of income-level has changed for 
several countries. If we apply the 2009 World Bank 
classification, in 2015 64% of all people with dementia 
are living in countries which were considered LMIC in 
2009, and this proportion would rise to 67% in 2030 
and 72% in 2050. According to the current World Bank 
classification (Figure 2.4) in 2015, 58% of all people 
with dementia live in LMIC, rising to 63% in 2030 
and 68% in 2050. 
The change of World Bank income classification for 
some of the countries (see details in Chapter 1) has had 
a relatively small impact on the repartition of people 
with dementia between LMIC and HIC as most of the 
changes occurred between the three LMIC groups 
(upper middle income, lower middle income and 
low income). The numbers and proportion of people 
with dementia living in what are now considered low 
income countries has reduced accordingly. The overall 
pattern reported in 2009, of a greater relative growth 
in numbers in less compared with more developed 
Figure 2.3  
Estimated prevalence of dementia for those aged 60 and over, standardised to Western Europe population, by GBD region
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Table 2.8 
Numbers of people with dementia (millions) according to the 2015 World Bank income classification
World Bank Income Group Number of People with Dementia (millions)
2015 2020 2025 2030 2035 2040 2045 2050
Low Income 1.19 1.42 1.68 2.00 2.41 2.90 3.55 4.35
Lower Middle Income 9.77 11.52 13.72 16.35 19.48 23.12 27.18 31.54
Upper Middle Income 16.32 19.36 23.33 28.39 34.28 40.43 46.90 53.39
High Income 19.50 21.97 24.73 27.95 31.72 35.71 39.14 42.18
World 46.78 54.27 63.45 74.69 87.88 102.15 116.78 131.45
Table 2.9  
Estimated number of people with dementia (2015, 2030 and 2050) and proportionate increases (2015-2030 and 2015-2050) 
according to wealth (GNP)
People with dementia (millions) (% of world total) Proportionate increase (%)
Region 2015 2030 2050 2015-2030 2015-2050
G7* 12.88 (28) 18.43 (25) 26.28 (20) 43 104
G20** 37.47 (80) 58.99 (79) 99.14 (75) 57 165
G20 excluding G7 24.59 (53) 40.56 (54) 72.86 (55) 65 196
Rest of the world (excluding 
G20)
9.31 (20) 15.70 (21) 32.31 (25) 69 247
World 46.78 (100) 74.69 (100) 131.45 (100) 60 181
* G7 countries: Canada, France, Germany, United Kingdom, Italy, Japan, and the United States
** G20 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Mexico, Russia, Saudi Arabia, South 
Africa, South Korea, Turkey, the United Kingdom, the United States and the remaining EU member countries (Cyprus, Austria, Belgium, Croatia, 
Czech Republic, Denmark, Finland, Greece, Ireland, Luxembourg, Malta, Netherlands, Portugal, Slovenia, Spain, Sweden, Poland, Romania, Slovak 
Republic, Bulgaria, Estonia, Hungary, Latvia, Lithuania)
Figure 2.4  
The growth in numbers of people with dementia (millions) in high income (HIC) and low and middle income countries (LMIC) 
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Table 2.10  
Total population over 60, crude estimated prevalence of dementia (2015), estimated number of people with dementia (2015, 2030 
and 2050) and proportionate increases (2015-2030 and 2015-2050) by GBD world region
GBD Region Over 60 
population 
(millions, 2015)
Crude estimated 
prevalence (%, 
2015)
Number of people with 
dementia
Proportionate increases (%)
2015 2030 2050 2015-2030 2015-2050
ASIA 485.83 4.7 22.85 38.53 67.18 69 194
Australasia 5.8 6.7 0.39 0.62 1.02 59 163
Asia Pacific High Income 52.21 7.0 3.64 5.68 7.81 56 115
Oceania 0.64 3.5 0.02 0.04 0.09 83 289
Asia, Central 7.43 4.2 0.31 0.44 0.88 43 184
Asia, East 218.18 4.5 9.77 16.60 28.64 70 193
Asia, South 139.85 3.7 5.13 8.61 16.65 68 225
Asia, Southeast 61.72 5.8 3.60 6.55 12.09 82 236
EUROPE 176.61 5.9 10.46 13.42 18.66 28 78
Europe, Western 107.89 6.9 7.45 9.99 14.32 34 92
Europe, Central 26.92 4.0 1.07 1.39 1.90 30 78
Europe, East 41.8 4.6 1.94 2.03 2.44 4 26
THE AMERICAS 147.51 6.4 9.44 15.75 29.86 67 216
North America 74.88 6.4 4.78 7.28 11.74 52 145
Caribbean 5.78 6.5 0.38 0.60 1.07 60 183
LA, Andean 5.51 6.1 0.34 0.64 1.43 88 322
LA, Central 26.64 5.8 1.54 2.97 6.88 93 348
LA, Southern 9.88 7.6 0.75 1.15 2.05 52 172
LA, Tropical 24.82 6.7 1.66 3.11 6.70 88 305
AFRICA 87.19 4.6 4.03 6.99 15.76 74 291
North Africa / Middle 
East
38.93 6.0 2.34 4.35 10.04 86 329
SSA, Central 4.78 3.3 0.16 0.26 0.54 60 238
SSA, East 19.86 3.5 0.69 1.19 2.77 72 300
SSA, Southern 6.06 3.9 0.24 0.35 0.58 46 145
SSA, West 17.56 3.1 0.54 0.85 1.84 58 241
WORLD 897.14 5.2 46.78 74.69 131.45 60 181
24
regions, holds true. Between 2015 and 2050, numbers 
in what are now HIC will increase by 116%, in UMIC by 
227%, in L-MIC by 223%, and in LIC by 264%.
13% of all people living with dementia live in the world’s 
seven richest economies (the G7), while 72% live in the 
world’s 20 richest countries (the G20) (Table 2.9). 
According to our revised estimates, in 2015, East Asia 
is the world region with the most people living with 
dementia (9.8 million), followed by Western Europe
(7.4 million). These regions are closely followed by 
South Asia with 5.1 million and North America with 4.8 
million. At the country level, ten countries are home to 
over a million people with dementia in 2015: China (9.5 
million), USA (4.2 million), India (4.1 million), Japan (3.1 
million), Brazil (1.6 million), Germany (1.6 million), Russia
(1.3 million), Italy (1.2 million), Indonesia (1.2 million) and 
France (1.2 million).
Our projections for growth in the number of people 
with dementia support our previous prediction that 
regional trends fall into three broad groups. Developed 
regions started from a high base but will continue to 
experience only a moderate proportionate increase. 
Latin America and Africa started from a low base but 
will continue to experience a particularly rapid increase 
in numbers. India, China, and their south Asian and 
western-pacific neighbours started from a high base 
and will also continue to experience relatively rapid 
growth. These trends are driven mainly by population 
growth and demographic ageing (Table 2.9). Over 
the next fifteen years we forecast a 28% increase in 
numbers in Europe, 52% in North America, 52% in 
the southern Latin American cone and 56% in the 
high income Asia Pacific countries. These rates are 
noticeably lower than the predicted 68% growth in 
South Asia, 70% in East Asia, 82% in Southeast Asia, 
86% in North Africa and the Middle East, and 88-93% 
in the rest of Latin America. Predictions of growth 
for Southern sub-Saharan Africa are more modest, 
consistent with projections for demographic ageing 
in the light of persistent high child mortality and the 
effects of the HIV epidemic.
2.4 Conclusions and 
recommendations
Through systematically reviewing the research 
evidence for dementia prevalence in population-
based surveys, and applying strict inclusion and 
exclusion criteria, we have identified 273 population-
based studies of the prevalence of dementia, with 
605,337 individual participants. This is 106 more 
studies than were identified in 2009. We identified 
sufficient studies to carry out quantitative regional 
meta-analyses applicable to 16 of the 21 WHO 
Global Burden of Disease regions, and several of 
the previous meta-analyses were enhanced by the 
inclusion of more recent studies. This is five more 
regions than we were able to meta-analyse in 2009, 
due to new evidence from Central Europe and sub-
Saharan Africa. The number of studies for East Asia 
has expanded considerably, both because of further 
studies published since 2009, and because we were 
now able to assess and include more pre-2009 
Chinese language publications. For regions in which 
we were unable to conduct a meta-analysis, we were 
able to supplement the previous ADI/Lancet estimates 
with data from well-conducted studies, which could 
be applied to the country concerned and, where 
appropriate, to some of its regional neighbours. Our 
estimates are therefore increasingly data-based, and 
we are close to achieving our aim of doing away with 
the need for estimates based upon expert opinion.
Our updated prevalence estimates suggest that our 
2009 meta-analysis underestimated the current and 
future scale of the dementia epidemic by 12-13%. In 
highlighting some of the key changes in estimates of 
regional prevalence, it is important to reiterate that 
these updated estimates reflect improvements in the 
extent and quality of the available evidence, and hence, 
we would hope, in the precision of the estimates. 
The increases in our estimates should certainly not 
be taken to imply that the underlying age-specific 
prevalence of dementia has changed over the short 
interval between the two reports.
•	 A considerable increase (6.6% vs. 3.2%) in the 
prevalence estimates for East Asia, a region that 
includes the vast population of China and an 
estimated 218 million older people in 2015.
•	 Modest to considerable increases (5.5% vs.  
2.1-4.0%) in the prevalence estimates for all four of 
the sub-Saharan Africa regions.
•	 An important increase (8.7% vs. 5.9%) in 
prevalence estimates for the North Africa/Middle 
East region, a region accounting for 45% of Africa’s 
population of people aged 60 years and over.
•	 A modest increase (5.8% vs. 4.8%) in the 
prevalence estimates for Southeast Asia, a region 
that includes the populous countries of Indonesia, 
the Philippines, Thailand and Vietnam, and an 
estimated 62 million older people in 2015.
The main limitations of this review are a) the 
persistently poor coverage of the evidence-base for 
several world regions, b) the relatively poor quality 
of many studies included in the review, and c) the 
between-study heterogeneity of prevalence estimates 
within regions. These limitations are each discussed 
below. The accuracy of our projections for future 
growth in the numbers of people with dementia is 
limited by their reliance on population projections, 
which have proven to be inaccurate in the past, with 
mis-estimations of trends in both fertility and mortality. 
Particular caution is advised for projections for specific 
countries, for population sub-groups, and for longer 
periods into the future. The projections also assume 
that age-specific prevalence in each region will remain 
constant over time, which is unlikely to be the case, 
particularly in regions undergoing rapid demographic, 
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epidemiologic and social change. The issue of possible 
secular (temporal) trends in prevalence is addressed in 
detail in Chapter 5.  
2.4.1 Coverage
For this World Alzheimer Report, coverage of evidence 
has improved significantly for the East Asia, sub-
Saharan Africa, Central Europe and North Africa/
Middle East regions. For the most part this relates to 
new evidence, from recent studies published since 
the World Alzheimer Report 2009. However, for East 
Asia, in 2009 we were dependent upon our own 
searches for English language publications, and a 
limited review that included some Chinese language 
publications (31 studies in all). We have now been 
able to access a large number of additional studies, 
which had been published in Chinese language 
journals. We are indebted to Dr Kit Yee Chan and 
Prof Igor Rudan for first drawing our attention to 
this issue through their landmark systematic review 
and meta-analysis of 75 studies, published in The 
Lancet in 2013(3). Once the additional studies were 
taken into account, the prevalence for China seemed 
substantially higher than we had previously suspected
(4). At around the same time, Dr Wu and colleagues 
published a further review, including studies also from 
Hong Kong SAR and Taiwan (72 publications in all), 
with findings on prevalence which were consistent 
with those of the Lancet review. Dr Wu kindly reviewed 
our 2009 database and removed studies that were 
not eligible. Dr Wu and Dr Chan then added to it from 
their previous review, updated from 2011 to the present 
day. Throughout, they applied the ADI World Alzheimer 
Report inclusion and exclusion criteria. The result is 89 
eligible studies from 1980 to 2015. 
Coverage in several other regions remains inadequate. 
Eastern Europe (including Russia) and Central Asia 
remain essentially uncovered by research, making our 
estimates for these regions highly tentative. Southeast 
Asia is represented by six studies, but none from 
Indonesia whose 22 million older people account for 
around 40% of the region’s total population aged 60+.
In 2009, we found that descriptive population-based 
research into dementia in high income countries 
peaked in the early 1990s and then sharply decreased. 
This trend has not been reversed in recent years. 
The relative lack of coverage by recent high quality 
studies is now becoming a serious concern across 
the developed world. Prevalence may change over 
time and future policymaking and planning require 
accurate up-to-date figures. These are no longer 
available for most high income countries. Apart from 
tracking changes in disease prevalence and incidence, 
descriptive surveys can be used to estimate access 
to care, and the cost of health and social services 
provided for people with dementia. It may be that 
biomedical research funding agencies view such 
research as unoriginal, and hence uncompetitive when 
compared with population research orientated to 
elucidation of risk factors. Arguably, the responsibility 
for commissioning and funding such research should, 
increasingly, be devolved to governments, whose 
ministries and agencies will be the main clients for 
the data generated. Nationally representative surveys 
provide the best information for policymaking and 
planning; however, there are still only five countries 
(USA(11), Canada(12), Mexico(13), Korea(14) and 
Singapore(15)) that benefit from such information. 
As with the USA-ADAMS survey, dementia can be 
efficiently studied, using a two-phase design nested 
within an ongoing, nationally representative survey 
of ageing and health (the US Health and Retirement 
Survey).  
2.4.2 Quality
In 2009, we expressed several concerns regarding 
the quality of prevalence studies as assessed in the 
reviews, particularly since the problems identified can 
all lead to biased, inaccurate estimates of prevalence 
and numbers. Two main issues were highlighted: 
•	 diagnostic procedures for dementia, which 
often lack a multi-domain cognitive test battery, 
an informant interview, a structured disability 
assessment (which could form part of the informant 
interview) and a clinical interview to exclude other 
causes of cognitive impairment. 
•	 misapplication of study designs involving two 
or more phases, when no screen negatives are 
included at the second stage and/or no weighting 
back is carried out in order to estimate the 
prevalence correctly. 
Encouragingly, there has been a noticeable 
improvement in diagnostic assessments in dementia 
prevalence surveys, as more than 50% of the most 
recent studies included a comprehensive dementia 
assessment. However, the informant interview is 
still frequently missing from this assessment. More 
worryingly, analysis of studies carried out post-2005 
reveals that multiphase studies remain enduringly 
popular (78% of all studies), but if anything somewhat 
less likely to be designed and/or implemented 
correctly (only 11% of multiphase studies). The correct 
procedures for designing, conducting and analysing 
multiphase studies are very well established(34), but it 
appears that awareness remains poor among dementia 
researchers. It is therefore important to reiterate our 
previous recommendations. Research funders and 
ethics committees should not fund or approve study 
designs that are faulty in this respect. Journals should 
adopt clear policies regarding multiphase studies. 
For studies that correctly sample a subset of screen 
negatives, journals should not publish findings until 
results are weighted back in the analysis to account 
for different sample fractions. Completed studies that 
did not perform diagnostic analysis on a sample of 
screen negatives should, of course, still be published, 
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but with the limitation clearly acknowledged, and a 
clarification that the study reports minimum prevalence 
of dementia.
It is both reassuring, and somewhat puzzling, that 
no clear effect on dementia prevalence of incorrect 
application of two-phase design, compared with 
one phase design, can be detected in either of the 
two regional meta-regressions carried out for this 
report. Neglecting to sample screen negatives, and/ 
or weight back should always tend to underestimate 
true prevalence. However, two phase studies have 
an additional generic problem of substantial attrition 
between the first (screening) and second (diagnostic) 
phases. Its effect is difficult to predict; true dementia 
cases would need to be under-represented among 
losses between the two phases to counteract the likely 
effect of incorrect application of the two phase design. 
Attrition can be minimised by shortening any delay 
between the two phases. Multiple imputation could 
be used to correct for the lost diagnostic data in the 
second phase.
Overall, we observed a tendency for improvement 
in study quality in recent years, with high quality 
studies especially in Latin America and sub-Saharan 
Africa. We have been able to perform a detailed 
quality assessment of Chinese studies, which was not 
possible in our previous reviews. These raise concerns 
over the quality of studies from that region, with only 
5% of multistage designs applied correctly and only 
15% of studies using a comprehensive diagnostic 
assessment. The overall quality score, of 6.2, is 
the lowest for all world regions. Efforts need to be 
made internationally to ensure dissemination of good 
research practice, possibly including the development 
of guidelines. 
2.4.3 Heterogeneity
A fundamental assumption, implicit in the modelling 
approach in this review, was that the prevalence 
of dementia was uniform within GBD regions. This 
could then be estimated from the available evidence 
and applied to all countries in that region. Similarly 
to our previous observations in 2009, we observed 
statistically significant heterogeneity of age- and 
gender-specific prevalence in almost all regions. 
Heterogeneity has slightly decreased for some regions, 
and increased for others. In many ways, this is not 
surprising given the varied languages, cultures, levels 
of development, and demographic compositions 
of the national and sub-national units that make up 
a GBD world region. Indeed, despite the statistical 
significance of the heterogeneity, arguably one should 
be more impressed by the similarity rather than the 
differences in prevalence between studies. 
We were only able to explore the possible factors 
explaining heterogeneity in two regions, Western 
Europe and East Asia, and with a limited number of 
covariates. For Western Europe, there seemed to be 
significant between-country variation, although this did 
not seem to follow any readily interpretable pattern. 
For East Asia, as noted in two previous meta-analyses, 
there was a substantial trend towards a higher 
prevalence for more recently conducted studies. While 
this may indicate an increase in the true underlying 
prevalence over time, Wu et al.(21) have pointed out 
that the temporal trend is considerably diminished 
when controlling for study methodological factors, 
particularly the diagnostic criteria applied. A higher 
prevalence was recorded in studies using more recent 
(DSM-IV, 10/66, GMS/AGECAT) versus older (DSM-
III, DSM-III-R and ICD-10) diagnostic criteria. It will, in 
truth, be difficult definitively to disentangle these two 
competing explanations for the striking temporal trend 
observed in the region. Our decision, to focus in our 
regional meta-analysis on more recent studies from 
China (post-2005), was justifiable, in our view, in either 
case.
Methodological variability can be reduced through 
standardisation of study procedures. Common sense 
indicates that the way in which the diagnosis of 
dementia is defined and applied may be among the 
most important sources of variability. Currently, DSM-
IV criteria is by far the most widely applied dementia 
diagnosis, and although it is not fully operationalised, 
it is possible to do so(35). It would also be desirable 
to reach an international consensus regarding what 
constitutes cognitive impairment, what constitutes 
social and occupational impairment, and how these 
should be measured. The new DSM-5 criteria for major 
neurocognitive disorder may be a step in this direction, 
but these criteria have yet to be widely adopted, and 
their validity are not established(36-38). Of course, 
cultural adaptations may need to be applied. Clinicians 
understandably resist the degree of straitjacketing 
that full operationalisation imposes, but a parallel set 
of more specific research diagnostic criteria would 
be highly valuable. Accurate delineation of temporal 
trends will require studies that maintain a constant 
methodology over time (see Chapter 4).
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chapTer 3 
The incidence of dementia
3.1 Introduction
In 2012, a systematic review of the incidence of 
dementia worldwide was published in the WHO report 
‘Dementia: a public health priority’(1). We found 39 
potentially eligible studies, of which 34 were fully 
eligible to be included in the meta-analysis. These 
studies covered 10 different regions (Western Europe, 
North America, East Asia, Latin America Andean, Latin 
America Central, Latin America Tropical, Caribbean, 
Australasia, Asia Pacific, and West Sub-Saharan 
Africa) and meta-analysed their results. The incidence 
of dementia increased exponentially with increasing 
age. For all studies combined, the incidence of 
dementia doubled with every 5.9 year increase in age, 
from 3.1/1000 person years (pyr) at age 60-64 to 175.0/ 
1000 pyr at age 95+. Dementia incidence appeared 
to be higher in countries with high incomes (doubling 
every 5.8 years from 3.4/1000 pyr to 202.2/1000 pyr) 
than in low or middle income countries (doubling every 
6.7 years from 2.9/1000 pyr to 99.4/1000 pyr).
The total number of new cases of dementia each year 
worldwide was then estimated to be nearly 7.7 million, 
implying one new case every 4.1 seconds.
The dementia incidence evidence-base found at that 
time was not as extensive as that for the prevalence of 
dementia, with good coverage for Europe, some recent 
studies for Latin America and China, but relatively few 
North American studies, underrepresentation of Africa 
and East Asia, and no evidence at all for South or 
South East Asia.
Since 2012, no further systematic reviews of the 
incidence of dementia have been published. A better 
understanding of the pattern and level of incidence in 
different world regions is essential.  
3.2 Methods
3.2.1 Systematic review
The systematic review on the incidence of dementia 
followed a similar process to the review of prevalence 
(see Chapter 2). We updated a systematic review of 
the world literature conducted in 2011 for the WHO 
report ‘Dementia: a public health priority’(1). We aimed 
to identify population-based studies of the incidence 
of dementia, defined according to DSM-IV, ICD-10 or 
similar clinical criteria, including people aged 60 years 
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and over, and for which the field work for the baseline 
phase started on or after 1st January 1980. 
Two teams searched English and Chinese databases 
separately to update our previous review. The following 
search strategy was used to identify relevant papers 
published in any language.
English Database Search 
Search date: February 2015 
Databases: EMBASE, Global Health, MEDLINE, 
PsychExtra and PsychInfo 
Search terms: dementia AND (incidence OR 
epidemiology)
Chinese Database Search 
Search date: March 2015 
Databases: CNKI, Wanfang, Airti 
Search terms: (癡呆/dementia OR 失智/dementia OR 
阿爾茨海默/Alzheimer) AND (發生率/incidence OR  
發病率/incidence OR 流行/epidemiology)
Again, all stages of the search were completed by 
two independent reviewers. For the English search, all 
abstracts were read by GA and by either YW or MG. 
Papers were excluded at this stage only when the 
abstract clearly demonstrated that the paper did not 
meet the above criteria. PDF copies of the remaining 
publications were read by GA and by either YW or 
MG, and a consensus was made on those that met 
all criteria. These papers were published in English, 
Spanish and Portuguese, all of which could be read by 
our team using translation programmes. The Chinese 
search was conducted independently by YW and KC, 
who compared their study selection at each stage of 
screening and review.
3.2.1 Data extraction
All eligible studies were systematically coded for their 
study design and characteristics according to the 
following criteria:
1 Country
2 WHO/Global Burden of Disease World Region 
(see Appendix A for list of countries and regions)
3 Inclusion of urban or rural areas 
4 Start and finish dates for fieldwork
5 Lower and upper age limits
6 Sampling strategy (whole population, catchment 
area, random sampling, stratified random 
sampling) 
7 Design (cohort study)
8 Overall sample size
9 Response rate 
10 Case ascertainment (community survey only or 
community + institution survey)
11 Diagnostic criteria (not specified, ICD, DSM, GMS/
AGECAT, CAMDEX, other clinical criteria)
12 Presence of clinical diagnosis
13 Diagnostic Instruments (GMS/AGECAT, 
CAMDEX, MMSE, Dementia Differential Scale, 
Hachinski Ischemic Index, consensus panel, 
physical/neurological examination, standardised 
questionnaire, clinical evaluation, other).
Incidence data was extracted from the studies as 
follows.
According to the data presented in the paper, we 
extracted numerator (case) and denominator (person-
years), incidence and standard error, or incidence 
and 95% confidence intervals. Where not provided, 
numerator and denominator could then be calculated 
from any of these combinations.
Incidence estimates were stratified differently in 
different publications. To maximise the precision of 
our meta-analysis, we required incidence estimates 
in five-year age-bands. If this was not available in the 
publication, we wrote to the authors to request age-
specific incidence data. We could therefore model the 
effect of age on dementia incidence for all included 
studies.  
3.2.2 Meta-analysis to estimate 
incidence rates and heterogeneity
As for the meta-analysis of prevalence data (see 
Chapter 2) we used a random effect exponential 
(Poisson) model to assess the effect of age on the 
incidence of dementia. The alpha coefficient is an 
estimate of over-dispersion and an index of between 
study heterogeneity. Age was coded as the mean for 
each age group reported. We conducted separate 
meta-regressions on all studies combined, and then 
separately for high-income countries, low and middle 
income countries, and for those regions where there 
was sufficient data to attempt a meta-analysis (Asia 
East, Western Europe, North America and Latin 
America and the Caribbean combined). We then 
applied the relevant mean ages to the coefficients 
estimated from the models, to estimate incidence in 
five years age-bands from 60-95 years, and for those 
aged 90 and over. We further estimated the effect of 
region and of high income country vs. low or middle 
income country location. 
3.3 Results
3.3.1 Number of studies
In total, 23 new potentially eligible incidence studies 
were identified (to add to the 39 potentially eligible 
studies already identified in 2011). Eleven of these had 
to be excluded from the meta-analysis because case 
(numerator) and person-years (denominator) data 
could not be extracted(2-12). We therefore identified 
twelve new fully eligible studies of which two had 
been conducted in Western Europe (Italy(13) and the 
Netherlands(14)), four in North America (all in the USA
(15-18)), one in Latin America (Mexico(19)), four in East 
Asia (China(20-23)) and one in South Asia (India(24)). 
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Added to the 34 studies included in the meta-analysis 
for the previous systematic review, 46 studies could be 
included in the global meta-analysis. For a complete 
list of studies included in the meta-analysis, see the 
online appendix at  
www.alz.co.uk/research/world-report-2015
3.3.2 Coverage
While the evidence base from Europe and North 
America dominated, 26 of the 62 studies were from 
outside these regions, and 23 studies were conducted 
in low- or middle-income countries. The proportion 
of new studies conducted in low- and middle-income 
countries was 48% (up from just 31% of studies in the 
original review). There were no studies at all from ten 
of the GBD regions: Oceania, Southeast Asia, Central 
Asia, Central Europe, Eastern Europe, North Africa/
Middle East, Southern, Central and Eastern Sub-
Saharan Africa and Latin America Southern. South 
Asia now has two studies (both from India) where 
previously there were none. Five studies (four in Europe 
and one in the USA) focused on those aged 80 or over, 
also known as ‘oldest old’.
3.3.3 Incidence study characteristics
Collectively, the meta-analysed studies included 
109,952 older people ‘at risk’ and accumulated 
332,323 person-years of follow-up. The median cohort 
size at risk was 1,774 (interquartile range 1,187-3,208) 
and the median person-years were 5415 (interquartile 
range 3,044-10,225). The Western European studies 
contributed 42% of the total person years, the North 
American studies 24%, the East Asian studies 
16%, and the Latin American studies 13%. Just 
5% of person-years are contributed by the studies 
from Australasia, Asia Pacific, South Asia and sub-
Saharan Africa West combined. For two studies, the 
research diagnostic criteria were not clearly specified. 
Accounting for the fact that in some studies more 
than one set of diagnostic criteria were applied, three 
studies applied DSM III criteria, 18 applied DSM-III-R 
criteria, and 21 applied DSM-IV criteria. The six 10/66 
Dementia Research Group studies applied their own 
10/66 Dementia Criteria, four applied ICD-10 criteria, 
and one applied GMS-AGECAT.
3.3.4 Estimation of the incidence of 
dementia 
The incidence of dementia increases exponentially 
with increasing age. For all studies combined, the 
incidence of dementia doubles with every 6.3 year 
increase in age, from 3.9/1000 person years (pyr) at 
age 60-64 to 104.8/1000 pyr at age 90+ (see Figure 
3.1). The incidence of dementia appears to be higher 
in countries with high incomes (doubling every 5.8 
years from 3.5/1000 pyr to 124.9/1000 pyr) than in low 
or middle income countries (doubling every 8.6 years 
from 5.2/1000 pyr to 58.0/1000 pyr). 
Overall the incidence of dementia in LMIC was only 
10% lower (RR 0.90, 95% CI: 0.70-1.15) than in 
countries with high incomes, and, in contrast to our 
previous meta-analysis, was not statistically significant. 
The use of the DSM-IV or the cross-culturally validated 
10/66 Dementia criteria in the 10/66 Dementia 
Research Group studies in Latin America and China 
did not make any difference to overall incidence 
estimates (RR 1.01, 95% CI: 0.78-1.31). There was 
significant heterogeneity in the incidence estimates 
when all studies were combined (alpha = 0.18, 95% 
CI: 0.12-0.28). Heterogeneity was similar for studies in 
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Figure 3.1  
Estimated age-specific annual incidence of dementia, derived from Poisson random effects models, for world regions for which 
meta-analytical synthesis was feasible
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HIC (0.17, 95% CI: 0.10-0.28) and LMIC  (0.16, 95% CI: 
0.08-0.34). Heterogeneity reduced somewhat when 
regions (alpha = 0.12, 95% CI: 0.08-0.19) were added 
to the model.
For the effect of region, compared to incidence in 
Western Europe, that in West sub-Saharan Africa
(0.86, 95% CI: 0.39-1.88), East Asia (0.87, 95% CI: 
0.62-1.21), North America 1.02, 95% CI: 0.75-1.39)  
and Latin America and the Caribbean (1.04, 95% CI: 
0.74-1.46) was similar; and that in Australasia (1.75, 
95% CI: 0.78-3.89) and Asia Pacific (1.86, 95% CI: 
0.85-4.08) somewhat higher. These findings need to be 
interpreted cautiously since sub-Saharan Africa, Asia 
Pacific and Australasia were each only represented by 
one or two studies. 
3.3.5 Estimation of the number of 
incident cases of dementia per year
We estimated the numbers of annual incident cases 
for each GBD world region by first estimating the 
numbers at risk (total population in each age group, 
minus numbers with prevalent dementia), and then by 
applying the appropriate incidence rate, as following:
•	 the Western Europe rate for the European regions, 
•	 the North American rate for the North American 
region,
•	 the Latin American rate for the Latin American and 
Caribbean regions, 
•	 the East Asian rate for the East Asian, South East 
Asian and South Asian regions, 
•	 the HIC rates for the Australasia, and Asia Pacific 
regions
•	 the LMIC rates for the sub-Saharan regions, North-
Africa/Middle East and Asia Central regions, 
•	 the Global rate for the Oceania region. 
The numbers of new cases increases and then 
declines with increasing age in each region. In Europe 
and the Americas peak incidence is among those 
aged 80-89 years, in Asia it is among those aged 
75-84, and in Africa among those aged 65-74 (Table 
3.2). We estimated over 9.9 million new cases of 
dementia each year worldwide, implying one new 
case every 3.2 seconds. These new estimates are 
almost 30% higher than the annual numbers of new 
cases estimated, for 2010, in the 2012 WHO/ADI report
(7.7 million new cases, one every 4.2 seconds). The 
regional distribution is similar to that which we had 
previously reported, with 4.9 million new cases (49% of 
the total) in Asia, 2.5 million (25%) in Europe, 1.7 million
(18%) in the Americas, and 0.8 million (8%) in Africa. 
Compared to our previous estimates, the proportion of 
Table 3.1  
Meta-analysed estimates of dementia incidence, generated from Poisson random effects models
Global Burden 
of Disease 
Region
Number 
of Studies 
Included 
in Meta-
Analysis
Age Group Age- and gender- 
standardised incidence,  
for those aged 60+ 
(using Western Europe as  
the standard population)
60-64 65-69 70-74 75-79 80-84 85-89 90+
GLOBAL 46 3.9 6.4 10.6 18.3 31.7 53.1 104.8 17.30
HIC 30 3.5 5.9 10.3 18.7 34.0 59.6 124.9 18.39
LMIC (DSM) 16 5.2 7.4 10.7 16.1 24.1 35.2 58.0 14.06
ASIA
East Asia 8 4.9 7.0 10.3 15.4 23.2 34.1 56.6 13.51
EUROPE
Western Europe 18 3.1 5.3 9.3 17.3 32.0 57.0 122.4 17.29
THE AMERICAS
North America 
(US Only)
8 3.8 6.3 10.6 18.7 32.8 55.7 112.0 17.82
Latin America 
and the 
Caribbean (DSM)
7 4.6 7.0 11.0 17.2 26.4 40.8 72.1 15.11
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new cases arising in Asia, the Americas and Africa has 
increased while it has decreased in Europe.
3.4 Discussion
While systematically reviewing the evidence for 
dementia incidence in population-based surveys, we 
have identified 12 new population-based studies of 
the incidence of dementia, including a total of 37,728 
new participants ‘at risk’ in our meta-analysis. New 
evidence was identified for 6 different regions of the 21 
WHO Global Burden of Disease regions. Only one of 
those regions (South Asia) was not represented in our 
last meta-analysis in 2012; the number of studies has 
expanded for four other regions.
The meta-analysed evidence-base for the incidence of 
dementia is still not as extensive, in terms of coverage, 
as that for the prevalence of dementia. While the 
coverage for Europe has not changed much, with only 
two new studies added to the meta-analysis, a clear 
improvement has been observed in North America 
with four new cohort studies included(15, 16, 18, 25).  The 
meta-analysis’s coverage for East Asia has increased 
with four new studies from China(20-23), but there is still 
no evidence from Central or Southeast Asia. Likewise, 
the African continent is currently still only represented 
by one study. 
With a larger number of studies, and only modest 
heterogeneity among studies included in this review, 
our new estimates indicated that the incidence 
of dementia in LMIC was only 10% lower than in 
countries with high incomes, a non-statistically 
significant difference. The use of the DSM-IV or the 
cross-culturally validated 10/66 Dementia criteria in 
the 10/66 Dementia Research Group studies in Latin 
America and China did not have a significant impact 
upon the meta-analysed estimate of global incidence. 
However, the incidence of 10/66 dementia is higher 
than that of DSM-IV dementia(26), and when the 10/66 
criterion is applied in the meta-analysis the HIC/LMIC 
Table 3.2  
Estimated annual numbers of incident cases of dementia, by age group and world region
Region 60-64 65-69 70-74 75-79 80-84 85-89 90+ Total
Australasia 5,302 7,963 9,970 13,142 15,871 16,734 16,098 85,081
Asia Pacific High Income 39,964 68,251 95,253 135,498 175,788 168,684 136,890 820,329
Oceania 952 1,059 1,140 1,115 895 505 307 5,973
Asia Central 13,845 11,839 10,615 17,134 12,287 7,805 4,243 77,767
Asia East 374,859 355,070 343,826 362,013 312,414 176,473 74,229 1,998,885
Asia South 248,166 238,021 245,465 229,362 173,095 98,859 55,871 1,288,840
Asia Southeast 105,806 99,019 100,042 102,452 85,281 57,518 36,835 586,953
ASIA 788,893 781,223 806,311 860,715 775,632 526,580 324,474 4,863,827
Europe Central 24,550 32,715 39,657 61,567 77,122 65,186 46,693 347,489
Europe Eastern 41,880 45,376 54,177 117,578 97,717 94,641 55,523 506,891
Europe Western 77,053 121,116 169,166 266,762 339,361 343,308 305,006 1,621,773
EUROPE 143,483 199,207 263,000 445,907 514,200 503,135 407,221 2,476,154
North America High Income 80,601 110,721 131,327 159,018 189,253 185,889 147,345 1,004,154
Caribbean 7,893 8,953 10,857 12,187 11,118 8,148 6,846 66,001
Latin America Andean 7,967 9,003 10,283 11,202 9,863 6,302 2,822 57,442
Latin America Central 37,194 40,078 45,438 45,695 42,095 29,051 14,507 254,059
Latin America Southern 12,577 15,517 18,717 20,695 20,592 15,549 7,873 111,520
Latin America Tropical 36,707 40,754 43,609 47,986 41,267 31,747 19,290 261,361
THE AMERICAS 182,939 225,026 260,231 296,784 314,187 276,687 198,683 1,754,536
North Africa / Middle East 70,550 66,606 67,520 68,282 57,115 29,324 12,140 371,538
Sub-Saharan Africa Central 8,904 9,352 9,115 7,827 5,285 2,430 816 43,729
Sub-Saharan Africa East 35,780 38,398 37,179 33,648 25,931 13,126 5,103 189,165
Sub-Saharan Africa Southern 10,863 11,324 10,775 10,358 8,161 6,512 1,719 59,713
Sub-Saharan Africa West 33,931 35,414 33,779 27,014 16,159 6,173 1,492 153,962
AFRICA 160,030 161,095 158,368 147,129 112,651 57,563 21,271 818,106
WORLD TOTAL 1,275,345 1,366,550 1,487,911 1,750,534 1,716,669 1,363,965 951,650 9,912,623
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country incidence rates converge. Hence, the drift 
of our findings support the conclusion that there is 
little variation in the incidence of dementia between 
countries and regions worldwide.
More research into the incidence of dementia is 
required to provide information on regions with no 
evidence, and better, more up to date and denser 
coverage in regions where some studies have been 
conducted. Incidence studies, should, ideally, be 
repeated using similar methodology in order to track 
secular trends in the incidence of dementia within 
populations (see Chapter 4). Incidence is most 
directly affected by changes in population exposure to 
modifiable risk factors, and would therefore be  
the most sensitive indicator of the success of primary 
prevention programs that seek to reduce dementia 
risk.
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chapTer 4 
current and future secular trends
4.1 Introduction
Almost all current projections of the scale of the 
coming dementia epidemic, including those published 
by Alzheimer’s Disease International(1;2) assume that 
the age- and gender-specific prevalence of dementia 
will not vary over time, and that population ageing 
alone (increasing the number of older people at risk) 
drives the projected increases(1-4). The basis for this 
assumption is doubtful, and secular trends (that is, 
gradual decreases or increases in prevalence over 
long-term periods) are perfectly plausible(5). The 
prevalence of any condition (the proportion of the 
population affected at a point in time) is a product of 
its incidence and the average duration of the disease 
episode. The incidence is the rate at which new 
cases develop within the population. The duration of 
dementia equates to time from incidence to death, 
given that recovery is, sadly, not possible. Changes in 
either or both of these indicators could lead to changes 
in age-specific prevalence(1). It should be noted that
a) Trends in the two indicators may not move in the 
same direction; for example reductions in incidence 
might be accompanied by increases in duration of 
survival with dementia, or vice versa; the one effect 
tending to cancel out the other in terms of their 
overall impact on prevalence.
b) One should not expect that secular trends will be 
the same across all world regions, or even among 
different population subgroups within one country. 
Experience with changing rates of cardiovascular 
disease, obesity, diabetes and cancer shows this 
clearly. The considerable variability in secular trends 
for these chronic diseases reflects different degrees 
of progress in improving public health, in improving 
access to healthcare, and in strengthening health 
systems and services to better detect, treat and 
control these conditions. 
4.1.1 Possible future trends in the 
incidence of dementia
A decline in age-specific incidence of dementia, 
at least in high income countries, is theoretically 
possible, driven by changes in exposure to suspected 
developmental, lifestyle and cardiovascular risk factors 
for dementia(5). The World Alzheimer Report 2014 
focused upon dementia risk reduction; the evidence-
base for modifiable risk factors for dementia(6). The 
strongest evidence for possible causal associations 
with dementia was for low education in early life, for 
hypertension in midlife, and for smoking and diabetes 
across the life course. In a recent modelling exercise, it 
was estimated that a 10% reduction in these and other 
key risk exposures would lead to an 8.3% reduction 
in the prevalence of dementia through to 2050, with a 
15.3% reduction in prevalence of dementia anticipated 
if there were a 20% reduction in exposure  
prevalence(7).
In most world regions, each generation is better 
educated than the one before. Although trends differ 
between countries, genders, age groups and time 
periods, there has been a general trend in many high 
income countries towards less smoking, falling total 
cholesterol and blood pressure levels, and increasing 
physical activity. On the other hand, the prevalence 
of obesity and diabetes has been increasing in most 
developed countries. The picture in many low and 
middle income countries is quite different; the trends 
in cardiovascular health among older people are in 
an adverse direction(8), with a pattern of increasing 
stroke(9) and ischaemic heart disease morbidity 
and mortality(10-12), linked to an epidemic of obesity, 
and increasing blood pressure levels(13). After a lag 
36
period, to the extent that these factors are genuinely 
causally associated with dementia, one would expect 
to see corresponding reductions (or increases) in the 
incidence of dementia. 
4.1.2 Possible future trends in survival 
with dementia
Secular trends in survival with dementia are difficult 
to measure. Estimates from clinical services are 
confounded by time of diagnosis. If diagnosis is being 
made at an earlier stage in the disease process, then 
duration of dementia may appear to be increasing, 
whereas this may only signify that people with 
dementia are in contact with services for a higher 
proportion of the overall disease duration. Estimates 
from cause of death on death certificates are generally 
uninformative for this purpose. In the first instance 
these provide information only on secular changes in 
the attribution of dementia as a cause of death, and 
not on the all-cause mortality rate among people with 
dementia. Second, the large increases in the age-
standardised rates of death attributed to dementia, for 
example in a recent analysis of trends in Europe from 
1979 to 2009(14), are likely to reflect a greater propensity 
to attribute deaths of people living with dementia to the 
disease, rather than to changes in dementia incidence 
or survival. 
A proper understanding of trends in survival with 
dementia will only come from monitoring all-cause 
mortality rates of those with and without the disease, 
and the ratio between them (standardised mortality 
ratio, or hazard ratio) over time. Mortality rates among 
older people continue to fall in all world regions, and 
for all age groups, accounting for impressive gains in 
life expectancy from age 60(15). This is now one of the 
main drivers of population ageing, particularly, but not 
exclusively, in higher income countries. An important, 
but as yet unanswered, question is whether these 
trends for declining mortality among older people in 
general apply equally to people living with dementia. 
Mortality rates among older people are much higher 
for those living with dementia. In the 10/66 Dementia 
Research Group studies in Latin America, India and 
China, after controlling for age and sex, in a Cox’s 
proportional hazards regression, hazard of death was 
1.56 to 5.69 times higher in those with dementia (meta-
analysed HR 2.80, 95% CI 2.48-3.15)(16). Effect sizes 
from studies in countries with low or middle incomes 
have tended to be higher than those indicated by a 
meta-analysis of studies principally from countries 
with high incomes (RR 2.63, 95% CI: 2.17-3.21)(17); a 
HR of 2.83 (95% CI: 1.10-7.27) in Nigeria(18), and HR of 
5.16 (95% CI: 3.74-7.12) in Brazil(19). If age-standardised 
mortality rates among people with dementia decline 
at the same rate as for those without dementia (i.e. 
the adjusted mortality ratio remains constant over 
time) survival with dementia, and hence disease 
duration, will increase progressively. Since most of the 
public health interventions that have been proposed 
to reduce the incidence of dementia (for example 
tobacco control, and prevention, and treatment of 
hypertension) also have benefits in reducing incidence 
and mortality from other chronic diseases, one 
should expect that reductions in prevalence arising 
from reduced incidence of dementia may be offset, 
at least to some extent, by reduced mortality and 
longer survival with dementia(20). Other factors; for 
example, improvements in standards of health and 
social care for people with dementia, and provision 
or withholding of life-prolonging critical interventions; 
might also be expected to have an influence on 
mortality rates among people living with dementia. In 
well-resourced advanced healthcare settings there is 
growing awareness that critical interventions should 
not be withheld, when these would improve quality of 
life, simply because someone has dementia, and in 
the context of end of life care the focus should be on 
palliation to improve quality of life, and interventions 
that merely prolong life with no other benefit or risk of 
harm to the patient should be withheld(21).
In low and middle income countries there is evidence 
that people with dementia currently have particular 
problems in accessing healthcare that might benefit 
their health and survival(22).
Finally, it should be noted that one of the indications 
of successful dementia risk reduction may be that 
the incidence of dementia is deferred to older ages. 
Thus, the average age of onset may increase over 
time. Under these circumstances age-specific or 
age standardised mortality for people with dementia 
may not change, but overall, for all people with 
dementia, mortality may be higher and survival with 
dementia shorter, reflecting that onset is occurring 
closer to the ‘natural’ end of life. Langa has described 
this phenomenon as ‘the compression of cognitive 
morbidity’(23), a desirable outcome for public health and 
individual quality of life, resulting in longer, healthier 
lives, with fewer years spent in a state of reduced 
independence and needing care. 
4.2 Research evidence
In 2009, what very few data were available from certain 
high income countries did not suggest any clear 
pattern of a decline or increase over time in either the 
incidence or prevalence of dementia(1;24;25). Meta-
analyses of European studies conducted since 1980 
also did not suggest any secular trend in prevalence. 
Just a few years later, and linked to a greatly increased 
interest in the potential for prevention of dementia by 
targeting modifiable risk factors(26;27), the quality and 
extent of the evidence has expanded greatly, with 
reports from several studies of trends in prevalence 
and/or incidence of dementia, and dementia mortality, 
within defined populations, using identical or very 
similar research methodology over time. 
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Table 4.1 
Studies estimating changes in prevalence of dementia or Alzheimer’s disease over time
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Table 4.2 
Studies estimating changes in the incidence of dementia or Alzheimer’s disease over time
Study Outcome/s Relative 
change (%)
Period Interval 
(years)
Relative 
change (%) 
per year
Other findings
Directly 
observed
1. USA, 
Indianapolis
African 
Americans, 
65 years and 
over(35) 
Dementia 
(DSM-III-R)
AD
55% reduction 
(dementia)
41% reduction 
(AD)
1991-
2002 
11 years -5.0%
-3.7%
Biggest reduction in youngest age groups.
See also notes for study 1, table 4.1
2. USA, 
Framingham, 
60 years and 
over(36) 
Dementia 
(criteria not 
specified)
42% reduction
AHR 0.58 
(0.38-0.86)
1980-
2006 
26 years -1.6% Biggest reduction in youngest age groups.
No reduction among the least educated.
Significant improvements in educational 
status, use of antihypertensive and statin 
medication, blood pressure and HDL levels, 
and prevalence of smoking, heart disease, 
and stroke, whereas prevalence of obesity 
and diabetes increased.
3. NL, 
Rotterdam, 60-
90 years(37) 
Dementia 
(DSM-III-R)
Non-significant 
25% reduction
RR 0.75 (0.56-
1.02)
1990-
2000 
10 years -2.5% Hypertension, diabetes and obesity increased. 
Higher education. More diabetes treatment, 
more antithrombotics and much more 
statins. More past but less current smoking. 
Substantial reduction in overall mortality - HR  
0.63 (0.52-0.77). 
4. Germany, 
insurance 
claims data, 
age 65 and 
over(38)
Dementia 
(ICD-10)
20% reduction 
(women)
19% reduction 
(men)
2004-
2007 / 
2007-
2010
3 years -6.7% Study used claims data of the largest public 
health insurance company in Germany. Data 
contained complete inpatient and outpatient 
diagnoses according to ICD-10. For the 
analysis of incidence two independent 
age-stratified samples were taken, the first 
comprising 139,617 persons in 2004 with 
a follow-up until 2007; the second 134,653 
persons in 2007 with a follow-up until 2010. 
Secular trends in clinical diagnosis or help-
seeking cannot be excluded.
5. USA, Chicago 
(30)
AD Stable
OR 0.97 (0.90-
1.04)
1997-
2008
11 years NA
6. Nigeria, 
Ibadan(35)
Dementia 
(DSM-III-R)
AD
Stable
1.5% vs 1.4% 
(dementia)
1.0% vs 1.3% 
(AD)
1991-
2002
11 years NA
Inferred
7. Stockholm, 
Sweden,  
75 years and 
over (28)
Dementia 
(DSM-III-R)
Reduced 
incidence 
inferred 
from stable 
prevalence 
but increased 
survival with 
dementia
1988-
2002
14 years Not 
reported
See also notes for study 5, table 4.1
40
Table 4.3  
Changes in mortality among people with dementia
Study Outcome/s Change in 
mortality and/or 
mortality hazard 
ratio
Period Interval (years) Other findings/notes
Directly observed
1. USA, HRS (23) Mortality hazard 
ratio
Non-significant 
increase, from HR 
2.53 to 3.11, p=0.09
1993-2002 9 years No report of absolute 
mortality rates, stratified 
or unstratified. However, 
given a presumed decline in 
overall mortality, it seems 
likely that mortality has also 
declined among people with 
dementia, but to a lesser 
extent
2. Stockholm, 
Sweden(28)
Mortality hazard 
ratio
Mortality rate 
among people 
with dementia
Stable HR – 2.42 
(2.03-2.87) vs. 2.47 
(2.03-3.00) 
29% reduction 
in mortality (HR 
0.71, 0.57-0.88) 
adjusted for age, 
sex, education and 
MMSE score
1988-2002 14 years Similar secular trend (30% 
reduction in mortality) to that 
for those with no dementia, 
and for both genders
3. Germany,  
insurance claims 
data, age 65 and 
over(31)
Mortality rate 
among people 
with dementia
11% increase in 
mortality among 
women (p<0.0001)
Stable mortality 
among men (1% 
increase, p=0.75) 
2004-2007 3 years
Inferred
4. USA, 
Indianapolis, African 
Americans, 65 
years and over(30;35)
Dementia 
duration
Increase in survival 
with dementia can 
be inferred from 
stable prevalence 
of dementia(30), 
but 55% fall in 
incidence(35)
1991-2002 11 years Extrapolation from reported 
prevalence and incidence 
rates at the two time points 
suggests that survival time 
with dementia is 2.4 times 
longer for the second cohort
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4.2.1 Studies of secular trends in 
dementia prevalence, incidence and 
mortality, applying constant methods to 
defined populations
These studies were identified from the systematic 
review of studies of dementia prevalence (see Chapter 
2), from searching the references of those relevant 
studies identified, and in the case of mortality, 
by conducting a search using the search terms 
“(dementia or alzheim*) and (mortality or survival) and 
trend*”. We identified nine studies that had tracked 
dementia prevalence, seven that had tracked dementia 
incidence, and four that had tracked mortality 
among people with dementia. Findings across these 
studies conducted, mainly, in high income countries, 
are currently too inconsistent to reach firm and 
generalisable conclusions regarding underlying trends 
(see Tables 4.1-4.3). 
Dementia prevalence
For studies of the prevalence of dementia, just one 
study, the MRC Cognitive Function and Ageing Study 
(MRC-CFAS) reports a statistically significant decline 
in the prevalence of dementia, between 1993 and 
2011. This is, however, consistent with a somewhat 
higher but statistically non-significant decline in the 
prevalence of dementia in Zaragoza, Spain, and with 
a decline in the prevalence of moderate to severe 
cognitive impairment seen in the USA National Health 
and Retirement Survey (HRS). The annual rates of 
relative change in prevalence were -1.7%, -3.6% and 
-3.2% per year respectively. Set against this, other 
studies from Sweden(28;29), and USA(30) indicated a 
stable prevalence of dementia, consistent with short-
term trends in German insurance claims data(31). In a 
third Swedish study of short-term trends in dementia 
prevalence among the oldest old, prevalence had 
increased by 40% between 2001 and 2006(32). In the 
Japan Hisayama study, there was a non-significant 
38% relative increase in the prevalence of dementia 
between 1985 and 2005, with a marked increase in 
the proportion of cases accounted for by Alzheimer’s 
disease(33). This is consistent with findings from one 
other Japanese study of secular trends, with a 23% 
increase in the prevalence of dementia between 
1980 and 2000(34). This study was excluded from this 
review because its ascertainment procedures did 
not meet the minimum criteria we have set for our 
global estimates of dementia prevalence (see Chapter 
2). However, although inadequate, they were held 
constant between the three waves of the study.
Dementia incidence
Evidence for a decline in the incidence of dementia is 
perhaps marginally stronger. Statistically significant 
reductions in the incidence of dementia were reported 
in two US population-based studies, one of African-
Americans in Indianapolis(35), the other from the 
Framingham study(36). The annual rates of relative 
change, -5.0% and -1.6% respectively, are consistent 
with a non-significant -2.5% annual rate of relative 
change in incidence reported in the Rotterdam 
study(37). A very substantial decline in dementia 
incidence was reported from analysis of German 
insurance claims data, but with only a three-year 
interval between the midpoints of the two follow-up 
periods, this seems unlikely to be explained by a 
genuine change in underlying population incidence(38). 
To the extent that changes in incidence can be inferred 
from changes in prevalence and mortality, data from 
repeated surveys in Stockholm, Sweden are also 
consistent with a decline in dementia incidence(28). On 
the other hand, population-based studies conducted 
in Chicago, USA(30), and Ibadan, Nigeria(35) indicated 
a stable incidence of dementia over 11 year periods. 
One study, reporting a stable incidence of dementia 
in Beijing China, was excluded from the review, since 
it used different diagnostic criteria at the two time 
points(39).
Dementia mortality
Very few of these longitudinal studies have taken the 
opportunity to study or report changes in mortality/
survival among people with dementia, or the ratio 
of mortality rates between those with and without 
dementia. In the Rotterdam study, overall mortality 
had declined by 37% in the 10 years between the two 
cohorts, but this was not stratified by dementia status. 
In the USA HRS, and in the Stockholm study(28), the 
mortality ratio remained relatively stable over time, 
suggesting that, if mortality rates were falling among 
those without dementia, there would have been similar 
rates of decline for those living with dementia. This was 
clearly demonstrated in the Stockholm study, where a 
relative decline in mortality rates of 30% over 14 years 
was seen for those with and without dementia, for both 
genders(28).  
The relationships between trends in prevalence, 
incidence and mortality are particularly unclear, 
partly because, in most studies, only some of these 
parameters were directly observed. In Stockholm 
(where prevalence and mortality were observed), 
and in Indianapolis (where prevalence and incidence 
were observed), findings are consistent with declining 
incidence, but stable prevalence, accounted for by 
increasing duration of dementia (declining dementia 
mortality). Only in the German insurance claims 
data were changes in prevalence, incidence and 
mortality reported, but these are mutually inconsistent, 
perhaps because different samples were used for the 
prevalence(31) and incidence/mortality analyses(38). 
If the onset of dementia occurs close to the end 
of the natural life span, fewer years may be lived 
with dementia. Two studies suggest that decline in 
incidence may be greater in younger age groups, 
suggesting that the incidence of dementia may be 
being deferred into older age(35;36). This may be 
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consistent with the observation of an increasing 
prevalence of dementia among the oldest in one 
Swedish study(32), but is inconsistent with the 
observation from the MRC-CFAS study of greater 
reductions of dementia prevalence among older age 
groups(40).
4.2.2 Secular trends within regions 
estimated from meta-analyses of 
individual studies
Another approach to estimating secular trends involves 
combining evidence from all studies conducted within 
a particular country or region, using a meta-analytical 
approach, and meta-regression to estimate the effect 
of time of study upon prevalence. This approach was 
used in the World Alzheimer Report 2009 to estimate 
secular trends in dementia prevalence in Europe(1). One 
problem with such exercises is that, in contrast with the 
studies previously reviewed (section 4.2.1), which hold 
such factors constant, there is inevitably considerable 
heterogeneity in the nature of the population studied, 
and the methods used for the surveys, which may 
in turn affect the prevalence recorded. It is therefore 
important, to the extent possible, to control for such 
effects in the meta-regression. 
In the European meta-analyses, we found no evidence 
for a trend in prevalence between 1980 and 2008, and 
this held true when we updated the evidence base to 
include more recent surveys, for the current report (see 
Chapter 2). 
East Asia is the one other world region with sufficiently 
numerous prevalence studies to permit meta-
regression and estimation of secular trends in dementia 
prevalence. A study of secular trends in Japan (part of 
the adjacent Asia Pacific High Income region) reported 
a tendency towards increasing prevalence, but this 
was based on only eight data points, including the four 
waves of the Hisayama study(33), and did not control for 
study methodology(41). The East Asia evidence-base, 
and the population of older people at risk is dominated 
by P.R. China, the focus for one meta-analysis(42), 
while a second also included studies conducted in 
Hong Kong SAR and Taiwan(43). Estimates taken from 
the China meta-analysis suggested a 46% relative 
increase in age-standardised prevalence from 1990 
to 2010 (+2.3% per year), while from the wider review 
the increase was 171% from studies conducted in 
the pre-1990 period to 2005-2012. However, in that 
study, the secular trend was considerably reduced, to 
72%, and was no longer statistically significant, having 
controlled for study methodology. The most important 
potential confounder appeared to be the choice of 
dementia diagnostic criteria. Older studies tended to 
use DSM-III or DSM-III-R criteria, which then tended 
to record a lower prevalence of dementia than those 
more recent studies that used DSM-IV dementia, 10/66 
Dementia Research Group criteria or GMS/AGECAT 
criteria. For the purposes of estimating current 
dementia prevalence, and numbers affected, this is 
an important finding, which motivated our decision to 
use estimates from our meta-analysis for the period 
2005 onwards in estimating current prevalence for 
China (see Chapter 2). Whether the higher estimates 
for this most recent period were explained by real 
underlying secular trends, or use of more updated 
and valid diagnostic criteria, or both, was relatively 
immaterial to this decision. However, for the purposes 
of forecasting future trends in prevalence and numbers 
in the region, the distinction is clearly crucially 
important(44). As previously indicated, there is evidence 
that cardiovascular health is deteriorating among 
older people in China(10), a trend also evident in other 
middle income countries(8). The prevalence of smoking 
among adult men in China is among the highest in the 
world, and an epidemic among younger women is well 
underway(45). Rapid dietary transition is leading to an 
epidemic of obesity and cardiometabolic disease(46). A 
recent modelling exercise assessed the likely impact 
of recent increases in obesity among middle-aged 
Chinese on dementia prevalence, assuming a causal 
link with dementia; it concluded that future dementia 
prevalence in China may have been underestimated by 
up to 19% given the additional impact of epidemiologic 
transition(47).
4.3 Conclusion
There is no clear evidence from this review to justify 
a departure from our current position of assuming 
constant age-specific dementia prevalence, when 
making projections of the numbers likely to be 
affected in the future. Prudent policymakers should 
also adopt this approach. Nevertheless, the future 
course of the global dementia epidemic, through 
to 2050 is likely to depend, at least to some extent, 
upon the success or otherwise of continuing efforts 
to improve public health(6;27). Those who will be 
old in 2050 were born around the 1970s, and have 
already received their basic education. They are 
now in their third and fourth decades of life, a crucial 
‘sensitive period’ where, evidence suggests, efforts 
to prevent, detect and control obesity, hypertension, 
diabetes and dyslipidaemia (high cholesterol) are 
likely to have maximum positive impact upon brain 
health and dementia risk in late-life(6;27). Such public 
health strategies, alongside secular improvements 
in education, are plausibly likely to result in a 
progressive decline in age-specific incidence of 
dementia in high income countries, the magnitude 
of which is currently uncertain. However, whether 
or not this is accompanied by a decline in the age-
specific prevalence of dementia will depend upon 
any coincident changes in survival/mortality patterns 
for people living with dementia, which are difficult 
to predict from current data. Most of the more 
plausible scenarios are more consistent with a stable 
or modestly increasing disease prevalence(20;48). 
43The Global ImpacT of DemenTIa
alzheImer’s DIsease InTernaTIonal: WorlD alzheImer reporT 2015
Current evidence of adverse trends in cardiovascular 
risk factors and morbidity in low and middle income 
countries are consistent with a future increase in 
dementia age-specific incidence and prevalence in 
those regions.
Studies that use fixed methodology to estimate 
changes in dementia prevalence, incidence and 
mortality over time, in defined populations, are 
uniquely valuable assets. It is important in the future 
that more such studies are commissioned. The most 
valuable will be those that track all three parameters 
over time, which none of the studies reviewed in this 
chapter did. Surveys with nationally representative 
samples will have the greatest generalisability, and 
the greatest potential both to inform and track the 
impact of national policies. Where trends are observed 
it will be important to relate these to compositional 
changes in the population, particularly to changes 
in levels of exposure to critical risk factors (see also 
following paragraph). However, very few studies made 
a comprehensive assessment of such compositional 
factors and their changes over time, and in only one 
study was there an attempt to attribute changes 
in dementia frequency to changes in risk factor 
exposure(23). It is clearly important that such studies do 
indeed hold methodology constant – several of those 
reviewed here did in fact make small changes between 
waves, the effect of which upon the observed trends 
cannot be determined with complete confidence(30;40). 
Naturally, diagnostic criteria change over time, but 
these too must be held constant to make meaningful 
comparisons, a problem that can be surmounted by 
using the updated alongside the original criteria, where 
feasible and considered important. More intractable 
problems are the probable changes in clinician training, 
practice, and opinions regarding the operationalisation 
of diagnostic criteria(44). This may also be countered 
through the application of structured assessments 
and diagnostic algorithms, such as the AGECAT 
computerised algorithm linked to the Geriatric Mental 
State(49), as employed in the MRC-CFAS  studies(40), or 
the 10/66 Dementia Research Group’s cross-culturally 
validated diagnostic algorithm(50;51).
Previous modelling exercises have sought to 
predict what might happen to the future prevalence 
of dementia, given our best estimates of risk 
associations, and possible changes in those risk 
factor profiles over time(7;47). In the light of the current 
review, these estimations appear over-optimistic. An 
alternative approach is to observe and correlate actual 
changes in risk factor profiles and dementia incidence 
over time. This is a well-established modelling 
approach in the cardiovascular disease field and 
has contributed greatly to our understanding of the 
potential for prevention, and the attribution of changes 
in disease incidence to specific factors, to further 
guide prevention strategies(52-54). Similar studies could, 
in the future, be carried out to monitor the impact of 
prevention programmes on the future scale of the 
dementia epidemic. 
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chapTer 5 
The impact of dementia worldwide
5.1 Introduction
In the World Alzheimer Report 2009, we highlighted 
that a better understanding of the growing numbers of 
people worldwide living with dementia was necessary, 
but insufficient to characterise the global impact of the 
epidemic. Numbers convey neither the quality of the 
individual experience of living with dementia, nor wider 
consequences for the household, family, community 
and society as a whole. We suggested that the impact 
of dementia could be understood at three inter-related 
levels:
1. The person with dementia, who experiences ill 
health, disability, impaired quality of life and reduced 
life expectancy.
2. The family and friends of the person with dementia, 
who, in all world regions, are the cornerstone of the 
system of care and support.
3. Wider society, which, either directly through 
government expenditure, or in other ways, incurs 
the cost of providing health and social care and the 
opportunity cost of lost productivity. Other social 
impacts may be harder to quantify, but no less real.
5.2 The Global Burden of Disease 
approach (GBD)
One approach for assessing the impact of dementia, 
and comparing it with other health conditions, is 
to use the Global Burden of Disease estimates. 
These provide information on the relative impact 
of different health conditions worldwide, and have 
influenced prioritisation for policymaking and planning 
nationally, regionally and internationally. The impact 
is referred to as ‘burden’ and expressed in terms of 
associated disability and mortality. The World Health 
Organization’s Global Burden of Disease Report 
was first published in 1996, and updated through to 
2004(1;2). The key indicator is the Disability Adjusted 
Life Year (DALY), a composite measure of disease 
burden calculated as the sum of Years Lived with 
Disability (YLD) and Years of Life Lost (YLL). Thus, 
the DALY summarises the effects of diseases, both 
on the quantity (premature mortality) and quality of 
life (disability). These effects are summed across 
estimated numbers of affected individuals to express 
the regional and global impact of disease. The effect 
of living for one year with disability depends upon 
the disability weight attached to the health condition 
concerned. In a wide international consensus 
consultation for the Global Burden of Disease report, 
disability from dementia was accorded a higher 
disability weight (0.67) than that for almost any other 
condition, with the exception of severe developmental 
disorders(3). This weight signified that each year lived 
with dementia entails the loss of two-thirds of one 
DALY.
5.2.1 The IHME Global Burden of Disease 
estimates
In the 2009 report we explained that the WHO GBD 
estimates were shortly to be comprehensively revised 
by the Institute of Health Metrics and Evaluation (IHME) 
with funding support from the Gates Foundation. IHME 
introduced three important innovations(4):
1. The revised estimates would be founded on 
new updated systematic reviews of prevalence, 
incidence and associated mortality for 291 
diseases and injuries. The reviews for dementia 
were conducted by ADI’s Global Observatory team, 
and comprised all of the evidence on dementia 
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prevalence, incidence and mortality summarised 
in the World Alzheimer Report 2009(5), and the 
subsequent joint WHO/ADI report(6). The evidence 
base had extended considerably from 1996, and 
our own analyses of these data suggested that 
prevalence and numbers of people with dementia 
may previously have been underestimated in several 
world regions.  
2. New disability weights would be calculated for an 
expanded set of 220 unique health states, based 
on the views of the general public, from surveys of 
representative samples of adults in several countries 
and cultures. Separate weights would be calculated 
for mild, moderate and severe dementia. Presciently, 
we warned that “the impact of these revised 
weights on Years Lived with Disability and Disability 
Adjusted Life Years is difficult to predict”.
3. Age-weighting, by which years lived in old age 
(and childhood) were accorded a lower value than 
those lived in ‘productive’ adulthood, and future 
discounting (on the basis that a year lived now is 
accorded greater value than one to be lived in the 
future) have rightly proved controversial and were 
abandoned in the IHME GBD. All other things being 
equal, this should have resulted in an increase in the 
relative contribution of dementia to global burden of 
disease. 
5.2.2 The IHME disability weights
The disability weights accorded to each health 
condition have a critical impact upon the estimates of 
years lived with disability (YLD), but not years of life 
lost (YLL). However, since DALYs are the sum of YLD 
and YLL, the impact upon YLD is also apparent in the 
summary DALY estimate. 
The disability weights for IHME GBD were estimated 
from population surveys of those aged 18 and over in 
Bangladesh, Indonesia, Peru, Tanzania and the USA 
(n=13,902), boosted by an international internet survey 
(n=16,328). The surveys used paired comparison 
questions, in which respondents considered two 
hypothetical individuals with different, randomly 
selected health states and indicated which person they 
regarded as healthier.
There was a high correlation among respondent 
judgments, and between countries. The correlation 
between the new IHME and original GBD disability 
weights was moderately high (0.70), although higher 
for moderate and severe than for milder health states. 
However, the IHME disability weights for dementia 
were considerably lower than those for the WHO 
GBD(3;7). The IHME weights for mild, moderate and 
severe dementia were 0.08, 0.35 and 0.44 respectively
(7), compared to a weight of 0.67 that was applied 
uniformly to all severities of dementia in the WHO 
GBD(3). The highest disability weights accorded in the 
IHME exercise were for schizophrenia; 0.76 during an 
acute episode, and 0.58 for the residual chronic state. 
For further contextualisation, IHME disability weights 
for mild, moderate and severe forms of other chronic 
diseases are summarised in Table 5.1. It can be seen 
that the weights for dementia are higher than those 
for hearing loss and distance vision impairment, heart 
failure and Chronic Obstructive Pulmonary Disease 
(COPD), similar to those for stroke and Parkinson’s 
diseases, and lower than those for alcohol use 
disorder, generalised musculoskeletal disorders, 
multiple sclerosis, and depression.
The IHME disability weights for dementia can also 
be compared with those from a Dutch study that 
used a similar approach to the WHO GBD, but a 
more structured two phase methodology; 0.27 for 
mild dementia (with impairments in daily activities 
of living), 0.63 for moderate dementia (unable to live 
independently), and 0.94 for severe dementia (requiring 
permanent supervision)(9). The later European Disability 
Weights project estimated a disability weight of 0.46 for 
mild dementia with little variation across panels from 
different European countries, and between health care 
professionals and lay raters(10). 
5.2.3 Comparing the WHO and IHME 
Burden of Disease estimates
The most recent WHO GBD estimates refer to the 
year 2004, while those for IHME refer to 2010. The 
frequency of conditions (prevalence and incidence) 
should not have changed markedly over this interval, 
but the size of the older population had increased from 
Table 5.1 
Disability weights for selected conditions (IHME GBD), in 
order of the weight allocated for severe disorder(8)
Condition Mild Moderate Severe
Hearing loss 0.01 0.02 0.03
Distance vision impairment 0.00 0.03 0.19
Heart Failure 0.04 0.17 0.19
Chronic Obstructive 
Pulmonary Disease
0.02 0.19 0.38
Dementia 0.08 0.35 0.44
Stroke with long term 
consequences
0.02 0.31 0.54
Parkinson’s Disease 0.01 0.26 0.55
Alcohol Use Disorder 0.26 0.39 0.55
Musculoskeletal problems, 
generalised
- 0.29 0.61
Major Depressive Episode 0.16 0.41 0.66
Multiple sclerosis 0.20 0.45 0.71
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658.7 million to 754.9 million. Direct comparisons can 
be made by considering the proportionate contribution 
of dementia to the total burden of disease, and by 
comparing estimates per capita (or more precisely 
per 1,000 older people). With either approach, it is 
clear that, while burden from years of life lost remains 
stable across the two methodologies, there has been 
a substantial reduction in the estimation of years lived 
with disability attributed to dementia, with a knock-on 
effect on the DALY estimates (Table 5.2). Per capita, 
the IHME GBD estimates of YLL are 0% lower than 
WHO GBD estimates, YLD 65% lower, and DALYs 54% 
lower. 
The IHME estimates were also calculated 
retrospectively for the year 1990, applying the same 
methodology, including disability weights, as for 
the 2010 estimate. This approach incorporates any 
changes in the estimates of disease frequency, and 
changes in the population distribution (in 1990 there 
were 487.5 million people aged 60 years and over 
compared with 754.9 million in 2010). Among older 
people, DALYs attributed to dementia had increased 
from 4.7 million in 1990 (1.1% of the total DALY burden) 
to 10.0 million (1.7%) in 2010. As highlighted in IHME 
GBD publications(11), the % DALY increase from 1990-
2010 for dementia (113%) is among the largest for any 
disease or disease group, comparing with 28% for 
ischaemic heart disease, 22% for stroke, 27% for all 
cardiovascular diseases, 79% for diabetes, 35% for 
cancer, 23% for digestive diseases, 46% for sensory 
impairment, and 55% for musculoskeletal diseases
(12). However, adjusting for population size, the DALYs 
per 1000 population for dementia were 9.6 million 
per 1000 in 1990 and 13.2 million per 1000 in 2010, 
indicating that most of this increase was accounted for 
by population ageing. 
5.2.3.1 Disability Adjusted Life Years 
(DALY) estimates
Disability Adjusted Life Years (DALYs) are the sum of 
Years Lived with Disability (YLD) and Years of Life Lost 
(YLL), hence combining the impact of disability and 
premature mortality into a single summary indicator. 
Years of life lost make much the larger contribution to 
the total. Thus, for the IHME GBD estimates overall 
there were 411.6 million years of life lost among people 
aged 60 years and over, and 162.8 million years lived 
with disability, signifying that, according to the GBD 
methodology, premature mortality contributes 72% 
of overall DALY burden, and disability 28%. This is 
reflected in the list of 10 conditions with the largest 
contribution to Disability Adjusted Life Years (Table 
5.3), which is dominated by ischaemic heart disease, 
stroke and chronic obstructive pulmonary disease, 
all conditions with a substantial associated mortality. 
Collectively, the ten conditions account for just over 
half of the total disease burden among older people. 
While the most burdensome conditions are similar 
across the two methodologies, their rank order has 
changed. Dementia has slipped from 5th to 9th place 
on the list, and visual impairment from 4th to 8th.  
According to IHME GBD, low back pain was now the 
5th most burdensome condition among older people. 
Considering people of all ages, dementia ranked 
the 49th most burdensome condition worldwide(11). 
However, it ranked between 12th and 20th in high 
income regions, 26th to 50th in Latin American regions, 
41st in East Asia, 70th in south east Asia, and between 
66th and 101st in sub-Saharan African regions. 
5.2.3.2 Years Lived with Disability (YLD) 
estimates
Dementia shortens the lives of those affected. 
However, it is prominent among those conditions 
of later-life, for which the contribution of chronic 
disability and needs for care is greater than that of 
premature mortality(12). It is therefore important also 
to analyse the contribution of dementia to years lived 
with disability (YLD), relative to that of other health 
conditions. For this purpose we used the second 
order IHME chronic disease clusters, other than for 
stroke and heart disease, and dementia, which is part 
of the neurological disorders cluster but accounts for 
the large majority of YLDs in this group. This analysis 
Table 5.2 
WHO GBD and IHME GBD estimates of Years of Life Lost, Years Lived with Disability and Disability Adjusted Life Years attributed to 
dementia condition among older people
WHO GBD (2004) IHME GBD (2010)
Aggregated estimates – 
millions of years (% of 
total burden)
Millions of years, per 
1,000 older people
Aggregated estimates – 
millions of years (% of 
total burden)
Millions of years, per 
1,000 older people 
Years of Life Lost 3.4 (0.9%) 5.2 3.9 (0.9%) 5.2
Years Lived with 
Disability
15.4 (13.1%) 23.4 6.2 (3.8%) 8.2
Disability Adjusted Life 
Years 
18.8 (4.2%) 28.7 10.0 (1.7%) 13.2
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reveals very important shifts in the rank order of 
disease contributions, between the GBD and IHME 
GBD estimates (Table 5.4). The YLDs attributed to 
dementia have been cut by 60%, those for visual 
impairment by 66%, those for hearing loss by 42%. 
Conversely, the YLDs attributed to mental disorders 
have increased by 131%, for musculoskeletal disorders 
by 275%, and those for genitourinary disorders by 
725%. Dementia has slipped from 2nd to 8th on the 
list of conditions making the most impact upon years 
lived with disability, visual impairment from 1st to 4th, 
and hearing loss from 3rd to 6th. Mental disorders 
have been elevated from 5th to 2nd place on the 
list, musculoskeletal disorders from 4th to 1st, and 
genitourinary disorders from 11th to 7th. 
5.2.4 Summary of findings from the 
Global Burden of Disease estimates
In summary, dementia is among the top 10 most 
burdensome conditions among older people 
worldwide. In contrast with other conditions, its impact 
comes mainly from years lived with disability, rather 
than years of life lost from premature mortality. The 
health loss attributed to dementia is much smaller 
in the latest IHME GBD estimates (2010) than in 
the previous WHO GBD estimates (2004), and its 
rank position relative to other impactful conditions 
has slipped accordingly. Dementia is not the only 
condition to be affected in this way. The relative 
impact of sensory impairment is much reduced, 
while that of mental and musculoskeletal disorders is 
much increased. This is, for the most part, because 
of changes in disability weights, rather than in the 
estimates of the frequency of these disorders. Seismic 
shifts in the burden of disease between the original 
WHO 2004 estimates(13) and the IHME 2010 estimates 
11 have neither been highlighted nor explained in IHME 
publications. Instead the focus has been upon the 
1990-2010 trends using the IHME methodology, which 
do indicate an important global increase in the impact 
of dementia(11).
5.2.5 Limitations of the Global Burden of 
Disease approach
Concerns have been expressed, in general, regarding 
the use of global burden of disease estimates to 
determine allocation of resources. An important 
critique is that such decisions should be based not 
on burden alone, but on potential to reduce burden 
through the scaling up of interventions that are cost-
effective(14;15). A counter argument for conditions such 
as dementia, where no such interventions yet exist, 
would be that the size of the burden should be an 
important factor in determining research spending into 
new treatments, and that diagnostic and supportive 
services are required to meet the need arising from the 
burden. 
Table 5.3  
The 10 leading contributors to Disability Adjusted Life Years burden among people aged 60 years and over, according to the WHO 
GBD (2004) and IHME GBD (2010) methodology
WHO GBD (2004) IHME GBD (2010)
Condition Million DALYs 
(% contribution 
to total)
Rank order Condition Million DALYs (% 
contribution to 
total)
Rank order
Ischaemic heart disease 67.6 (15.0%) 1 Ischaemic heart disease 77.7 (13.5%) 1
Stroke 55.4 (12.3%) 2 Stroke 66.4 (11.6%) 2
Chronic obstructive pulmonary 
disease
33.1 (7.3%) 3 Chronic obstructive 
pulmonary disease
43.3 (7.5%) 3
Visual impairment 30.9 (6.9%) 4 Diabetes 22.6 (3.9%) 4
Dementia 18.8 (4.2%) 5 Low back pain 19.1 (3.3%) 5
Diabetes 13.9 (3.1%) 6 Trachea, bronchus or lung 
cancer
18.6 (3.2%) 6
Hearing loss 13.0 (2.9%) 7 Falls 12.4 (2.2%) 7
Trachea, bronchus or lung 
cancer
12.8 (2.8%) 8 Visual impairment 10.4 (1.8%) 8
Hypertensive heart disease 9.7 (2.2%) 9 Dementia 10.0 (1.7%) 9
Osteoarthritis 8.1 (1.8%) 10 Tuberculosis 9.2 (1.6%) 10
Total (all conditions) 450.9 Total (all conditions) 574.4
49The Global ImpacT of DemenTIa
alzheImer’s DIsease InTernaTIonal: WorlD alzheImer reporT 2015
The Disability Adjusted Life Year (DALY) metric gives 
undue prominence to those conditions strongly 
associated with mortality (principally cardiovascular 
disease and cancer), diverting attention from other 
conditions; for example dementia, stroke, COPD and 
vision impairment; where the burden of disease arises 
as much, if not more, from disability than mortality(16), 
and where long-term care costs can dwarf health 
expenditure. The societal costs of these disorders are 
enormous, particularly in high income countries with 
welfare-based social care systems. 
Perhaps the most important limitation arises from the 
disability weights attached to individual conditions. The 
IHME disability weights have proved to be one of the 
most controversial elements of the new Global Burden 
of Disease estimates. Other specialist groups have 
raised concerns, the most telling of which has been 
that some of the weights fail to pass the ‘common 
sense test’, for example that severe distance vision 
impairment (in effect, blindness) should be accorded 
a lower weight (0.20) than mild alcoholism (0.26), 
moderate rheumatoid arthritis (0.29) or neck pain  
(0.22) (17). However, one should be cautious when 
critiquing the new weights. As the leaders of the IHME 
exercise have pointed out, the weights were developed 
using a robust methodology that was approved in 
advance by the expert groups, who themselves drafted 
the vignettes that were submitted to the respondents in 
an unprecedentedly extensive international survey(18). 
The stratification of many conditions into mild, 
moderate and severe forms was a valuable innovation 
introduced by IHME, reflecting the fact that a small 
minority of people affected by most conditions are 
living with the most severe form of the disorder. For 
dementia, arguably, the application of a very high 
weight (0.67) to all people with dementia regardless 
of disease stage may have led to an overestimation 
of impact in the WHO GBD. Apparently, most of the 
expert groups, including that for dementia, have 
complained that the IHME weights for their condition 
were too low, and as the IHME leaders point out, they 
cannot all be right(18). There are, however, several valid 
concerns. 
1. Disability weights will be affected by choice 
of respondents used to determine them. The 
WHO GBD weights(3) were determined through 
a consensus of international experts with the 
experience of treating and caring for people with 
the health conditions, whereas the IHME weights 
reflected, mainly, judgments of the general public(7). 
Who is best placed to judge the lived experience 
of someone with a health condition, the person 
themselves, a carer, a health professional, or 
a representative sample of the general public, 
comprising a relatively small proportion of those 
with more direct experience?
2. The information provided about the health states, 
and the precise wording of the vignettes used to 
describe each of the health states is likely to have 
an important impact upon respondent perceptions. 
The instruction for the IHME weighting exercise 
was that the condition could only be described in 
lay language, and in terms of its impact on health 
(symptoms and impairments) rather than the wider 
impact on disability and functioning. This was a 
Table 5.4  
The 12 leading contributors to Years Lived with Disability among people aged 60 years and over, according to the WHO GBD (2004) 
and IHME GBD (2010) methodology
WHO GBD (2004) IHME GBD (2010)
Chronic disease/ condition Million YLD (% 
contribution to total)
Rank order 
(YLD)
Chronic disease/ condition Million YLD (% 
contribution to total)
Rank order 
(YLD)
Visual impairment 30.9 (26.4%) 1 Musculoskeletal disorders 42.0 (25.8%) 1
Dementia 15.4 (13.1%) 2 Mental disorders 16.2 (10.0%) 2
Hearing loss 13.0 (11.1%) 3 Chronic respiratory 11.8 (7.2%) 3
Musculoskeletal disorders 11.2 (9.6%) 4 Visual impairment 10.4 (6.4%) 4
Mental disorders 7.0 (6.0%) 5 Diabetes/ endocrine 9.0 (5.5%) 5
Chronic respiratory 5.8 (5.0%) 6 Hearing loss 7.5 (4.6%) 6
Heart disease 4.7 (4.0%) 7 Genitourinary disorders 6.6 (4.1%) 7
Diabetes/ endocrine 4.6 (3.9%) 8 Dementia 6.2 (3.8%) 8
Stroke 4.4 (3.8%) 9 Heart disease 4.8 (2.9%) 9
Cancer 2.6 (2.2%) 10 Stroke 3.0 (1.8%) 10
Genitourinary disorders 0.8 (0.7%) 11 Cancer 2.9 (1.8%) 11
Digestive disorders 2.2 (1.9%) 12 Digestive disorders 1.0 (0.6%) 12
Total YLD burden (all 
diseases) 
117.0 (100%) 162.8 (100%)
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particular challenge for the dementia vignettes, 
which are provided in full in Box 5.1. 
3. Perhaps the most significant issue is the way in 
which the questions were framed. Respondents 
were asked to compare two health states, and 
decide which person was ‘the healthier’, not ‘the 
least disabled’, nor ‘the best able to function 
independently’. This is consistent with the IHME 
concept of ‘health loss’, which is central to the new 
GBD enterprise. However, this is some way from the 
original WHO conceptualisation, which was more 
closely linked to the WHO International Classification 
of Impairment, Disability and Handicap (ICIDH), 
and the later WHO International Classification of 
Functioning (ICF), which consider the impact of 
health conditions and context upon activity and 
participation. IHME weights are, in reality, ‘health 
weights’ rather than ‘disability weights’, since they 
do not measure the limitations of functioning, 
activity, or social participation that by international 
consensus define disability(19). 
5.2.6 Does the under-prioritisation 
of dementia in the Global Burden of 
Disease estimates matter?
The WHO, and now the IHME GBD estimates have 
been highly influential in setting national, regional and 
intergovernmental priorities for policy development and 
investment in health care. An example is the WHO’s 
Mental Health Gap Action Plan (mhGAP); dementia was 
one of nine priority mental and neurological disorders 
selected explicitly on the basis of their contribution to 
global burden of disease (WHO GBD in this instance), 
as well as the size of the treatment gap in resource 
poor settings(20). The WHO has been criticised in the 
past for failing to align its budgetary allocation to 
disease burden(21). Similar considerations applied to 
the identification of cardiovascular disease, diabetes, 
cancers and COPD as leading priorities for the UN 
high-level meeting on non-communicable disease 
prevention and control, and the acknowledgment that; 
“Mental and neurological disorders, including 
Alzheimer’s disease, are an important cause 
of morbidity and contribute to the global non-
communicable disease burden, for which there 
is a need to provide equitable access to effective 
programmes and health-care interventions.”(22) 
Global Burden of Disease estimates have also been 
used to hold governments and other bodies to account 
for the rationality of allocation of research grant 
funding(23-25), and the generation of research evidence 
through clinical trials(26) and Cochrane systematic 
reviews(27).
5.3 Alternative approaches to 
understanding the impact of 
dementia
The most important critique of the Global Burden of 
Disease estimates is that these fail, in important ways, 
to capture the true impact of different chronic diseases 
upon disability, needs for care, and attendant societal 
costs(19). This limitation is most evident for older 
people, among whom most of these needs arise, and 
for conditions such as dementia, vision and hearing 
loss and musculoskeletal disorders, where most of the 
impact comes from disability rather than associated 
mortality(12). This was already a problem for the WHO 
Box 5.1
Ihme vignettes for mild, 
moderate and severe 
dementia health states
Mild dementia: The person has noticed 
deterioration in their memory, particularly for 
recent events. For example, they may forget 
that their daughter had visited the previous 
day, or when or whether they had taken their 
last medication. They also find it difficult to 
concentrate, think flexibly, plan, and take 
decisions. They are likely to feel bewildered, 
anxious and sad. They may become angry and 
defensive when others point out errors.
Moderate dementia: The person has severe 
memory problems. Only early memories are 
retained. Recent events are not remembered, or 
rapidly forgotten. They may not know the day, 
date or time of day. They often do not know 
where they are. They cannot communicate 
clearly, having problems finding the right word 
and using the wrong words. They may hear 
voices or see things that are not there, and can 
develop false beliefs, for example that children 
are entering their house and stealing things. They 
are likely to be anxious, sad, bewildered, and can 
become agitated or aggressive. 
Severe dementia: The person has complete 
memory loss. They may no longer recognise 
their close family. They have severe speech 
difficulties or are unable to communicate. They 
may be apathetic and totally inactive, but at 
times can be agitated and verbally and physically 
aggressive. They cannot coordinate their physical 
movements; may have lost the ability to walk and 
feed themselves and have difficulty swallowing. 
They are likely to be incontinent of urine and 
faeces. 
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GBD estimates(16), and has been greatly exacerbated 
with the shift to the IHME system with its new weights, 
and its focus upon ‘health loss’.  
One approach would be simply to stop using currently 
formulated DALYs (or the YLD component) when 
assessing the impact of disabling conditions(19). There 
is, at least, a strong case for renaming the IHME 
indicators as Health Adjusted Life Years (HALYs) and 
Years of Health Lost (YHL), to limit the potential for 
misinterpretation. 
An alternative approach would be to incorporate 
direct survey assessments of activity limitation, and 
participation restriction derived from information 
gathered from those affected. Such an approach 
has been advocated in the past(16;19;28), and seems 
to be being given active consideration by the IHME 
leadership(7). The IHME burden of disease estimates 
are highly discrepant with findings from studies of the 
directly measured disability, dependence, and cost 
associated with chronic diseases, which provide a 
very different picture regarding the societal impact 
of dementia relative to other non-communicable 
conditions. The ‘evidence test’ is much more important 
than the ‘common sense’ test referred to earlier. The 
relevant evidence has been reviewed previously in the 
World Alzheimer Report 2009 and the World Alzheimer 
Report 2013(5;29), and is updated and summarised 
briefly here:
1. Dementia and cognitive impairment are by far the 
leading chronic disease contributors to disability, 
and, particularly, needs for care (dependence) 
among older people worldwide. While older 
people can often cope well and remain reasonably 
independent even with marked physical disability, 
the onset of cognitive impairment quickly 
compromises their ability to carry out complex but 
essential tasks and, later, their basic personal care 
needs. The need for support from a caregiver often 
starts early in the dementia journey, intensifies as 
Table 5.5  
Prevalence ratios (PR)* for the independent associations between health conditions (impairments and diagnoses) and a) 
disability(16) and b) dependence(30)
Associations with disability Associations with dependence
Health conditions, ranked in order of 
contribution to dependence
Meta-analysed 
PR (95% CI)
Median PAPF 
(range by site)
Meta-analysed PR 
(95% CI)
Median PAPF 
(range by site)
Dementia 1.9
(1.8-2.0)
25%
(19-44%)
4.5
(4.0-5.1)
34%
(23-59%)
Limb paralysis or
weakness 
1.8
(1.7-1.9)
11% 
(6-34%)
2.8
(2.4-3.2)
9%
(1-46%)
Stroke 1.4
(1.3-1.5)
11%
(2-21%)
1.8
(1.6-2.1)
8%
(2-17%)
Depression 1.4
(1.3-1.5)
8%
(1-23%)
1.7
(1.5-2.0)
8%
(0-27%)
Eyesight problems 1.1 
(1.1-1.1)
7%
(2-18%)
1.2
(1.1-1.3)
6%
(0-16%)
Arthritis or rheumatism 1.3
(1.3-1.4)
10%
(3-35%)
1.1
(1.0-1.3)
4%
(0-6%)
Stomach or intestine problems 1.1 
(1.1-1.2)
7%
(0-23%)
1.1
(1.0-1.3)
2%
(0-16%)
Hearing difficulty 1.1
(1.1-1.2)
2%
(1-9%)
1.1
(0.9-1.2)
1%
(0-5%)
Difficulty breathing 1.2
(1.1-1.3)
4% 
(2-9%)
1.2
(1.0-1.4)
1%
(0-6%)
* Adjusted for age, sex, education, marital status and other health conditions. 
Figures in italics indicate conditions not statistically associated with dependence that have positive PAPF values
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the illness progresses over time, and continues until 
death(29).
2. For low and middle income countries, the 
population-based surveys carried out by the 10/66 
Dementia Research Group have shown clearly that 
disorders of the brain and mind (dementia, stroke 
and depression) make the largest independent 
contribution, both in terms of the strength of 
the association and the ‘population attributable 
prevalence fraction’ (PAPF), to disability(16) and 
dependence(30) (see Table 5.5). Dementia makes 
the dominant contribution, particularly to needs 
for care. These findings are consistent with a large 
body of pre-existing evidence from population-
based studies conducted in Canada(31), the USA
(32), Sweden(33;34), and Hong Kong(35), all of which 
attest to the leading contribution of dementia and/
or cognitive impairment to prevalent or incident 
disability, controlling for comorbidity with other 
chronic diseases.  
3. Dementia is typically associated with a particular 
intensity of needs for care, exceeding the demands 
associated with other conditions. In the USA, 
caregivers of people with dementia were more likely 
than caregivers of people with other conditions to 
be required to provide help with getting in and out 
of bed (54% vs. 42%), dressing (40% vs. 31%), 
toileting (32% vs. 26%), bathing (31% vs. 23%) 
managing incontinence (31% vs. 16%) and feeding
(31% vs. 14%)(36). These findings were confirmed 
in reports from the 10/66 Dementia Research 
Group; in the Dominican Republic and in China 
among those needing care, those with dementia 
stood out as being more disabled, as needing more 
care (particularly support with core activities of 
daily living), and as being more likely to have paid 
caregivers - dementia caregivers also experienced 
more strain than caregivers of those with other 
health conditions(37;38).  
4. Another proxy indicator of the relevance of dementia 
to dependence is the extent to which older people 
with dementia use different types of care services 
that reflect increasing levels of needs for care, 
and the extent to which they are over-represented 
among older users of those services. In the USA, 
it has been estimated that people with dementia 
account for 37% of older people who use non-
medical home care services, at least half of 
attendees at adult day centres, 42% of residents 
in assisted living and residential care facilities, and 
64% of Medicare beneficiaries living in a nursing 
home(36). In a US study of older people who needed 
help with personal care or instrumental activities 
of daily living, those with cognitive impairment 
were more than twice as likely as others to receive 
paid home care, and used the services twice as 
intensively as did cognitively normal users of paid 
home care(39). Approximately 30-40% of older 
Americans with dementia live in a care home, 
compared with just 2% of older adults without 
dementia(36;40).
5. Moving into a care home is generally a marker of 
particularly high needs for care, although other 
factors can be involved. Predictors of transition 
into a care home in the USA have been studied in a 
review including 77 reports across 12 data sources 
that used longitudinal designs and community-
based samples(41). Cognitive impairment was 
the health condition that most strongly predicted 
transition, with a 2.5 fold increased risk (RR 2.54, 
95% CI: 1.43-4.51). Other major chronic conditions 
also conferred a significantly increased risk: RR 
1.04 for hypertension, 1.15 for cancer and 2.35 for 
diabetes, but these were modest compared to the 
risk associated with cognitive impairment. Other 
chronic conditions including arthritis, lung disease or 
cardiovascular disease did not show any significant 
association. In a study conducted in Sweden, 
dementia was the main predictor of transition into a 
care home, with a population attributable fraction of 
61%(42).
6. Therefore, the current and future costs of long-term 
care will be driven to a very large extent by the 
coming epidemic of dementia(29). Our success in 
designing and implementing successful strategies 
for the prevention of dementia(6), and in identifying 
treatments that can alter the course of the disease 
will be important determinants of future health and 
social care costs, currently rising inexorably in the 
context of population ageing. 
7. The enormous global societal costs of dementia 
were estimated in the World Alzheimer Report 
2010, and these estimates have been updated to 
2015 in the next chapter. There have been relatively 
few attempts to compare dementia costs with 
those of other chronic diseases. In the UK, it was 
estimated that the health and social care costs for 
dementia (£23billion in 2008), almost matched the 
combined costs of cancer (£12bn), heart disease 
(£8bn) and stroke (£5bn)(43). In the US ADAMS study 
the national societal cost of dementia in 2010 was 
estimated in the range of US$159bn to US$215bn 
annually; the component of this that related to care 
purchased in the marketplace (i.e. excluding informal 
family care costs) was US$109bn, higher than that 
for heart disease (US$102bn) and cancer (US$77bn)
(44). In a Swedish study(22), the annual costs of 
dementia (50bn SEK) exceeded those of depression
(32.5bn SEK), stroke (12.5bn SEK), alcohol abuse
(21-30bn SEK) and osteoporosis (4.6bn SEK). Few 
of these studies take into account comorbidity, 
and estimate the independent or ‘attributable’ 
costs of dementia. Dr Zhaorui Liu carried out such 
an analysis using data from the 10/66 Dementia 
Research Group baseline surveys in Latin America, 
India and China (Table 5.6)(45). For all countries 
other than India, the attributable cost of dementia 
exceeded that of other conditions (depression, 
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hypertension, diabetes, ischaemic heart disease 
and stroke). Medical care costs for dementia were 
negligible, reflecting limited access to services, but 
dementia costs dominated for social care, informal 
care ad, paid home care.
5.4 Conclusion
The purpose of this section of the report has been 
to provide information about the contribution of 
dementia to disability, mortality and dependence, 
and, at the societal level, to economic costs. We 
have aimed to compare the effects of dementia with 
those of other important chronic diseases, taking 
account, where possible, of the frequent comorbidity 
between physical, mental and cognitive disorders. We 
have highlighted that the Global Burden of Disease 
estimates fail to reflect the societal impact of dementia, 
relative to other chronic diseases and, as such, cannot 
be considered to be a reliable tool for prioritisation 
for research, prevention, and health or social care 
among older people. As Dr Margaret Chan, Director-
General of the World Health Organization, expressed 
in her opening remarks at the First WHO Ministerial 
Conference on Global Action Against Dementia 
(Geneva, 15th March 2015):
“I can think of no other disease that has such 
a profound effect on loss of function, loss of 
independence, and the need for care. I can think 
of no other disease so deeply dreaded by anyone 
who wants to age gracefully and with dignity. I can 
think of no other disease that places such a heavy 
burden on families, communities, and societies. 
I can think of no other disease where innovation, 
including breakthrough discoveries to develop a 
cure, is so badly needed.”
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chapTer 6 
The worldwide costs of dementia 
6.1 Introduction
In 2010 ADI presented estimates of the global societal 
economic impact of dementia(1). The global cost in 
2010 was estimated to be US$ 604 billion. This figure 
constituted around 1% of the aggregated world Gross 
Domestic Product (GDP), indicating a particularly 
significant global socioeconomic impact for this one 
condition. Although most people with dementia live in 
low or middle income countries (LMIC), almost 90% 
of the costs were incurred in high income countries. 
These estimates, also included in the WHO/ADI 
2012 report, Dementia: a public health priority(2), and 
published as a scientific paper(3), have been widely 
cited, generally accepted, and influential in raising 
awareness of the scale and impact of the current 
global epidemic*. 
Five years have passed. Our estimates of the likely 
prevalence of dementia have changed for some 
regions, and the numbers affected have increased 
for all regions in line with the increase in the older 
population (see Chapter 2). Cost of illness (COI) 
estimates have improved, with more recent and 
comprehensive studies from several high income 
*  See for example WHO Director-General Margaret Chan’s 
opening comments to the WHO First Ministerial Conference on 
Dementia (http://www.who.int/dg/speeches/2015/dementia-
conference/en/) and UK Prime Minister David Cameron’s speech 
to the first G7 Global Action on Dementia Legacy Event (https://
www.gov.uk/government/news/pm-launches-next-phase-of-
britains-fight-against-dementia)
countries, and with coverage extended to include more 
high and middle income countries. Thus, it is time to 
update our global estimates of the economic impact of 
dementia. 
6.2 Methods
6.2.1 General approach
The estimates of the global societal economic cost of 
dementia provided in this report have been generated 
using the same general approach as for the 2010 
report. Costs are estimated at the country level and 
then aggregated in various combinations to summarise 
worldwide cost, cost by Global Burden of Disease 
world region, cost by World Bank country income 
level (high income, upper middle income, lower middle 
income, and low income countries), and costs for the 
G7 and G20 countries. For each country there is a 
cost per person (per capita) estimate which is then 
multiplied by the number of people estimated to be 
living with dementia in that country. The per capita 
costs are divided into three cost sub-categories: 
direct medical costs, direct social care costs (paid and 
professional home care, and residential and nursing 
home care) and costs of informal (unpaid) care. The 
base option for costing informal care is an opportunity 
cost approach, valuing hours of informal care by the 
average wage for each country.
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Wang(11) Zhaorui Liu’s thesis(10)
China Latin 
America
Asia All
Direct medical 
costs
0.67 0.74 0.66 0.73
Social care 
sector costs
0.33 0.26 0.34 0.27
6.2.2 What is new?
These new estimates should be considered to be a 
partial update of the previous (2010) estimates, rather 
than a full-scale revision. They do benefit from a fully 
systematic review of the prevalence of dementia, and 
numbers affected (see Chapter 2). We did not carry out 
a fully systematic review of service utilisation and cost 
of illness studies. However, we have identified several 
important cost of illness studies published since 2010. 
We have selected those that could be used to replace 
much older (and hence outdated) COI data, or could 
provide data-based estimates for countries where 
estimates had previously had to be imputed due to lack 
of relevant data, and have a significant influence on 
previous cost estimates. From high income countries, 
we have included new cost estimates from the USA(4), 
UK(5), Germany(6), Norway(7) Sweden(8), and Ireland (9).  
For middle income countries, there is more information 
available regarding costs of dementia care, and their 
distribution between sub-categories, from seven 
countries surveyed by the 10/66 Dementia Research 
Group: China, India, Cuba, Peru, Venezuela, Dominican 
Republic and Mexico (PhD thesis by Dr Zhaorui Liu(10)).
As in 2010, for countries with no cost data, cost 
estimations are derived by imputation. The assumption 
for the imputation is that there is a relationship 
between a country’s per capita GDP and annual per 
capita direct costs of dementia. In the 2010 report, 
for LMIC, the partitioning of the imputed total direct 
costs into direct medical and social care sector costs 
was derived from the only available relevant study, 
from China (Wang et al(11)), where two-thirds of the 
direct costs were medical and one-third derived from 
the social care sector. These proportions were used 
as a basis for imputation in many Asian and African 
countries. Now there is more information available 
from the 10/66 COI studies (China, India, Cuba, Peru, 
Venezuela, Dominican Republic and Mexico)(10), where 
the proportions are similar to those from Wang et al, 
but with a higher proportion of medical care costs 
in Latin America (Table 6.1). Data from Africa is still 
lacking. 
Table 6.1 
Proportional distribution of direct medical and social care 
costs, by sector
For the 2010 report, there was only one published 
cost of illness study from Latin America(12), which was 
used for imputation of estimates across the region. 
Zhaorui Liu’s thesis has broadened the available 
information from Latin America considerably, making 
the imputations much more representative. For further 
details and discussions of the principles for imputation, 
please see the 2010 report. The correlation between 
GDP per capita and annual direct costs of dementia in 
the updated set of cost of illness studies used in the 
current report is 0.86 (p<0.001).
6.2.3 Updating cost estimates from 2010 
to 2015
For the current estimates, all costs are expressed 
as 2015 US$. In the USA, one dollar in 2010 would 
purchase US$1.09 in 2015, a cumulative inflation 
rate over the five years of 9.4%, based on the US 
consumer price index. The IMF/WEO (International 
Monetary Fund/World Economic Outlook) database 
(consumer prices index) was used to generate similar 
cost adjustments, between 2010 and 2015, for each 
country(13). For countries where no such figures were 
available, imputations based on trends from 2010 to 
latest available CPI were used (for example: trends 
between 2010 and 2012 were applied between 2010 to 
2015). For a few countries with very small populations 
and not included in the WEO database, United Nations 
country profiles were used(14) .
Such imputations were not required for any country 
with a major impact on the costs. 
6.2.4 Comparing 2010 and 2015 
estimates
Besides the updated estimates of prevalence and 
numbers, the additional cost of illness data, the 
enhancements to the imputation process, and the cost 
adjustments, two other issues are important when 
interpreting comparisons between 2010 and 2015 
costs.
First, there have been shifts in the World Bank (WB) 
classification of country income level between 2010 
and 2015 (several countries have been “upgraded”, 
see Chapter 1). To facilitate ‘like for like’ comparisons 
between 2015 and 2010, the 2015 costs by country 
income level are presented according to both a) the 
current 2015 World Bank Classification, and b) the 2010 
World Bank Classification, which was used to generate 
the estimates for high income countries (HIC), upper 
middle income countries (UMIC), lower middle income 
countries (L-MIC) and low income countries (LIC) 
presented in the World Alzheimer Report 2010.
Second, our current revised estimates of regional 
dementia prevalence arguably provide a better 
estimate of likely numbers of people with dementia 
in 2010, as well as 2015 (Chapter 2). For the World 
Alzheimer Report 2009, we estimated 35.6 million 
people with dementia in 2010. However, if we apply 
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the prevalence estimates from the current report, than 
we would have estimated 40.1 million people with 
dementia in 2010. The estimated numbers for China 
have increased considerably as have those for some 
countries in Northern Africa, while the estimates for 
some high income countries (for example the USA 
and UK) are somewhat lower. The 2010 estimates 
based on the original prevalence estimates from the 
World Alzheimer Report 2009 will be labelled in tables 
as ‘WAR 2009’, while those based on the prevalence 
estimates from the current report will be labelled as 
‘WAR 2015’. 
6.2.5 Forecasting beyond 2015
Using the trends (2010-2015) in per capita cost 
and numbers of people with dementia, both based 
upon World Alzheimer Report 2015 prevalence, it is 
technically possible to make tentative forecasts of 
future growth in costs. We present the estimated costs 
in 2030 as well as an estimate of the date when global 
cost will cross the threshold of US$ 1 trillion. 
6.2.6 Sensitivity analyses
Three sensitivity analyses have been included.
In the 2010 report, the most significant effect in the 
sensitivity analysis was the method of quantifying 
informal care(1, 3). In the main option, informal care is 
quantified in terms of time spent assisting with basic 
and instrumental ADLs (activities of daily living), while 
a lower cost (only basic ADLs) and a higher cost (basic 
and instrumental ADLs, and time spent in supervision) 
are included. In the 2010 report, different alternatives 
for costing informal care (regression, replacement cost, 
25% and 50% of average wage) were used as well as 
PPPs (purchase power parities) instead of currency 
exchange rates, but these alternative inputs had 
smaller effects on the resulting costs than the variation 
in caregiver time, and have not been repeated here. 
The CPI is used for cost adjustments between 2010 
and 2015 in the base option. In a second sensitivity 
analysis, the change in GDP in the different countries is 
used instead for the cost adjustments.
In a third ‘fixed costs’ sensitivity analysis, a crude 
prevalence-based alternative is presented, without 
any new cost of illness data included and without cost 
adjustments. This sensitivity analysis focuses on the 
impact on costs of the changes in numbers of people 
affected.
6.3 Results
6.3.1 Aggregated costs, worldwide, and 
by country income level
In the base option, the global costs of dementia 
have increased from US$ 604 billion in 2010 to 
US$ 818 billion in 2015 (Table 6.2), an increase 
of 35.4%. Our current estimate of US$ 818 billion 
represents 1.09% of global GDP, an increase from 
our 2010 estimate of 1.01%. However, while in HIC the 
proportion has increased from 1.24% to 1.42%, there 
have been slight falls in costs as a proportion of GDP 
in LIC (0.24% to 0.21%), L-MIC (0.35% to 0.29%), and 
UMIC (0.50% to 0.46%). Excluding informal care costs, 
total direct costs account for 0.65% of global GDP. 
The proportion of costs incurred in high income 
countries (HIC) is similar to that reported in the World 
Alzheimer Report 2010. Since many countries that 
were classified as low income or low middle income 
countries in 2010 have been “upgraded” (see Chapter 
1), the proportion of worldwide costs incurred in upper 
middle income countries (UMIC) has increased from 
5.4% to 10.5%, and the proportion incurred in LIC and 
L-MIC has decreased commensurately compared with 
2010.
The effect of the World Bank reclassification of country 
income status is clearer if we compare 2010 and 2015 
cost distributions, on a ‘like for like’ basis, using the 
2010 WB classification for both time points (Table 
6.3). On this basis, the proportion of costs incurred in 
what were low and middle income countries in 2010 
Table 6.2 
Worldwide costs of dementia in 2010 and 2015 (billion US$), based on current World Bank country classification each year
Year for cost estimates (basis for prevalence 
estimates)
2010 (WAR 2009) 2015 (WAR 2015)
World Bank Country Classification Year 2010 2015
US$ (billions) Per cent US$ (billions) Per cent
Low income 4.4 0.7% 1.2 0.1%
Lower middle income 29.2 4.8% 15.3 1.9%
Upper middle income 32.5 5.4% 86.3 10.5%
High income 537.9 89.1% 715.1 87.4%
Total 604.0 100.0% 817.9 100.0%
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(particularly middle income countries) has increased, 
and the proportion in what were HIC has decreased. 
To complete the adjustments for a ‘like for like’ 
comparison, we adjusted the 2010 cost of illness 
estimates to take account of the revised estimates of 
the regional prevalence of dementia published in this 
report, which were used to estimate the 2015 costs 
(Table 6.4). Despite the 4.9 million (14%) increase in 
the estimated numbers of people with dementia in 
2010 when applying the World Alzheimer Report 2015 
prevalence estimates, the total (worldwide) cost for 
2010 has increased only marginally, from US$ 604.0 
billion to US$ 606.7 billion. The explanation for this 
is that most of the upwards adjustments of numbers 
of people with dementia occurred in low and middle 
income countries (where per capita costs are low), 
while there were some downwards adjustments in 
the estimates of numbers of people affected in HIC 
(e.g. USA, Germany, UK) where per capita costs are 
high. On the basis of this completely ‘like for like’ 
comparison, it is clear that there have been only 
modest changes in the distribution of costs by country 
income level, with a modest increase in the proportion 
arising in countries classified in 2010 as UMIC, and a 
modest reduction in the proportion arising in countries 
classified in 2010 as HIC. Global costs have increased 
by 35%, HIC costs by 31%, UMIC costs by 71%, L-MIC 
costs by 39%, and LIC costs by 27%. 
The G7 countries have initiated and lead the ‘Global 
Action Against Dementia’ accepting dementia as 
a national and global public health priority. We 
also thought that it would be instructive to analyse 
worldwide costs according to membership of the G7 
and the wider G20 group of nations (Table 6.5). This 
analysis reveals a striking concentration of global 
costs among the world’s wealthiest nations. Although 
the G7 countries account for just over a quarter of 
global prevalence, over three-fifths of global costs are 
incurred in these seven countries. The G20 nations 
account for a remarkable 92% of global costs. The 
182 nations that are members of neither G7 nor G20 
account for 20% of the global prevalence, but just 8% 
of the costs.  
6.3.2 Aggregated costs by cost sub-
category
The pattern of distribution of costs between the three 
major sub-categories (direct medical, social care, and 
informal care) has not changed substantially (Table 
6.6). As reported in 2010, the proportional contribution 
of direct medical care costs is modest, particularly 
Table 6.3  
Worldwide costs of dementia in 2010 and 2015 (billion US$), based on World Bank country classification 2010
Year for cost estimates (basis for 
prevalence estimates)
2010 (WAR 2010) 2015 (WAR 2015)
World Bank Country Classification Year 2010 2010
US$ (billions) Per cent US$ (billions) Per cent
Low income 4.4 0.7% 6.6 0.8%
Lower middle income 29.2 4.8% 57.1 7.0%
Upper middle income 32.5 5.4% 84.5 10.3%
High income 537.9 89.1% 669.6 81.9%
Total 604.0 100.0% 817.9 100.0%
Table 6.4  
Worldwide costs of dementia in 2010 and 2015 (billion US$), based on World Bank country classification 2010 and adjusted 
prevalence figures for 2010
Year for cost estimates (basis for prevalence 
estimates)
2010 (WAR 2009) 2015 (WAR 2015)
World Bank Country Classification Year 2010 2010
US$ (billions) Per cent US$ (billions) Per cent
Low income 5.2 0.9% 6.6 0.8%
Lower middle income 41.2 6.8% 57.1 7.0%
Upper middle income 49.4 8.1% 84.5 10.3%
High income 510.9 84.2% 669.6 81.9%
Total 606.7 100.0% 817.9 100.0%
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in HIC. There is an increasing relative contribution 
of direct social care sector costs and a decreasing 
relative contribution of informal care costs with 
increasing country income level. 
6.3.3 Aggregated costs by Global Burden 
of Disease regional country classification
According to the Global Burden of Disease regional 
country classification (Table 6.7), the regional 
distribution of costs has not changed markedly 
from those published in 2010. Cost estimates have 
increased for all world regions. The greatest relative 
increase occurred in the African and in East Asia 
regions, driven, largely, by the upwards revision of the 
prevalence estimates for those regions. 
The partition of total costs by sub-categories (direct 
medical care costs, social care costs, and informal 
care) varies by region, consistent with the pattern 
Table 6.6 
Sub-category costs of dementia in 2010 and 2015 (billion US$, and percent of total costs), by country income level based on 
current World Bank country classification
Direct medical costs Direct social sector costs Informal care costs
US$ (billions) Per cent US$ (billions) Per cent US$ (billions) Per cent
2010 (WAR 2009)
Low income 0.1 22.3% 0.1 11.5% 0.3 66.2%
Lower middle income 2.9 29.4% 1.6 16.4% 5.3 54.2%
Upper middle income 12.6 28.1% 8.3 18.6% 23.9 53.3%
High income 80.8 14.7% 245.7 44.8% 222.4 40.5%
Total 96.4 16.0% 255.7 42.3% 251.9 41.7%
2015 (WAR 2015)
Low income 0.2 20.4% 0.1 10.4% 0.8 69.2%
Lower middle income 3.7 23.9% 2.0 13.2% 9.6 62.9%
Upper middle income 19.3 22.4% 17.7 20.5% 49.3 57.1%
High income 136.0 19.0% 308.1 43.1% 271.1 37.9%
Total 159.2 19.5% 327.9 40.1% 330.8 40.4%
Table 6.5 
Costs of dementia in 2015 (billion US$), by G7 and G20 country classification
2015 (WAR 2015)
US$ (billions) Per cent of costs Numbers of people with 
dementia (millions)
Per cent of prevalence
G7* 508.7 62.2% 12.9 27.6%
G20** 754.2 92.2% 37.5 80.1%
G20 excluding G7 245.5 30.0% 24.6 52.6%
Rest of the world (excluding 
G20)
63.6 7.8% 9.3 19.9%
World 817.9 100% 46.8 100%
* G7 countries: Canada, France, Germany, Great Britain, Italy, Japan, and the United States
** G20 countries: Argentina, Australia, Brazil, Canada, China, France, Germany, India, Indonesia, Italy, Japan, Mexico, Russia, Saudi Arabia, 
South Africa, South Korea, Turkey, the United Kingdom and the United States. The EU is the 20th ’country’ in the G20, for the purposes of 
this analysis the remaining EU member countries (Cyprus, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, Greece, Ireland, 
Luxembourg, Malta, Netherlands, Portugal, Slovenia, Spain, Sweden, Poland, Romania, Slovak Republic, Bulgaria, Estonia, Hungary, Latvia, 
Lithuania) were allocated to the G20 group.
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of variation by country income level. The relative 
contribution of informal care is greatest in the African 
regions and lowest in North America, Western Europe 
and some South American regions (Table 6.8), while 
the reverse is true for social sector costs.
6.3.4 Annual costs per person with 
dementia 
The comparison of costs per person with dementia, 
between the World Alzheimer Report 2010 and 
the current update, is most easily summarised 
and understood stratified by Global Burden of 
Disease region. The issue of whether the World 
Alzheimer Report 2010 or World Alzheimer Report 
2015 prevalence estimates are applied to the 2010 
population to generate numbers of people with 
dementia is not relevant, because the prevalence 
estimates are region specific, and these are per capita 
estimates. For our updated estimates annual costs per 
person range from US$872 (South Asia) to US$56,218 
(North America). For all but two regions, the estimate 
of per person costs has increased. The median change 
among regions was +26.3% (interquartile range +7.8% 
to +57.9%)
Direct comparison of costs per person by World Bank 
country income level is complicated both by the year 
of the World Bank classification (2010 vs 2015), and 
the basis for prevalence estimates (WAR 2009 vs 
WAR 2015). The optimal ‘like for like’ comparison uses 
the World Bank classification of 2010 and the World 
Alzheimer Report 2015 prevalence estimates for both 
the 2010 and 2015 time points (column 3 vs. column 
5 in Table 6.10 below). According to each of four 
approaches, per person costs increase steeply with 
Table 6.7   
Costs of dementia in 2010 and 2015 (billion US$, and percent of worldwide costs), by Global Burden of Disease world region 
classification
Year for cost estimates (basis for 
prevalence estimates)
2010 (WAR 2009) 2015 (WAR 2015) 2010-2015
US$ (billions) Per cent US$ (billions) Per cent Per cent change
Australasia 10.1 1.7% 14.1 1.7% 39.6%
Asia Pacific High Income 82.1 13.6% 109.9 13.4% 33.9%
Oceania 0.1 0.0% 0.2 0.0% 59.0%
Asia Central 0.9 0.2% 1.2 0.1% 28.6%
Asia East 22.4 3.7% 42.9 5.2% 91.7%
Asia South 4.0 0.7% 4.5 0.5% 11.8%
Asia Southeast 4.0 0.7% 7.3 0.9% 81.9%
Europe Central 14.2 2.3% 15.0 1.8% 5.7%
Europe Eastern 14.3 2.4% 23.5 2.9% 64.3%
Europe Western 210.1 34.8% 262.6 32.1% 25.0%
North America High Income 213.0 35.3% 268.9 32.9% 26.3%
Caribbean 3.0 0.5% 3.5 0.4% 18.2%
Latin America Andean 0.9 0.2% 1.1 0.1% 27.0%
Latin America Central 6.6 1.1% 15.9 1.9% 140.8%
Latin America Southern 5.1 0.8% 10.1 1.2% 98.7%
Latin America Tropical 7.3 1.2% 15.6 1.9% 113.8%
North Africa / Middle East 4.5 0.7% 16.7 2.0% 270.7%
Sub-Saharan Africa Central 0.1 0.0% 0.3 0.0% 198.6%
Sub-Saharan Africa East 0.4 0.1% 1.5 0.2% 267.4%
Sub-Saharan Africa Southern 0.7 0.1% 2.3 0.3% 221.7%
Sub-Saharan Africa West 0.2 0.0% 0.8 0.1% 298.6%
Total 604.0 100.0% 817.9 100.0% 35.4%
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country income status. Comparison of column 2 with 
column 3 illustrates that the reclassification “upwards” 
of populous countries that are still poorer than most 
of those in the group that they join brings down the 
average per person cost for the higher income level 
group. Thus (column 3) in 2015, according to the 
latest World Bank income level classification, there is 
now little difference in mean per capita cost between 
LIC and L-MIC. According to the optimal ‘like for like’ 
comparison (column 4 vs column 3), per person costs 
have increased at each of the 2010 country income 
levels between 2010 and 2015, but most markedly in 
what were, in 2010, upper middle income countries. 
In 2015, the mean cost per person with dementia 
was US$ 43,680 in G7 countries, US$ 20,187 in G20 
countries, and US$ 6,757 in countries that were 
members of neither G7 nor G20.
6.3.5 Sensitivity analyses 
Depending on how informal care is quantified, there is 
great variability in worldwide costs, from US$651 bn 
(only basic ADLs) to US$ 1,057 billion (all ADLs, and 
supervision), but with little variation in distribution by 
country income level (Table 6.11). 
If the change in per capita GDP, rather than CPI is used 
to update costs from 2010 to 2015 (Table 6.12), the 
total costs are somewhat higher than for the CPI base 
option (Table 6.2). The marked increase in estimated 
costs for upper middle income countries had the most 
significant impact on worldwide costs, resulting in a 
lower proportion of the total costs for high income 
countries compared with the main CPI based option. 
Evidently, this reflects patterns of global economic 
growth over the period, with a recession in many HIC, 
but sustained growth rates in many UMIC.
Table 6.8  
Costs of dementia in 2015 (US$ billions), by Global Burden of Disease region classification. Costs in cost categories. Percentages 
of each GBD region class costs
Cost sub-category Direct medical costs Direct social sector costs Informal care costs
GBD World region US$ (billions) Per cent US$ (billions) Per cent US$ (billions) Per cent
Australasia 1.0 6.9% 7.1 50.3% 6.0 42.8%
Asia Pacific High Income 7.0 6.3% 56.4 51.3% 46.5 42.4%
Oceania 0.0 17.4% 0.0 8.6% 0.1 74.0%
Asia Central 0.3 29.6% 0.3 25.3% 0.5 45.1%
Asia East 2.2 5.2% 10.2 23.8% 30.5 71.0%
Asia South 0.5 10.7% 0.1 3.3% 3.8 86.0%
Asia Southeast 2.7 36.8% 1.3 18.2% 3.3 45.0%
Europe Central 2.8 18.8% 3.1 20.4% 9.1 60.8%
Europe Eastern 5.7 24.1% 4.9 20.7% 13.0 55.2%
Europe Western 50.8 19.3% 113.0 43.0% 98.9 37.6%
North America High Income 61.1 22.7% 115.5 43.0% 92.3 34.3%
Caribbean 0.8 21.3% 0.8 21.8% 2.0 56.9%
Latin America Andean 0.2 17.8% 0.4 32.6% 0.6 49.5%
Latin America Central 6.2 39.2% 5.5 34.3% 4.2 26.5%
Latin America Southern 2.8 27.8% 2.6 25.2% 4.8 47.0%
Latin America Tropical 5.7 36.8% 5.2 33.4% 4.7 29.9%
North Africa / Middle East 8.5 50.7% 1.2 7.2% 7.0 42.0%
Sub-Saharan Africa Central 0.1 28.5% 0.0 14.1% 0.2 57.3%
Sub-Saharan Africa East 0.3 20.8% 0.2 10.3% 1.0 68.9%
Sub-Saharan Africa Southern 0.4 16.4% 0.2 8.1% 1.7 75.6%
Sub-Saharan Africa West 0.2 22.8% 0.1 11.3% 0.5 66.0%
Total 159.2 19.5% 327.9 40.1% 330.8 40.4%
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Table 6.9 
Costs of dementia in 2010 and 2015 (costs per person with dementia, US$, and percentage change from 2010 to 2015), by Global 
Burden of Disease regional classification
2010 (WAR 2009) 2015 (WAR 2015) Change (%) in per capita costs 
(2010-2015)
Australasia 32,370 36,404 12.5%
Asia Pacific High Income 29,057 30,206 4.0%
Oceania 6,059 7,021 15.9%
Asia Central 2,862 3,723 30.1%
Asia East 4,078 4,397 7.8%
Asia South 903 872 -3.5%
Asia Southeast 1,601 2,021 26.3%
Europe Central 12,891 14,056 9.0%
Europe Eastern 7,667 12,104 57.9%
Europe Western 30,122 35,255 17.0%
North America High Income 48,605 56,218 15.7%
Caribbean 9,092 9,387 3.2%
Latin America Andean 3,663 3,375 -7.9%
Latin America Central 5,536 10,349 86.9%
Latin America Southern 8,243 13,448 63.2%
Latin America Tropical 6,881 9,426 37.0%
North Africa / Middle East 3,926 6,955 77.2%
Sub-Saharan Africa Central 1,081 1,880 74.0%
Sub-Saharan Africa East 1,122 2,120 89.0%
Sub-Saharan Africa Southern 6,834 9,490 38.9%
Sub-Saharan Africa West 969 1,482 53.0%
Table 6.10  
Per person costs of dementia (US$) in 2010 and 2015, based on World Bank country classification (2010 or 2015) and prevalence 
estimates (WAR 2009 or 2015)
2010 2015
Column 1 2 3 4 5
Year for cost estimates 
(basis for prevalence 
estimates)
2010 (WAR 2010) 2010 (WAR 2015) 2015 (WAR 2015) 2015 (WAR 2015) Change (%) in 
costs per person 
(WAR 2015)
World Bank Country 
Classification Year
2010 2010 2015 2010 2010
Low income 868 875 1,019 939 7.3%
Lower middle income 3,109 3,259 1,560 3,865 18.6%
Upper middle income 6,827 7,224 5,284 10,467 44.9%
High income 32,865 34,735 36,669 39,595 14.0%
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If a prevalence-based option is used (holding the costs 
per person fixed, and ignoring new cost of illness data), 
worldwide costs increase by US$ 91.2 billion (15.1%) 
compared with US$ 213.9 billion (35.4%) (Table 6.13), 
suggesting that just less than half of the increase in 
costs between the 2010 and 2015 World Alzheimer 
Report estimates are accounted for by increases in 
prevalence and numbers affected. The proportion of 
costs incurred in HIC decreases somewhat, reflecting 
the fact that the greatest increase in estimates of 
numbers of people with dementia (between World 
Alzheimer Report 2009 and World Alzheimer Report 
2015) occur in low and middle income countries. 
6.3.6 Forecasts beyond 2015
To make a forecast of future trends in the global 
societal economic cost of dementia, we need to 
estimate trends in the numbers of people with 
dementia, and trends in the per person costs. 
Trends per annum between 2010 and 2015 need to 
be estimated on a ‘like for like’ basis. This means a) 
applying the World Alzheimer Report 2015 prevalence 
estimates to the 2010 and 2015 population structures 
to estimate numbers of people with dementia at both 
time points, and b) using the same approach, for each 
country, to weight the worldwide aggregation of mean 
per capita costs. 
Based on the estimates from the World Alzheimer 
Report 2010, the number of people with dementia has 
increased by 31.5% between 2010 (35.6 million) and 
2015 (46.8 million). However, if we adjust the estimated 
numbers for 2010, by applying the updated prevalence 
estimates generated for this report, there would have 
been 40.1 million with dementia in 2010, and the 
numbers would have increased by 16.6%, or by 3.3% 
per year. During the same period the aggregated costs 
increased by 35% (7.0% per year), this estimate being 
very little affected if calculated instead on the basis 
of the adjusted numbers for 2010, applying World 
Alzheimer Report 2015 prevalence estimates  
(see Table 6.4).  
Between 2010 and 2015, the average worldwide cost 
per person (a weighted average across countries, 
calculated on a ‘like for like’ basis) increased from 
US$15,122 to US$17,483 US$ per year (an increase of 
15.6% or 3.1% per year).
The overall annual trends can then be calculated as the 
product of the annual inflation factors from increasing 
numbers (1.033) and increasing per capita costs (1.031) 
= 1.033 x 1.031 = 1.065, or around 6.5% per annum. 
Table 6.11  
Costs of dementia in 2015 (billion US$), by 2015 World Bank country income level, according to different approaches to costing 
informal care based on different caregiver inputs
Base option More restrictive More inclusive
All ADLs Only basic ADLs All ADLs and supervision
US$ (billions) Per cent US$ (billions) Per cent US$ (billions) Per cent
Low income 1.2 0.1% 0.9 0.1% 1.6 0.2%
Lower middle income 15.3 1.9% 10.7 1.6% 21.7 2.1%
Upper middle income 86.3 10.5% 75.0 11.5% 121.2 11.5%
High income 715.1 87.4% 564.9 86.7% 912.2 86.3%
Total 817.9 100.0% 651.5 100.0% 1056.8 100.0%
Table 6.12 
Costs of dementia in 2010 and 2015 by World Bank country income level (billion US$ and percent of total costs), based on current 
World Bank country classification for each year and cost adjustments (2010-2015) based on change in per capita GDP in each 
country
2010 (WAR 2009) 2015 (WAR 2015, GDP based cost adjustments)
US$ (billions) Per cent US$ (billions) Per cent
Low income 4.4 0.7% 1.1 0.1%
Lower middle income 29.2 4.8% 15.0 1.7%
Upper middle income 32.5 5.4% 182.4 21.0%
High income 537.9 89.1% 671.0 77.2%
World 604.0 100.0% 869.6 100.0%
64
The contribution of the increase in numbers of people 
with dementia and the increase in cost per person with 
dementia have a similar impact.
Applying this constant annual inflation factor, the 
costs in 2030 will be around US$ 2 trillion and the 
threshold of US$ 1 trillion will be crossed in 2018 
(Figure 6.1).  
6.4 Discussion
6.4.1 The results
The global societal economic cost of dementia, 
US$ 818 billion, is an enormous sum; similar in 
magnitude to the Gross Domestic Product (GDP) of 
countries like Indonesia, the Netherlands, and Turkey, 
the 16th to 18th largest economies in the world. The 
global costs are also larger than the market values 
of companies such as Apple (US$ 742 billion), 
Google (US$ 368 billion) and Exxon (US$ 357 
billion) (source Forbes: 2015 ranking). 
As we reported in 2010, the costs remain concentrated 
in countries with higher income levels. There is 
a disjunction between the global distribution of 
prevalence, 58% of which is accounted for by people 
with dementia living in LMIC, and costs, 87% of which 
are incurred in HIC. This is accounted for by the lower 
per person costs in LMIC, reflecting lower wage costs 
and a higher proportion of care provided by informal 
unpaid carers rather than professional home carers or 
residential care. Costs when expressed as a proportion 
of GDP are certainly not negligible in LMIC (ranging 
from 0.2 to 0.5%) but again lower than those in HIC
(1.4%). Differences in per person costs by country 
income level were only slightly attenuated when the 
different purchasing power of one US$ was taken 
into account in sensitivity analyses conducted for the 
2010 World Alzheimer Report. The uneven distribution 
of global costs is even more striking when stratified 
according to G7 (62% of worldwide costs incurred by 
just seven nations) or G20 membership (92% of global 
costs).
Our sensitivity analysis confirms that the assumptions 
regarding costing of informal care have a great impact 
upon the total costs. Although difficult to quantify, 
supervision is an important and significant part of 
daily informal care with significant opportunity cost 
for carers. If that component is included, the costs 
Table 6.13 
Costs of dementia in 2010 and 2015 (billion US$), using World Bank country classification 2010 and cost adjustments (2010-
2015) based on a prevalence-based option
2010 (WAR 2009) 2015 (WAR 2015)
US$ (billions) Per cent US$ (billions) Per cent
Low income 4.4 0.7% 6.1 0.9%
Lower middle income 29.2 4.8% 48.2 6.9%
Upper middle income 32.5 5.4% 57.8 8.3%
High income 537.9 89.1% 583.0 83.9%
World 604.0 100.0% 695.2 100.0%
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Forecasted global costs of dementia 2015-2030
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increase considerably. Other assumptions may have 
a lesser impact upon the results and comparisons. 
Transparency regarding assumptions is crucial to make 
comparisons meaningful in any cost of illness analysis. 
Our current estimates of global societal costs 
of dementia have increased by around 35% 
compared with those published in the World 
Alzheimer Report 2010. Interpreting these increases 
is complex given the multiplicity of plausible underlying 
explanations. Increases in aggregated costs can arise 
from increases in numbers of people with dementia, 
and/or increases in per person costs. The exploratory 
analyses that we have conducted suggest that 
these two elements each contribute around one half 
of the total increase. This estimate is based upon 
standardising age-specific prevalence estimates to 
those generated for the current report (World Alzheimer 
Report 2015) on the assumption that the revised 
prevalence estimates merely reflect an enhancement in 
the evidence-base rather than any underlying secular 
trends in age-specific prevalence between 2010 and 
2015 (see Chapters 2 and 4). Therefore, the increase 
in numbers, for the purposes of these cost trend 
analyses, arises solely from the effects of population 
ageing, which is occurring more rapidly in LMIC than 
in HIC. Changes in per capita costs are even harder to 
interpret. The one thing that is certain is that the cost of 
any given service or item of care inflates over time. We 
have adjusted costs between 2010 and 2015 according 
to consumer price indices (CPI) in each country. On 
this basis cumulative cost inflation in the USA was 
around 9.4% over the five year period. As developing 
economies grow, the cost of salaries and services 
tend to inflate more rapidly than prices (a ‘positive 
income elasticity effect’), so this approach may have 
underestimated cost inflation in LMIC relative to HIC, 
as indicated by our GDP-based inflation sensitivity 
analysis. In either scenario, cost inflation can have 
accounted for only part of the increase in per capita 
costs. 
Per capita costs may also increase because;
a) we have estimated them better, with more up to 
date studies, larger and more precise studies, and 
studies that have taken a more comprehensive 
approach to the range of costs estimated;
b) some services have become more costly, over and 
above the rate of inflation;
c) new services have been established, or the coverage 
of existing services has improved, or existing service 
users are using the same services more intensively.
We do not have adequate data to discern between 
these three sets of explanations; a) seems plausible, 
since the inclusion of new cost of illness studies has 
generally led to increases in estimated per capita 
costs for the countries concerned; b) would require 
carefully conducted comprehensive unit cost estimates 
updated over time, which do not exist or are not readily 
accessible (most COI studies use our approach of 
updating costs in line with inflation); c) would require 
representative population-based surveys of people 
with dementia (rather than clinical samples) repeated 
over time, to determine secular trends in service 
utilisation, which, again are not readily available. Some 
studies suggest that the proportion of people with 
dementia living in residential care has begun to decline 
in HIC, consistent with policy initiatives to provide care 
at home where possible(15). However, such a strategy 
may not be associated with reduced costs, when all 
of the costs of home care, including informal care, are 
properly accounted for(16). It has also been suggested 
that cost reduction initiatives may be reducing the 
intensiveness of home care (for example shorter and 
less frequent care worker visits) in the UK(5).  
Economic development is proceeding apace in many 
low and, particularly, middle income countries. This 
has posed a challenge for us in making meaningful 
comparisons between country income level groups for 
2010 and 2015, since a significant number of countries, 
some of them very populous, have moved “upwards” 
in the World Bank classification. The average cost 
per person with dementia in the higher WB groups 
is “diluted” by newly promoted countries with lower 
economic strength than the original countries in that 
particular WB group. At the same time, the remaining 
lower income countries are “drained” by the loss of 
more prosperous countries that have moved upwards 
in the WB classification. We addressed this problem by 
stratifying the 2015 estimates according to the 2010 as 
well as the 2015 classification.
However, the important issues here are that these 
trends for economic growth may result in increased 
awareness, help-seeking and medical diagnosis 
(leading to increased direct medical care costs) and a 
shift from unpaid informal care to direct costs from the 
social care sector. The long term care sector is very 
underdeveloped in most LMIC, but economic growth, 
accompanied by social and demographic change may 
increase demand resulting in the establishment and/
or expansion of a formal long term care sector as a 
complement to informal care. If so (and there is some 
support for such trends in the current report), the 
increase in costs per person with dementia may be 
much greater than the basic assumption used for our 
forecast of dementia costs globally. 
6.4.2 Methodological issues
Although the basics for the global cost estimates 
are available cost of illness studies of dementia, the 
costing model imputes missing country data based 
on the assumed relationship between the economic 
strength of a country and resources for dementia 
care. For details, please see the World Alzheimer 
Report 2010(1). Despite an improvement in coverage, 
COI studies from LMIC are rare, with, therefore, a 
greater reliance on imputation for these countries. 
Nevertheless, the correlation between the GDP per 
66
capita and direct costs per person with dementia 
seems to be robust.  
The current report is not a complete systematic 
update, although some important new COI studies are 
added as well as data on resource use and costs from 
the 10/66 Dementia Research Group. However, the 
number of cost components that are included in cost 
of illness studies varies, which can make comparisons 
problematic. For example, in the new UK report, a 
cost estimate of people who had gone missing due to 
dementia was included(5) and in the Swedish update, 
detailed costs of drug use were included(8). The use 
of consumer prices is not the optimal way of adjusting 
care costs. Price inflation indices specific to the health 
care and social care sector would be better, but 
such data are not yet available globally. For the cost 
estimates of informal care, an update of the country-
specific average wage would have been preferable.   
The cost forecasts should be treated with particular 
caution. Besides the generic heterogeneity of COI 
studies, and the uncertain impact of including more 
recent, but also more comprehensive estimates, 
we also had to make assumptions regarding the 
appropriate age-specific prevalence estimates to 
use at each time point. Furthermore, the dynamics of 
change in care patterns across regions, the impact of 
diagnostic and treatment strategies such as the ‘Global 
Action Against Dementia’ aspiration for a disease 
modifying treatment for Alzheimer´s disease by 2025, 
and the potential for effective primary prevention 
programs for dementia, are all hard to forecast. The 
assumption of constant annual growth in costs may 
well not be correct. As with all forecasts, the near 
future (US$ 1 trillion by 2018) is easier to predict than 
the distant future (over US$2 trillion by 2030). 
6.4.3 The future
It is our hope that more service utilisation and cost 
of illness studies will be carried out, improving the 
overall quality, coverage and recency of the evidence 
base, which, coupled with an ongoing commitment 
to monitor trends in prevalence and numbers, will 
allow us to estimate global costs and trends with more 
accuracy. Our first outstanding task is to address the 
limitations with the current estimates, in particular by 
completing and documenting a fully systematic review 
of relevant studies, and exploring more effective ways 
of capturing cost inflation. We are eager to integrate 
this work within plans for a Global Observatory to be 
coordinated by the World Health Organization, and 
to provide regular updates accessible and analysable 
through a web interface.
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7.1 Summary
7.1.1 Prevalence and numbers affected
We estimate that there are now 46.8 million people 
living with dementia worldwide, with numbers 
projected to nearly double every 20 years, increasing 
to 74.7 million by 2030 and 131.5 million by 2050. 
These estimates are 12-13% higher than those for the 
corresponding years in our World Alzheimer Report 
2009. The increases are accounted for by two factors. 
First, the 2012 UN population estimates include larger 
numbers of older people than had previously been 
thought. Second, the evidence base regarding the 
prevalence of dementia has expanded considerably, 
particularly for East Asia, sub-Saharan Africa and 
North Africa/Middle East. The enhanced evidence 
base indicates a higher age-standardised prevalence 
of dementia in those regions than had previously been 
estimated, but does not necessarily indicate a secular 
trend towards increased prevalence over time. 
We estimate that 58% of people with dementia live in 
low or middle income countries, a proportion that is 
anticipated to rise to 63% by 2030 and 68% by 2050. 
Increases in numbers of people with dementia will 
be much steeper in low and middle income countries 
(LMIC) than in high income countries (HIC). The 
numbers of people living with dementia will double in 
HIC and more than treble in LMIC through to 2050.  
From our comprehensive review and meta-analysis 
of incidence rates worldwide, we estimate that there 
will be 9.9 million new cases of dementia in 2015, or 
one every 3.2 seconds. 49% of these will arise in Asia, 
compared with 25% in Europe, 17% in the Americas 
and 8% in Africa. The estimate of annual new cases for 
the 2012 WHO/ADI report (7.7 million, or one new case 
every 4.1 seconds) referred to 2010, and is therefore 
not directly comparable. 
7.1.2 Possible future trends in prevalence 
and incidence
Our current projections for numbers and costs 
assume that the age-specific prevalence of dementia 
will remain stable over time. While there has been 
much interest in the possibility that the age-specific 
prevalence of dementia may have been declining 
recently in high income countries, the evidence to 
support this is currently weak and inconclusive. Some 
studies do support such a secular trend, but others 
do not, and the number of studies that have been 
able to address this question using standardised 
methodology, applied to comparable populations over 
time has been quite limited. Evidence for a decline in 
incidence in HIC studies is slightly stronger, although 
still inconclusive. For high income countries, a pattern 
of stable or increasing prevalence despite declining 
incidence seems plausible and is suggested by 
findings from some studies and modelling exercises. 
The public health improvements that may drive 
declining incidence rates may also result in improved 
survival of people living with dementia. There is a 
consistent trend from several reviews for an increasing 
chapTer 7
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trend in the recorded prevalence of dementia in East 
Asia, and in China specifically. However, it is uncertain 
whether this relates to a genuine trend in underlying 
prevalence, or an artefact arising from changes in 
diagnostic criteria over time.
7.1.3 Impact
While dementia shortens the lives of those affected, 
its greatest impact is upon the quality of life, both 
of those living with dementia, and their family and 
caregivers. A large body of evidence, reviewed in this 
report, suggests that, among older people and at 
the population level, dementia makes a much larger 
contribution than other chronic physical and mental 
disorders to disability, needs for care and attendant 
costs. These findings are not, however, reflected in 
the results of the Global Burden of Disease Study 
most recently conducted by the Institute of Health 
Metrics and Evaluation (IHME), and, previously, 
by the WHO. The IHME findings are particularly 
discrepant with other data sources and methodological 
approaches. The problem appears to arise first from 
the Disability Adjusted Life Year (DALY) metric of 
overall disease burden, which gives a much greater 
weight to conditions associated with mortality, even 
in later life, and second from the methods used to 
attribute disability weights to individual conditions and 
health states. This is a matter of concern given the 
importance accorded to the Global Burden of Disease 
estimates as a guide to prioritisation for research, 
health and social care investment.  
7.1.4 Cost
We have carried out a provisional update of our 
previous estimates of the global societal economic 
cost of dementia. We estimate the global societal 
economic cost of dementia for 2015 to be US$818 
billion, a 35% increase from the cost estimate for 
2010, which was US$604 billion. Projecting this 
trend forwards, we estimate that the global cost of 
dementia will have reached US$1 trillion in 2018. 
Around half of this increase can be attributed to growth 
in the numbers of people with dementia, and half to 
increases in per capita costs, particularly in low and 
middle income countries. 
88% of the costs in 2015 were incurred in what are 
currently high income countries. If the same country 
classification (World Bank 2009) is applied for 2015 as 
for 2010, then the proportion of global costs incurred 
in what were then LMIC has risen from 11% to 18%. 
Box 7.1
G7 Dementia Legacy Events
The key developments have been:
•	 An explicit acknowledgement that dementia is a global issue, and that the effects of the future epidemic 
will be felt particularly in low and middle income countries
•	 A better understanding of the extent of the current treatment gap in terms of diagnosis, treatments, 
services and support, and the need for ‘care now’, if we must wait for ‘cure later’
•	 The need for a public health approach to treatment and care, with more focus on raising awareness, 
creating Dementia Friendly Communities (DFCs), and providing accessible health and social care services 
for all 
•	 A recognition of the importance of prioritisation of efforts towards brain health promotion and dementia 
risk reduction, in an effort to reduce the future toll  
•	 New, and broader, priorities for research, going far beyond the original aim of developing a disease-course 
modifying treatment
•	 A commitment in principle to continue the G7 process, with sustainable leadership, and a defined set of 
agendas
Sponsoring G7 
countries
Setting Date Agenda
UK London June 2014 Finance and social impact investment
Canada and 
France
Ottawa September 2014 Harnessing the Power of Discoveries: Maximizing Academia and Industry 
Synergies
Japan Tokyo November 2014 New Care and prevention models
USA NIH Bethesda February 2015 State of the Science/Global Research Collaboration
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While the G7 countries alone account for 62% of the 
costs, a remarkable 92% of the costs arise in the 
broader group of G20 countries. 
Around one fifth of total costs are attributed to direct 
medical care with little variation by country income 
level. However, the distribution between formal social 
care and unpaid informal care varies considerably by 
country income level with formal costs preponderating 
in HIC while informal care is responsible for most costs 
in LMIC. 
This update benefited from a) the fully revised 
and updated estimates of numbers of people with 
dementia, b) improved data on per capita costs from 
new cost of illness studies or analyses from several 
high income countries (USA, UK, Germany, Norway, 
Sweden, and Ireland), and c) more detailed data to 
inform the imputation of the distribution of direct 
medical and social care costs in low and middle 
income countries from the 10/66 Dementia Research 
Group studies in countries in several countries in 
Latin America, India and China. We did not, however 
conduct a fully systematic review of resource utilisation 
and cost studies, and we updated cost estimates 
solely on the basis of country-specific consumer price 
index ratios between 2010 and 2015.   
7.2 Global Action Against 
Dementia
In December 2013, the UK government used its 
presidency of the group of the world’s leading 
economies (the so called ‘G8’ which later became the 
G7 – United States, Japan, Germany, France, UK, Italy, 
Canada - following the suspension of Russia) to launch 
a Global Action Against Dementia. The outcome of 
the first summit was an impressive commitment to set 
an ambition to identify a cure, or a disease-modifying 
therapy, for dementia by 2025. This was supported 
by a series of initiatives linked to research; increasing 
funding, promoting participation in trials, collaboration 
to share information and data; and the appointment of 
a new global envoy for dementia innovation, Dr Dennis 
Gillings. Over the course of four ‘Legacy Events’ (see 
Box 7.1) this agenda has broadened substantially, 
with significant input from civil society (including 
Alzheimer’s Disease International), the World Health 
Organization, the Organization of Economic Co-
operation and Development (OECD), G7 governments 
and their policymakers, and dementia experts from 
many fields. The voices and opinions of people with 
dementia, who were not given a platform at the first 
event, began to be heard. 
Earlier this year, as a final event linked to the G7 
Global Action Against Dementia, the World Health 
Organization convened a ‘First WHO Ministerial 
Conference on Global Action Against Dementia’ with 
the participation of 80 member states, 80 philanthropic 
foundations, 45 NGOs and 4 UN Agencies. This was 
a truly global event, offering proper representation 
to the world’s 127 low and middle income countries, 
alongside the G7 and the 67 other high income 
countries. The ‘call for action’* was unanimously 
adopted on 17th March 2015. Given the enormous 
impact of the condition worldwide, the call notes that: 
*  http://www.who.int/mediacentre/news/releases/2015/action-on-
dementia/en/
Box 7.2
Overarching principles, integral 
to global efforts
•	 Empowering and engaging the full and active 
participation of people living with dementia, 
their caregivers and families, as well as 
overcoming stigma and discrimination;
•	 Fostering collaboration between all 
stakeholders to improve prevention and care, 
and to stimulate research;
•	 Incorporating the aspects of dementia 
prevention, care and rehabilitation in 
policies related to ageing, disability and 
noncommunicable diseases, including mental 
health;
•	 Building on and utilising existing expertise, 
collaborative arrangements and mechanisms 
to maximise impact;
•	 Balancing prevention, risk reduction, care 
and cure so that whilst efforts are directed 
towards finding effective treatments and 
practices and risk reduction interventions, 
continuous improvements are made on care 
for people living with dementia and support 
for their caregivers;
•	 Advocating for an evidence-based approach 
and shared learning, allowing advances 
in open research and data sharing to be 
available to facilitate faster learning and 
action;
•	 Emphasising that policies, plans, 
programmes, interventions and actions are 
sensitive to the needs, expectations and 
human rights of people living with dementia 
and their caregivers;
•	 Embracing the importance of universal health 
coverage and an equity-based approach 
in all aspects of dementia efforts, including 
facilitation of equitable access to health and 
social care for people living with dementia 
and their caregivers.
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“A sustained global effort is thus required to 
promote action on dementia and address the 
challenges posed by dementia and its impacts. No 
single country, sector or organization can tackle this 
alone.”
The call for action identifies eight overarching 
principles (Box 7.2), and 11 action points (Box 7.3).
7.3 Beyond the G7 process 
The G7 countries, and their heads of government, 
are to be congratulated for the priority that they have 
accorded to dementia over the past two years. This is 
on the back of new national policy initiatives, dementia 
plans and strategic investment in most of these 
countries, in the years leading up to the G7 process. 
The ‘game changer’ introduced by UK Prime Minister 
David Cameron was the acknowledgement that 
dementia was too big and too global an issue to be 
addressed by nation states in isolation, and that trans-
national approaches and solutions would be required, 
with an accent on cooperation and collaboration. 
It was natural, in many ways, that the G7 should 
initiate and lead this process. The world’s wealthiest 
nations have borne the brunt of the first wave of the 
dementia epidemic, and it is in these countries that 
the fiscal challenges of meeting the rising demand for 
health and social care are currently most acute. The 
search for a treatment or cure is led by multinational 
pharmaceutical industries based mainly in these 
countries. However, it became clear to most over the 
course of the G7 process that with a global epidemic 
concentrated in low and middle income countries(1), 
substantial problems with service coverage and access 
to care(2), and, realistically, only modest expectations 
for therapeutic advances(3), a much broader agenda 
would be required. This would need to be supported 
by a wider international coalition, and sustained over a 
much longer period than the first phase of the Global 
Action Against Dementia.
7.4 Building upon the Global 
Action Against Dementia   
The broader agenda comprises five key elements; 
a global approach to a global problem; the need for 
‘care now, if cure later’; a public health orientation 
(awareness, accessible services, and prevention); a 
focus on equity and rights; and a rational approach to 
research prioritisation.
7.4.1 A global approach, with an accent 
on low and middle income countries
The world’s seven wealthiest economies, the G7, 
currently account for 10% of the world’s population, 
nearly half of its GDP and two thirds of net global 
wealth. 21% of the world’s population of older people 
live in G7 countries, and 28% of all people living 
Box 7.3
Actions for people living with 
dementia, their caregivers, 
families and community
•	 Raising the priority accorded to global efforts 
for dementia on the agendas of relevant high-
level forums and meetings of national and 
international leaders;
•	 Strengthening capacity, leadership, 
governance, multisectoral action and 
partnerships to accelerate responses to 
address dementia;
•	 Promoting a better understanding of 
dementia, raising public awareness and 
engagement, including the respect for 
their human rights, reducing stigma and 
discrimination, and fostering greater 
participation, social inclusion and integration 
of people living with dementia;
•	 Advancing prevention, risk reduction, 
diagnosis and treatment of dementia, 
consistent with current and emerging 
evidence;
•	 Facilitating technological and social 
innovations to meet the needs of people living 
with dementia and their caregivers;
•	 Increasing collective efforts in dementia 
research and fostering collaboration;
•	 Facilitating the coordinated delivery of 
health and social care for people living with 
dementia, including capacity building of the 
workforce, supporting mutual care taking 
across generations on an individual, family 
and society level, and strengthening support 
and services for their caregivers and families;
•	 Supporting a gender-sensitive approach 
in the elaboration of plans, policies and 
interventions aimed at improving the lives of 
people living with dementia;
•	 Promoting further work in identifying and 
addressing barriers to dementia care, 
particularly in low-resource settings;
•	 Strengthening international efforts to support 
plans and policies at all levels for people 
living with dementia, in particular in low- and 
middle-income countries;
•	 Supporting the efforts of the World Health 
Organization, within its mandate and work 
plans, to fulfil its leadership role in full 
collaboration with national and international 
partners, to promote and monitor global 
efforts on dementia.
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with dementia, generating 62% of all global societal 
economic costs linked to dementia. 
The world’s 20 major economies, the G20, account 
for 64% of the world’s population. 76% of the world’s 
population of older people live in these 43 countries, 
and 80% of all people living with dementia, accounting 
for 92% of all global societal economic costs. 
Projecting forwards from 2015, global numbers of 
people with dementia will have increased by nearly 85 
million by 2050. 16% of these additional cases will be 
in G7 countries, and 67% in G20 countries; therefore, 
more than half of the growth will be occurring in G20 
countries who are not members of the G7. Most 
significantly, these include the populous and rapidly 
developing middle income countries where population 
ageing will be occurring most rapidly, represented in 
the G20 by China, India, Indonesia, Brazil, Mexico and 
Turkey. 
Demand will rise most rapidly in low and middle 
income countries, as the increasing numbers of people 
affected drive increasing awareness. However, the 
supply of services is restricted, given limited resources. 
This applies most particularly to specialist healthcare 
services, and the whole apparatus of long-term 
community-based and residential care(4). Also, primary 
care services are currently neither appropriately 
designed nor trained to assume responsibility for 
primary attention and continuing care; this is a general 
problem for management of non-communicable 
diseases in an ageing population(5), with particular 
implications for dementia care(6). The seamlessness of 
traditional extended family care systems was probably 
always exaggerated(7;8), and will, increasingly, come 
under strain given the pace of social, demographic 
and economic change. The fiscal implications of these 
transitions, in the context of increasing demands for 
state-assured social protection and long-term care, 
need urgent consideration by countries well beyond 
the confines of the OECD(4;9). 
It would seem logical for the G20 to assume political 
leadership of the Global Action Against Dementia, 
hence ensuring the involvement of countries in all 
continents, including those that will be most affected 
by the growing numbers of people with dementia 
over the next generation. A petition to the Australian 
government, to put dementia on the G20 agenda in 
2014, although widely supported, was not successful. 
Turkey will host the next G20 summit in Antalya, 15-
16th November 2015, and then hand over the chair 
to China, home to the world’s largest population of 
people living with dementia. This is therefore a highly 
opportune moment to renew this call. 
The World Health Organization Ministerial Conference 
‘call for action’ has asked the WHO ‘to fulfil its 
leadership role in full collaboration with national and 
international partners, to promote and monitor global 
efforts on dementia’. This is a welcome development. 
The WHO is concerned, first and foremost, with 
global public health. It has a role in monitoring health 
trends, disseminating information, and providing 
leadership, policy guidance and technical assistance 
to governments. Much of its work is focused upon 
resource-limited low and middle income countries. The 
WHO has been particularly energetic and effective in 
recent years in the dementia field. In 2009, dementia 
was included among 10 ‘priority neurological and 
mental disorders’ for the WHO Mental Health Gap 
Action Plan (mhGAP), seeking to close the treatment 
gap by scaling up evidence-based packages of care to 
be delivered by trained and supervised non-specialist 
health workers(10;11). The WHO/ADI joint report, 
published in 2012, signalled, through its title ‘Dementia: 
a public health priority’, a new approach, emphasising 
the need for awareness, policies and plans, scaled up 
services accessible to all on an equitable basis, and a 
focus upon prevention(12). The 2015 WHO World Health 
Report focuses upon ageing and health. The WHO’s 
contribution to the G7 process has evidently been 
another potential ‘game-changer’. However, we need 
to be aware that the ‘call for action’ is currently nothing 
more than that. It does not commit nation states, 
individually or collectively to any specific investments, 
policies or actions. The ‘call for action’ specifies, 
in carefully chosen language that the signatories 
will be ‘supporting the efforts of the World Health 
Organization, within its mandate and work plans’. 
These can only be extended through a motion for a 
resolution proposed by several Member States, to the 
World Health Assembly. This could call, for example, 
for the WHO Secretariat to work with Member States to 
develop a ‘Dementia Action Plan’. Such a plan, as was 
the case, with the ‘WHO Comprehensive Mental Health 
Action Plan 2013-2020’(13), could include specific 
actions for Member States, international, regional and 
national level partners, and the WHO Secretariat with 
indicators and targets that can be used to evaluate 
levels of implementation, progress and impact, and 
hold governments to account.  
7.4.2 Care now/cure later
On the one hand, 2025 is a cruelly long time to wait for 
a cure or disease-modifying treatment for dementia. 
On the other hand most participants in the G7 
process acknowledged that even this would be a very 
challenging target. While there has been a productive 
pipeline of promising new agents with plausible 
targets linked to Alzheimer's disease pathology, there 
has been a dispiritingly high proportion of failures 
in phase II human trials, and phase III definitive 
randomised controlled clinical trials(2). This raises 
legitimate questions regarding the validity of our 
current disease models, and the continued willingness 
of pharmaceutical companies to meet the heavy 
research and development costs. Partnership between 
industry, governments and universities, international 
collaboration, and data and information sharing all 
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potentially have much to offer in maintaining and 
increasing efforts in this direction. 
In the meantime, clearly we cannot and should not 
wait to implement currently available evidence for 
services, treatments and care that improve the health 
and wellbeing of people with dementia and their 
carers. There are considerable challenges in achieving 
acceptable levels of coverage and access to care. 
Currently, far too few people with dementia receive a 
diagnosis, let alone treatment and support. Around 
half of those affected are not diagnosed in HIC, the 
proportion diagnosed falling to below 10-20% in 
LMIC where awareness is even lower(14-17). Even if the 
progressive course of dementia cannot be altered, 
symptomatic treatments and support are helpful. 
Earlier diagnosis allows those affected to participate in 
advanced care planning while they still have capacity 
to do so(15). Education, training and support for carers 
is effective in reducing carer strain and psychological 
morbidity, and, in HIC, in delaying or avoiding transition 
into care homes(18). Such interventions may be more 
effective early in the disease course(15;19). Support 
groups for people with dementia, acetylcholinesterase 
inhibitors and cognitive stimulation to improve 
cognitive function, and behavioural interventions for 
depression are all effective interventions in early-stage 
dementia(15). Early diagnosis and intervention is likely to 
be cost-effective in HIC, assuming delayed or averted 
transfer into costly institutional care settings(15). The 
cost-effectiveness of scaling up diagnosis and care 
in LMIC is unknown. However, the psychological and 
economic strain on caregivers is substantial, and 
compensatory benefits practically non-existent(20;21). 
While we wait, in hope, for technological advances in 
diagnosis, treatment and care we should be mindful 
that delivery systems are currently hugely ineffective 
worldwide, with very limited coverage of even the most 
basic services. These problems need to be addressed, 
urgently, with a balanced research agenda that gives 
equal priority to translation of existing knowledge 
into policy and practice (see section 7.4.6). Failure to 
address these limitations also risks substantial ethical 
problems regarding the ability of lower versus higher 
income countries to implement, and benefit from 
advances in treatment and care (see section 7.4.4). 
7.4.3  A public health approach
Awareness
Raising awareness is a cornerstone of the public health 
approach to addressing the dementia epidemic. In 
Chapter 6 of the WHO/ADI report, Dementia: a public 
health priority, a six stage incremental “Acceptance 
of Dementia” model was proposed in which countries 
might progress from stage 1) Ignoring the problem, 
to 2) Some awareness, 3) Building dementia 
infrastructure, 4) Advocacy efforts, 5) Policies and 
dementia plans or strategies, to 6) Normalisation. 
Pragmatically, it may not be possible to miss out 
stages in this essentially bottom-up process, although 
political will, prioritisation and investment from 
governments will help to speed the transition. 
For governments that have developed policies and 
plans, the concept of ‘Dementia Friendly Communities’ 
has been particularly popular(22). The UK Prime 
Minister’s Challenge on Dementia* emphasises the 
central role of people with dementia;
“We would like people living with dementia to be 
able to say that they know what they can do to help 
themselves and who else can help them, and that 
their community is working to help them to live well 
with dementia.”
The term “dementia friendly” has been applied 
both to physical environments and communities. It 
addresses in particular the lived experience of people 
with dementia, seeking among other things, a change 
in attitudes and behaviours towards dementia, for 
people with dementia and their carers to be treated 
with dignity and respect, for an end to stigma, and for 
communities to be enabled to support people affected 
by dementia so they can ‘live well with dementia’. A key 
example is that of the Japanese ‘Dementia Friends’ 
model (copied in the UK) where a remarkable 6 million 
friends (4.6% of the population), lightly trained by 
105,000 dementia champions, are driving innovative 
community programs across the country†. The US 
National Dementia Plan focuses more upon the 
concept of ‘dementia capable’ workforces, programs, 
services, and systems, with a practical focus upon 
building knowledge, capacity and skills in key services 
to better meet the needs of people with dementia and 
their caregivers(22). 
In a thoughtful review, Lin and Lewis have highlighted 
the complementary nature of the two approaches, 
which both encourage inclusion and acceptance. 
At the same time, they argue the need for a third 
component, ‘dementia positivity’(22);
“At first glance, this society (dementia capable 
and dementia friendly) seems to have everything 
to ensure a good life for people with dementia 
and their families. However, without dementia 
positivity, it is merely a society that tolerates and 
respects differences. It is merely a society that 
supports or takes care of its members. It is not a 
society that truly sees people with dementia as 
equal contributors. The desires of people with 
dementia to make contributions to society and be 
seen as persons with strengths and abilities have 
been documented in books written by people 
*  Delivering major improvements in dementia care and research 
by 2015 (Department of Health, 2012) https://www.gov.uk/
government/uploads/system/uploads/attachment_data/
file/215101/dh_133176.pdf
†  See Dr Mayumi Hayashi’s recent blog at https://ageingissues.
wordpress.com/2015/03/20/dementia-care-in-japan-is-being-
solved-through-volunteer-schemes-not-government/
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with dementia and their advocates alike, such as 
Christine Bryden’s (2012) Who Will I Be When I Die, 
John Zeisel’s (2010) I’m Still Here, and Anne Davis 
Basting’s (2009) Forget Memory, to name a few. 
People with dementia want society to accept their 
disabilities. They also want society to see their 
strengths and abilities. Without dementia positivity, 
regardless of how well the society provides 
resources, accommodations, services, activities, 
and opportunities for people with dementia and 
their families to stay engaged, it is merely a pseudo 
social inclusion.”
Accessible services
At the United Nations Second World Assembly on 
Ageing (Madrid, 2002), governments of 159 nations 
adopted the Madrid International Plan of Action on 
Ageing (MIPAA), to respond to the challenges of 
population ageing (23). The plan stressed the need 
for equitable, affordable access to age-appropriate 
healthcare, reflecting also the universal right to health 
and access to medical care enshrined in the Universal 
Declaration of Human Rights (1948), and the UN 
Convention on the Rights of Persons with Disabilities 
(2006), and consistent with the concept of universal 
coverage that is likely to be at the heart of the UN’s 
new Sustainable Development Goals. Unfortunately, 
in 2012, a 32 country case study conducted for a 
UNFPA 10 year review of MIPAA(24) found that very little 
progress has been made towards the achievement 
of these objectives, particularly in LMIC and other 
resource poor settings. 
Problems of access to services are complex, and 
include low awareness linked to limited help-seeking, 
and financial barriers, when the need for care is 
continuing, and reimbursement for health or social 
care is either means-tested, or subject to insurance for 
which coverage is less than complete, and where older 
people have insufficient personal incomes to meet out-
of-pocket payments(4;6;25).  
For low and middle income countries, a lack of 
coverage of services is an even more pressing 
problem. There are simply too few specialists 
(geriatricians, psychiatrists, neurologists, 
psychologists, specialist nurses, occupational and 
physical therapists, and nutritionists) to provide 
services for more than a tiny proportion of people 
with dementia, mainly restricted to urban centres. 
Similar resource limitations have been identified for 
other chronic disease domains including global mental 
health(26), palliative care(27), and global surgery(28). The 
challenge for dementia care is particularly acute, given 
that the demand for services will increase sharply, 
and likely outstrip any efforts to expand the specialist 
workforce. An important part of the solution must be a 
move towards a ‘task-shifting’ or, more appropriately, 
a ‘task-sharing’ approach, where much of the onus for 
delivering care is placed upon non-specialist primary 
care and community services, trained and supported 
by more experienced specialists. This approach 
has been championed in the global mental health 
field(10;27;29). Scaling up such services is a complex 
process, requiring changed roles and responsibilities, 
additional resources, and new models for the delivery 
of care. Specialists need to focus as much upon 
service management, training and supervision, as on 
the delivery of frontline care (reserved for complex 
cases). In essence, they need to become agents of 
public health, and attend as much to the coverage 
of services, as to the quality of care provided to their 
limited caseload. 
Global problems require global solutions, and it is likely 
that the ‘task-sharing’ solution will have applications 
in high income as well as low and middle income 
country settings. It is becoming abundantly clear 
that, in the face of the current dementia epidemic, all 
health and social care systems should be considered 
to be ‘resource-poor’. Given that half or more of all 
people with dementia have not received a dementia 
diagnosis, there are, arguably, insufficient specialist 
services in high income countries to perform this 
task in a timely fashion. The coordination or case 
management of health and social care for people with 
dementia across the evolving journey of care is both 
critically important, and neglected(4). These roles are 
probably best embedded in integrated community 
health and social care services(30), and at the level of 
primary care, where staff are best acquainted with the 
person with dementia and their family, and best placed 
to deliver person-centred care based on individual 
values and preferences. Task-sharing models aim for 
allocative efficiency, either by extending the coverage 
of services at a similar cost, or providing the same 
level of care output at a lower cost(31). These are highly 
relevant objectives for health and social care systems 
around the world. Rich developed nations do not have 
a monopoly on solutions, and may have developed an 
over-specialised model of care. There is potential here 
for ‘south-north’ as well as ‘north-south’ learning and 
knowledge translation.
Prevention
On the basis of the reviews conducted for the World 
Alzheimer Report 2014, ‘An analysis of modifiable risk 
factors for dementia’ we concluded that the strongest 
evidence for possible causal associations with 
dementia (plausible, consistent, strong associations, 
relatively free of bias and confounding) are those of 
low education in early life, hypertension in midlife, and 
smoking and diabetes across the life course(32). While 
there was consistent evidence from several studies 
for an inverse association between both physical 
and cognitive activity and dementia incidence, more 
research is necessary to confirm a causal relationship. 
The pattern of association suggests two important 
general mechanisms; a) cognitive or brain reserve 
(education and occupational attainment enhancing 
brain structure or function, modifying the impact of 
neurodegenerative brain damage in late-life(33)) and; 
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b) vascular pathology, through which the effects of 
midlife hypertension, smoking and diabetes may 
be mediated. The report has added to a growing 
consensus that risk reduction may, indeed be possible, 
and that further research, and health promotion actions 
are indicated(34;35). The first necessary step is a wider 
acknowledgement and understanding that dementia 
may, at least to some extent, be a preventable 
condition.  
Our best hope of ascertaining the likely impact of 
increasing levels of education and improvements in 
cardiovascular health may be to observe populations in 
which such trends are prominent, to see whether these 
are associated with a decline over time in the age-
specific incidence of dementia. The review carried out 
for this report, of secular trends in dementia prevalence 
and incidence, provides equivocal evidence some of 
which is consistent with the notion that the disease 
frequency may already have started to decline in some 
high income countries. However:
a) More robust research is required, in more settings, 
and over longer periods into the future to determine 
trends with more precision and their variation 
between regions, countries and sub-populations.
b) It is perfectly possible that reductions in risk factor 
exposures, linked to improvements in public health, 
may reduce the incidence of dementia, but prolong 
survival, with an uncertain, but possibly neutral 
effect on age-specific prevalence. 
c) While levels of education have increased all around 
the world, cardiovascular health is becoming 
increasingly compromised in many low and 
middle income countries. Even with priority action 
to address this problem(36), trends in dementia 
incidence and prevalence in these settings may 
therefore be in the adverse direction, at least in the 
short- to medium-term. 
We have not yet found sufficient evidence to alter 
our assumption, for future projections, that the age-
specific prevalence of dementia will remain constant 
over time. For the time-being, prudent policymakers 
should adopt a similar perspective. That should not, 
however, deter them from vigorous attempts to reduce 
the incidence of dementia by acting on the evidence 
regarding modifiable risk factors. Detection and 
treatment of diabetes and hypertension, reduction 
in levels of obesity, smoking cessation, increased 
physical activity, and better education are already 
public health priorities for most countries worldwide. 
Nevertheless, the message that dementia, alongside 
heart disease, stroke and cancer, may be prevented 
through increased adoption and more effective 
implementation of these public health strategies is one 
that policymakers and public need to hear. Failure to 
act risks missed opportunities to mitigate the scale 
of the future epidemic, or even allowing it to advance 
more rapidly than we are currently predicting.      
7.4.4  Equity and rights
There is much that is fundamentally unfair about 
dementia and its impact upon individuals and 
societies. It selectively impacts upon the old and frail, 
women, those with less education, and fewer assets. 
It rarely, but very significantly, blights the hopes and 
expectations of those in the prime of their lives. It dims 
the voices of those affected, just when they might have 
most to tell us about their experiences of living with the 
condition, and how they would wish their rights to be 
respected. Given different global rates of population 
ageing, the future epidemic will be concentrated in low 
and middle income countries, where there are currently 
the lowest levels of awareness, and the fewest 
resources to meet the coming demand. 
Equity is different. The basic principle is that all people 
affected by the condition should be acknowledged 
as having equal status and value, and should be 
accorded equal access to diagnosis, and evidence-
based treatment, care and support, regardless of 
age, gender, socioeconomic status, ethnicity, or (at a 
global level) country of residence. Evidently, from the 
evidence presented in this report, and summarised in 
this chapter, we are a very long way from achieving this 
objective. 
It is very encouraging that the WHO ‘call for action’ 
makes frequent reference to the inalienable human 
rights of those affected, and to the need to give special 
and focused attention to low and middle income 
countries, and, above all emphasises;
“a universal health coverage and an equity-based 
approach in all aspects of dementia efforts, 
including facilitation of equitable access to health 
and social care for people living with dementia and 
their caregivers.”
Unless these problems are addressed, equity, 
particularly for the majority of people with dementia 
living in the world’s poorer countries will not be 
achieved. With the focus on therapeutic innovations (a 
disease-course altering treatment by 2025), there is a 
danger that the lessons of the AIDS epidemic will be 
forgotten. Nowadays, those living in Los Angeles and 
Lusaka, Birmingham and Blantyre, and Phnom Penh 
or Paris have an approximately equal opportunity, in 
principle, to access an affordable HIV diagnosis and 
life-changing treatment. However, the journey to this 
point since the advent of antiretroviral therapy has 
been far too long, with millions of lives lost. The rate 
limiting step, after the affordability of medications was 
addressed, was the weakness of healthcare delivery 
systems. The belated achievement is, nevertheless, 
a triumph for global health, and demonstrates that 
with political galvanised by advocacy, and with global 
collaboration, equity is attainable.  
We would like, in this year’s World Alzheimer Report, 
to draw attention to two further important equity 
issues. One, gender, was highlighted in an ADI report 
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issued earlier this year(37). The other, younger-onset 
dementia, has been perennially neglected, including 
in this report, due to a relative lack of high quality 
data, and an accurate perception that, being a rare 
condition it contributes relatively little to the overall 
burden. However, this has resulted in a neglect of the 
heightened individual impact, and the special needs of 
those affected, which are poorly met.
Gendering 
As highlighted earlier this year in an Alzheimer’s 
Disease International global research review on women 
and dementia, too little attention has been given to 
the gendered aspects of the epidemic(37). Women 
predominate amongst older people with dementia. This 
is mainly because of women’s greater life expectancy. 
However, as highlighted earlier in this report (Chapters 
2 and 3), age-specific prevalence and incidence of 
dementia are also higher among women, particularly 
at older ages. The reasons for this are not clearly 
established, and more research would be justified, 
seeking options for prevention and treatment. The ADI 
report also revealed that there has been surprisingly 
little research into the effect of gender upon care needs 
and preferences from the perspective of the person 
with dementia. 
Care for people with dementia is also overwhelmingly 
provided by women. Men and women approach the 
caring role, cope, and seek support in different ways. 
However, very little work has been carried out to 
determine how health and social care professionals 
should incorporate gender awareness into the support 
that they provide to people with dementia and their 
informal carers. The paid professional health and social 
care workforce is, probably, even more overwhelmingly 
female. In the UK, it has been estimated that 87% 
of the dementia care workforce is female, a greater 
proportion than the care workforce overall(38). 
Dementia care workers were more likely to be female, 
temporary agency staff and from an ethnic minority 
group. As highlighted in the World Alzheimer Report 
2013, there are widespread problems across high 
income countries with the low status, low pay and lack 
of professional development opportunities for the care 
workforce, all of which pose considerable challenges 
for maintaining and improving care quality(4). Paid or 
unpaid, the fact that most carers across most if not all 
cultures are women, needs to be carefully considered 
from an equity standpoint. Women are already likely to 
be relatively disadvantaged with respect to education, 
career opportunities across the life course, income, 
assets and (in older age) pension entitlements. Taking 
on caring responsibilities for a person with dementia 
can lead to social isolation, cutting back or stopping 
work, and risks to physical and mental health(4). 
Needs of younger people with dementia
Younger onset dementia (sometimes referred to as 
early-onset) is typically defined as onset before the 
age of 65 years. This is a rare condition(12), which, 
unlike late-onset dementia, will not be apt to increase 
in terms of numbers affected over time. However, 
people with younger onset dementia and their 
caregivers have specific age-related needs. The low 
prevalence, unusual presenting features (particularly 
neuropsychiatric symptoms) and broader differential 
diagnosis may all contribute to a substantial delay 
in obtaining a diagnosis (4.4 vs 2.8 years for late-
onset dementia in one Dutch study)(39), which is likely 
to have led to a substantial underestimate of true 
prevalence(12). Younger-onset dementia is particularly 
likely to have a genetic cause, and depending upon 
the type of dementia and the family history, genetic 
counselling and testing may be indicated(40). Few 
studies have compared carer strain between younger-
onset and late-onset dementia, but it is plain from a 
comprehensive review of the literature that levels of 
strain, anxiety and depression are very high among 
carers (usually spouses and children), and family 
conflict is often reported(41). There are likely to be 
multiple contributory factors. People experiencing 
dementia at a younger age may still be employed and 
bringing up children; they are faced, while physically 
robust, with the prospect of losing their active roles 
and needing fundamentally to reappraise their future 
hopes and plans. Carers, as well as the people 
living with dementia, are more likely to be employed 
than spouses of late-onset dementia patients, and 
often need to take early retirement or reduce their 
working hours. Financial difficulties were common(40), 
exacerbated by health and social care systems in 
some countries that do not provide the same range 
of benefits and reimbursements for younger as for 
older families(42). In most countries there are few or 
no designated services for people with younger onset 
dementia, and there are real challenges in meeting 
this need, given the small numbers and geographic 
dispersion of those affected(42). This was a significant 
cause of distress for caregivers, who can be left feeling 
angry and guilty when offered no option other than to 
accept services designed for older people(41). 
Many of these issues are addressed authentically and 
sensitively in the novel ‘Still Alice’ by Lisa Genova*, and 
the film of the same name, for which Julianne Moore 
was awarded the Academy Award (Oscar) for Best 
Actress in 2014.
There is a clear need, enunciated by people living with 
young onset dementia at several recent meetings, for 
supported employment initiatives for people living with 
younger onset dementia. As retirement ages increase 
worldwide beyond the age of 65 years, this will be an 
issue for late-onset dementia also. Carers, as well as 
people with dementia, would benefit from more flexible 
work arrangements.  
*  Gallery Books/ ISBN 9781439102817/ January 2009 
- http://books.simonandschuster.com/Still-Alice/Lisa-
Genova/9781439102817#sthash.SRRJJALd.dpuf
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Workplaces should be highlighted not only as a unique 
place to support people living with dementia and their 
carers, but also to encourage lifestyle changes to 
reduce the risk of dementia. 
7.4.6 Research prioritisation
Dementia research is currently grossly underfunded 
with respect to the burden of disease, and the 
societal economic cost. ADI, in conjunction with 42 
other international and national non-governmental 
organisations, has called for nation states to contribute 
1% of their respective societal economic costs to 
dementia research funding. This modest proposal, if 
initiated, would result in research investment being 
increased to over US$ 8 billion per annum. Currently, 
the USA, by far the largest national contributor to 
research, invests some US$731 million annually 
through Federally-funded National Institutes of Health 
programs. The $8.4 billion contribution would be 
distributed pro rata, with US$6.9 billion from high 
income countries, US$1.4 billion from middle income 
countries, and US$19 million from low income 
countries. This would amount to only around 0.003% 
of GDP in low income countries, and 0.014% of GDP in 
high income countries. A proportion of this fund could 
be hypothecated to a ‘Global Fund’ to address major 
cross-national questions, and to give a much needed 
focus to service development in low and middle 
income countries. 
The key question remains; to which priorities should 
this research funding be directed? ADI and its INGO 
partners have recommended that in addition to 
search after a treatment or cure, governments should 
‘increase efforts in other areas of research, such 
as research into effective care models; prevalence, 
incidence and mortality, prevention and risk reduction 
to a comparable level, and increase the focus on 
translating research into practice’. This chimes with the 
recommendation from a Lancet Editorial that;
 “Little research is carried out on scaling up of cost-
effective care strategies and integrated models of 
care. Little is known about, for example, alternatives 
to antipsychotic treatment, non-drug approaches, 
or the place of cognitive stimulation. The dementia 
research agenda should include studies of disease 
mechanisms, epidemiology, early diagnosis, 
prevention, risks and social determinants, nondrug 
based approaches, and quality of life. The quest for 
new drugs must not overshadow improving today’s 
care and patients’ lives.”(2)
There is clearly a move towards a more balanced 
research agenda. The WHO has led a research 
prioritisation exercise, using well established Child 
Health and Nutrition Research Initiative (CHNRI) 
methodology, that essentially seeks to use the ‘wisdom 
of crowds’ to establish key priorities on the basis of 
feasibility, answerability, potential to reduce disease 
burden, and equity of impact(43). The results of this 
exercise will be updated following expansion of the 
consultation to include a broader base of stakeholders 
and world regions, and then published in full and final 
form. However, preliminary findings presented at the 
WHO Ministerial Conference indicated that six of the 
top 10 overall priorities were orientated to the delivery 
of prevention and care (Table 7.1), whereas ratings on 
the basis of ‘potential for conceptual breakthrough’ 
Table 7.1  
Preliminary findings from the WHO research prioritisation 
exercise – overall priorities (presented at WHO Ministerial 
Conference, March 2015)
1 Identify clinical practice and health system-based 
interventions that would promote a timely and accurate 
diagnosis of dementia in primary health care practices.
2 Develop and validate biomarkers – including biological, 
genetic, behavioral and cognitive markers – for 
neurodegenerative brain diseases causing dementia, to 
identify similarities and differences between diseases 
and dementia subtypes, and assess progression from 
pre-manifest (pre-symptomatic) to late stage diseases.
3 Identify strategies to anticipate and deliver effective 
and cost-effective late life and end of life care for 
people with dementia, including advance care planning.
4 Determine the most effective interventions for 
educating, training and supporting formal and informal 
carer(s) of people with dementia.
5 Identify, validate and apply better outcome measures 
for clinical trials of cognition, function and other 
biomarkers for neurodegenerative diseases causing 
dementia.
6 Understand the contributions of vascular conditions to 
neurodegenerative diseases causing dementia.
7 Explore single and multi-domain approaches for 
primary and secondary prevention of dementias 
based on evidence on risk/protective factors and the 
relationship with other chronic diseases.
8 Establish norms and standards for the highest 
quality of care in residential and nursing homes and 
approaches to assist families of people with dementia 
to determine the optimal time to consider placement.
9 Evaluate the relative effectiveness and identify the 
optimal models of care and support for people with 
dementia and their carers in the community (e.g. 
collaborative care, integrated health and social care, 
case management) across the disease course.
10 Establish norms/standardize clinical trial methodology 
and ethics of conducting research with new 
pharmacological agents, and non-pharmacologic 
interventions for diseases causing dementia.
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favoured more basic research into disease 
mechanisms. 
In reality, both approaches are required, and the only 
question is the relative balance of research investment 
into each area. 
Given the focus for this report, we must also highlight 
the need, worldwide, but especially in high income 
countries, to re-engage with the neglected task of 
monitoring the prevalence of dementia worldwide, 
accompanied, ideally, with observation of any secular 
trends in incidence and mortality, where longitudinal 
research is feasible. Such studies should, ideally, be 
conducted on nationally representative samples, and 
could conveniently be performed nested within national 
surveys of health and ageing. This would facilitate 
secondary aims including a) monitoring changes in 
dementia diagnostic coverage, access to and receipt 
of dementia-specific services, b) changes in the 
exposure to hypothesised modifiable risk factors for 
dementia, and relating these to changes in dementia 
prevalence and incidence, c) changes in formal and 
informal care arrangements, and healthcare for people 
with dementia, and their attendant societal costs.  
7.5 Final conclusions and 
recommendations   
Alzheimer’s Disease International;
•	 Applauds	the	action	taken	by	the	G7	in	launching	
a ‘Global Action Against Dementia’ and recognises 
the considerable efforts of the Global Dementia 
Envoy, the World Dementia Council, and the G7 
governments over the past 18 months
•	 Hopes	and	expects	that	this	initiative	will	now	be	
continued, with a broader agenda and a wider 
representation of countries and regions most 
affected by the ongoing epidemic
•	 Would	support	and	advocate	for	a	transfer	of	
political leadership to the G20 group of nations, 
assuming continued commitment and engagement 
of the G7 nations to the cause 
•	 Wholeheartedly	endorses	all	aspects	of	the	‘call	
for action’ issued at the WHO first Ministerial 
Conference for Dementia
•	 Welcomes	the	leadership	role	outlined	for	WHO	in	
the ‘call for action’ and will continue to work closely 
with this body and its member states to ensure 
that people with dementia and their families are put 
at the centre of all policies, in pursuit of equitable 
access to comprehensive services for all people 
with dementia worldwide, and the realisation of the 
full potential for living well with dementia.
•		 Believes	work	on	the	quality	of	care	should	be	
a priority and applauds OECD’s commitment to 
evaluate dementia care models and make outcomes 
measurable and transparent
Call to action
Alzheimer’s Disease International;
1. Recognises the need for the ‘call for action’ to be 
translated into an operationalised ‘Global Dementia 
Action Plan’, with clear targets and deliverables, 
and will both advocate for and support interested 
Member States to propose motions to the World 
Health Assembly
2. Proposes that the elements of planning for dementia 
at the global and country level that has the objective 
Table 7.2  
Preliminary findings from the WHO research prioritization 
exercise – potential for conceptual breakthrough (presented 
at WHO Ministerial Conference, March 2015)
1 Understand the basic biological mechanisms of 
neuronal cell death involved in the initiation/onset and 
progression of neurodegenerative diseases causing 
dementia.
2 Understand the basic biological mechanisms 
of dysfunction of cellular metabolism, and their 
regulation in the initiation/onset and progression of 
neurodegenerative diseases that lead to dementia.
3 Understand the role of inflammation and of the immune 
system in the initiation/onset and progression of 
neurodegenerative diseases that lead to dementia.
4 Determine the roles of non-neuronal brain cells 
(such as microglia, astrocytes and macrophages) in 
pathogenesis and progression of neurodegenerative 
diseases that cause dementia.
5 Identify underlying mechanisms of resilience to 
neurodegenerative diseases causing dementia at all 
stages (such as cognitive reserve, protective genotypes, 
and neuroprotection).
6 Understand the impact of the neurodegenerative 
diseases causing dementia upon the structure and 
function of neural systems and networks with the aim 
of identifying new therapeutic targets.
7 Understand protein misfolding and propagation in 
the brain and their role in the initiation/onset and 
progression of neurodegenerative diseases causing 
dementia.
8 Investigate how intrinsic biological ageing processes 
may contribute to the neurodegenerative diseases 
causing dementia.
9 Understand the contributions of vascular conditions to 
neurodegenerative diseases causing dementia.
10 Understand the contribution of environmental factors to 
neurodegenerative diseases causing dementia and their 
interactions with other pathophysiological processes at 
the epigenetic, molecular and systems levels.
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of supporting the person with dementia to stay in 
the community for as long as possible include;
a) Awareness raising of dementia
b) Creation of dementia friendly communities that 
reduce stigma associated with the disease
c) Promotion of risk reduction measures 
d) Measures to improve diagnosis and reduce the 
average length of diagnosis
e) Support for family carers including through 
information, social support, respite and 
counselling
f) Access to long term community and residential 
dementia care services and to enhanced care for 
people dementia in hospitals 
g) A commitment to person centred care and to 
care that minimises the use of medical and 
physical restraint
h) Workforce strategies including training 
i) The use of technology to assist the person with 
dementia in the home and to extend service 
reach in rural areas
j)  Recognition that people with dementia deserve 
good quality end-of-life care with respect to their  
dignity and personal wishes
3. Calls for a focus on strengthening primary health 
care as the key part of the health system to respond 
to the dementia challenge
4. Calls for risk reduction for dementia to be made an 
explicit priority with linked actions, including setting 
of some targets and indicators, to the general work 
steam on non-communicable diseases that is led by 
the World Health Organization
5. Calls for a significant upscaling of research 
investment, proportionate to the societal cost 
of the disease, and for a balanced investment in 
research into prevention, treatment, care and cure, 
with a specific work stream for lower and middle-
income countries, developing programmes to raise 
awareness and improve health system responses 
with the inclusion of partners from those countries.
6. Supports the need for a Global Dementia 
Observatory, coordinated by WHO to; support and 
monitor policy development; monitor the scale of the 
epidemic; assess opportunities for prevention, their 
implementation and impact; and monitor progress 
towards increasing the available resources for 
treatment and care, and their coverage worldwide. 
7. Recommends that every country should develop 
its own national dementia plan or strategy as a 
framework for action across government sectors; 
and monitor the results and renew the plan on a 
regular basis.
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Appendix A: Global Burden of Disease (GBD) Regions
Table A.1 
GBD regions for which meta-analysis could be conducted
GBD Region Countries (those with one or more studies 
underlined)
Relationship to WHO 
regions used for ADI/ 
Lancet estimates
Approach used to generate 
regional prevalence and 
numbers
ASIA
Australasia Australia, New Zealand WPRO A Apply estimates from meta-
analysis. 
Asia Pacific, High 
Income
Brunei-Darussalam, Japan, Republic of Korea, Singapore WPRO A except for Korea 
(WPRO B)
Apply estimates from meta-
analysis.
Asia, East China, Democratic People’s Republic of Korea, Hong Kong SAR, 
Taiwan, Macao SAR
WPRO B except for Democratic 
People’s Republic of Korea 
(SEARO D)
Apply estimates from meta-
analysis. 
Asia, South Afghanistan, Bangladesh, Bhutan, India, Nepal, Pakistan SEARO D except for 
Afghanistan and Pakistan 
(EMRO D)
Apply estimates from meta-
analysis.
Asia, Southeast Cambodia, Indonesia, Lao People’s Democratic Republic, 
Malaysia, Maldives, Mauritius, Mayotte, Myanmar, Philippines, 
Reunion, Seychelles, Sri Lanka, Thailand, Timor-Leste, Viet Nam 
Mainly SEARO B and WPRO B Apply estimates from meta-
analysis.
EUROPE
Europe, Central Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Czech 
Republic, Hungary, Poland, Romania, Serbia, Montenegro, 
Slovakia, Slovenia, The Former Yugoslav Republic of Macedonia
EURO B, except for Croatia, 
Czech Republic and Slovenia 
(EURO A)
Apply estimates from meta-
analysis.
Europe, Western Austria, Belgium, Channel Islands, Cyprus, Denmark, Finland, 
France, Germany,  Greece, Iceland, Ireland, Israel, Italy, 
Luxembourg, Malta, Netherlands, Norway, Portugal, San Marino, 
Spain, Sweden, Switzerland, United Kingdom
EURO A Apply estimates from meta-
analysis.
THE AMERICAS
North America Canada, United States of America AMRO A Conduct meta-analysis for USA. 
Apply CSHA data for Canada, 
then aggregate
Latin America, 
Andean
Bolivia (Plurinational State of), Ecuador, Peru AMRO D Apply estimates from meta-
analysis conducted across all 
four regions
Latin America, 
Central
Colombia, Costa Rica, El Salvador, Guatemala, Honduras, Mexico, 
Nicaragua, Panama, Venezuela (Bolivarian Republic of)
AMRO B except for Guatemala 
and Nicaragua (AMRO D)
Latin America, 
Southern
Argentina, Chile, Uruguay AMRO B
Latin America, 
Tropical
Brazil, Paraguay AMRO B
AFRICA
Sub-Saharan 
Africa, Central
Angola, Central African Republic, Congo, Democratic Republic of 
the Congo, Equatorial Guinea, Gabon
A mixture of AFRO D and 
AFRO E
Apply estimates from meta-
analysis in sub-Saharan Africa 
conducted across all four 
regions
Sub-Saharan 
Africa, East
Burundi, Comoros, Djibouti, Eritrea, Ethiopia, Kenya, Madagascar, 
Malawi, Mozambique, Rwanda, Somalia, South Sudan, Sudan, 
Uganda, United Republic of Tanzania, Zambia
AFRO E except for Comoros 
(AFRO D) and Somalia and 
Sudan (EMRO D)
Sub-Saharan 
Africa, Southern
Botswana, Lesotho, Namibia, South Africa, Swaziland, Zimbabwe AFRO E
Sub-Saharan 
Africa, West
Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Cote d’Ivoire, 
Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, Sierra Leone, 
Togo
AFRO D
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Table A.2 
GBD regions for which meta-analysis could not be conducted
Region Countries (those with one or more studies 
underlined)
Relationship to WHO regions used 
in ADI/ Lancet
Approach
ASIA
Asia, Central Armenia, Azerbaijan, Georgia, Kazakhstan, 
Kyrgyzstan, Mongolia, Tajikistan, Turkmenistan, 
Uzbekistan
EURO B, except for Kazakhstan 
(EURO C)
Apply relevant Lancet/ ADI estimates to 
each country and aggregate
Oceania Fiji, French Polynesia, Guam, Kiribati, Micronesia 
(Federated States of), New Caledonia, Papua New 
Guinea, Samoa, Solomon Islands, Tonga,  Vanuatu
WPRO B Data from one study in Guam only 
(indigenous Chamorros islanders. 
Therefore use Lancet/ ADI WPRO B for all 
countries
EUROPE
Europe, Eastern Belarus, Estonia, Latvia, Lithuania, Republic of 
Moldova, Russian Federation, Ukraine
EURO C Apply Lancet/ ADI EURO C estimates
THE AMERICAS
Caribbean Antigua and Barbuda, Aruba, Bahamas, Barbados, 
Belize, Cuba, Curacao, Dominican Republic, French 
Guiana, Grenada, Guadaloupe, Guyana, Haiti, 
Jamaica, Martinique, Puerto Rico, St. Lucia, St. 
Vincent and the Grenadines, Suriname, Trinidad and 
Tobago, United States Virgin Islands
AMRO B, other than Haiti (AMRO 
D) and Cuba (AMRO A)
Use meta-analysed estimates for Cuba, 
10/66 estimates for Dominican Republic 
and Puerto Rico for those countries. 
Jamaica prevalence for this country. 
Apply relevant Lancet/ ADI estimates to 
other countries and aggregate
AFRICA
North Africa / 
Middle East
Algeria, Bahrain, Egypt, Iran (Islamic Republic of), 
Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, 
Oman, Qatar, Saudi Arabia, State of Palestine, 
Syrian Arab Republic, Tunisia, Turkey, United Arab 
Emirates, Western Sahara, Yemen
EMRO B, except for Egypt, Iraq, 
Morocco and Yemen (EMRO D), 
Algeria (AFRO D) and Turkey 
(EURO B)
Apply meta-analysed Turkey estimates to 
Turkey. 
Apply Egypt meta-analysed estimates 
to Egypt and other EMRO D and AFRO D 
countries. 
Apply relevant Lancet/ ADI estimates to 
other countries and aggregate
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About ADI
Alzheimer’s Disease International (ADI) is the international 
federation of Alzheimer associations throughout the 
world. Each of our 83 members is a non-profit Alzheimer 
association supporting people with dementia and their 
families.
ADI’s vision is an improved quality of life for people with 
dementia and their families throughout the world. ADI 
aims to make dementia a global health priority, to build 
and strengthen Alzheimer associations, and to raise 
awareness about dementia worldwide. Stronger Alzheimer 
associations are better able to meet the needs of people 
with dementia and their carers.
What we do
•	 Support the development and activities of our member 
associations around the world.
•	 Encourage the creation of new Alzheimer associations 
in countries where there is no organization.
•	 Bring Alzheimer organizations together to share and 
learn from each other.
•	 Raise public and political awareness of dementia.
•	 Stimulate research into the prevalence and impact of 
Alzheimer’s disease and dementia around the world.
•	 Represent people with dementia and families in 
international platforms at the UN and WHO
Key activities
•	 Raising global awareness through World Alzheimer’s 
Month™ (September every year).
•	 Providing Alzheimer associations with training 
in running a non-profit organization through our 
Alzheimer University programme.
•	 Hosting an international conference where staff and 
volunteers from Alzheimer associations meet each 
other as well as medical and care professionals, 
researchers, people with dementia and their carers.
•	 Disseminating reliable and accurate information 
through our website and publications.
•	 Supporting the 10/66 Dementia Research Group’s 
work on the prevalence and impact of dementia in 
developing countries.
•	 Supporting global advocacy by providing facts and 
figures about dementia, and monitoring as well as 
influencing dementia policies.
ADI is based in London and is registered as a non-
profit organization in the USA. ADI was founded in 1984 
and has been in official relations with the World Health 
Organization since 1996. You can find out more about 
ADI at www.alz.co.uk.
About Bupa
Bupa’s purpose is longer, healthier, happier lives.
As a leading global health and care company, we 
offer health insurance, medical subscription and 
other health and care funding products; we run care 
homes, retirement and care villages, primary care, 
diagnostic and wellness centres, hospitals and 
dental clinics. We also provide workplace health 
services, home healthcare, health assessments and 
long-term condition management services.
We have 29m customers in 190 countries. With no 
shareholders, we reinvest our profits to provide more 
and better healthcare and fulfil our purpose.
We employ almost 80,000 people, principally in the 
UK, Australia, Spain, Poland, New Zealand and Chile, 
as well as Saudi Arabia, Hong Kong, India, Thailand 
and the USA.
For more information, visit bupa.com.
About Bupa’s social care services 
around the world
Bupa is committed to tackling the toughest 
challenges in healthcare, including dementia. We 
want to set the standard for person-centred care and 
be recognised as a global leader in helping people 
live well with dementia and Alzheimer’s disease.
Bupa has significant expertise and networks, with 
approximately three-quarters of residents in our care 
homes living with dementia, making us the leading 
international provider of specialist dementia care. 
During a given year, we care for more than 65,000 
people in over 450 care homes and retirement 
villages in the UK, Spain, Australia, New Zealand  
and Poland. 
We combine experience and expertise to care for 
our residents living with dementia. Our philosophy 
of care is based on a ‘person first’ approach 
which revolves around each person’s background, 
experiences, values, hobbies and what makes them 
happy, and seeks to understand who they are and 
the reality in which they are living. 
We are committed to shaping a world where people 
can live well with dementia today, and reduce the risk 
of dementia for future generations. That is why we 
are proud to partner with ADI, and together we have 
outlined for the first time what we believe are the 
rights of people living with dementia, wherever they 
are in the world. Our joint Global Dementia Charter 
‘I can live well with dementia’ has been endorsed by 
people living with dementia, and together with ADI 
we intend to make it a reality. 
To download the charter and find out more, visit 
www.bupa.com/dementia 
Alzheimer’s Disease International: 
The International Federation 
of Alzheimer’s Disease and 
Related Disorders Societies, Inc. 
is incorporated in Illinois, USA, 
and is a 501(c)(3) not-for-profit 
organization
Alzheimer’s Disease International
64 Great Suffolk Street
London SE1 0BL
UK
Tel: +44 20 79810880
Fax: +44 20 79282357
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